American College of Allergy, Asthma & Immunology

Precision Medicine in Allergy Practice
A rich history. A strong future.

October 26 – 30, 2017
Hynes Convention Center
Boston, Massachusetts

2016 – 2017 Officers and Board of Regents

Stephen A. Tilles, MD, FACAAI
President .............................. 2017

Bryan L. Martin, DO, FACAAI
Immediate Past President ................. 2017

Bradley E. Chipps, MD, FACAAI
President-Elect ............................. 2017

Todd A. Mahr, MD, FACAAI
Vice President .............................. 2017

Luz S. Fonacier, MD, FACAAI
Treasurer ................................. 2017

James L. Sublett, MD, FACAAI
Past Immediate Past President .............. 2017

Santiago E. Martinez, MD, FACAAI .............. 2017
William S. Silvers, MD, FACAAI ................. 2017
Cherie Y. Zachary, MD, FACAAI ................. 2017
Jayesh G. Kanuga, MD, FACAAI ................. 2018
Michael E. Manning, MD, FACAAI .............. 2018
James M. Tracy, DO, FACAAI ..................... 2018
Larry Borish, MD, FACAAI ...................... 2019
Mitchell R. Lester, MD, FACAAI ................. 2019
Noel Rodriguez, MD, FACAAI ..................... 2019

FIT Representatives: Tammy Peng, MD (’17) and Amar Dixit, MD (’18)
Speaker of the House of Delegates: Maeve E. O’Connor, MD, FACAAI (’17)
Executive Medical Director: Michael S. Blaiss, MD, FACAAI (’19)
Annals Editor-in-Chief: Gailen D. Marshall, MD, PhD, FACAAI (’21)
Alliance President: Charlotte Meadows (’17)
The American College of Allergy, Asthma and Immunology recognizes the indispensable role that health care companies play in furthering the mission of the College. ACAAI would like to thank the following companies for their generous support of this year’s Annual Meeting.

**ACAAI Premier Partners**

**Diamond**  
$500,000 and above  
Sanofi Genzyme and Regeneron Pharmaceuticals  
Teva Respiratory

**Platinum**  
$300,000 - $499,999  
CSL Behring

**Gold**  
$100,000 – $299,999  
Aimmune Therapeutics  
ALK, Inc.  
AstraZeneca  
DBV Technologies  
Genentech Inc. and Novartis Pharmaceuticals Corporation  
GlaxoSmithKline  
Mylan  
Shire

**Silver**  
$50,000 – $99,999  
Boehringer Ingelheim Pharmaceuticals, Inc.  
Boston Scientific  
Circassia Pharmaceuticals, Inc.  
Johnson & Johnson Consumer Inc.  
kaléo®  
Pharming NV  
Stallergenes Greer

**Other Contributors**

KARL STORZ Endoscopy-America, Inc.  
Lincoln Diagnostics, Inc.  
Micro Direct, Inc.  
Nestlé Nutrition Institute  
Pfizer, Inc.  
Sunovion Pharmaceuticals Inc.
ACAAI Premier Partners ........................................... 2
Message From the Program Chair ............................ 5
2017 Award Winners ............................................. 7
Gold Headed Cane Award ....................................... 9
Corporate Supporters ........................................... 10
Commercial Supporters ....................................... 11
Special Announcements ........................................ 13
Education Information ......................................... 17
Maintenance of Certification .................................. 18
Evaluation and Credit Claiming ............................... 19
Daily Events ....................................................... 20
Committee Meetings ............................................ 27
Featured Lectures ................................................ 28
Tracks ............................................................ 29
Workshops ........................................................ 33
Thursday Program ............................................... 42
Friday Annual Literature Review .............................. 44
Friday General Sessions ....................................... 45
Friday Town Hall Meeting
Hosted by House of Delegates ................................ 49
Saturday General Sessions .................................... 50
Saturday Awards Ceremony and
President’s Welcome Reception ................................ 54
Sunday Meet the Professor Breakfasts ..................... 55
Sunday General Sessions ...................................... 57
Sunday Oral Abstracts ......................................... 60
Monday Meet the Professor Breakfasts ..................... 64
Monday General Sessions ..................................... 66
Monday Annual Business Meeting ......................... 66
Monday Oral Abstracts ......................................... 68
Fellows-in-Training Programs ................................. 72
Friday Office Administrators
Practice Management Course ................................. 74
Friday Advanced Practice Health Care Providers Course ......................................................... 76
Saturday Allied Health Professionals Course ............. 78
Sunday Allied Health Professionals Course ................ 80
Non-CME Corporate Forums ................................. 81
E-poster Presentations ......................................... 84
Featured Lecturers and Faculty ............................. 109
Faculty Index ..................................................... 118
Social Events ...................................................... 120
Alliance of the ACAAI Program ............................ 121
Product Theaters ................................................. 122
Exhibits .......................................................... 124
Index of Exhibits ............................................... 138
Index of Exhibitors ............................................. 140
Exhibit Hall Map ................................................ 142
Hynes Convention Center Maps ............................ 143
Sheraton Boston Hotel Maps ............................... 146

2017 Annual Meeting Program Committee
Bradley E. Chipps, MD, Chair • Todd A. Mahr, MD, Vice chair
Anne K. Ellis, MD, MSc • Sandra M. Gawchik, DO • Alan B. Goldsobel, MD • Matthew Greenhawt, MD, MBA, MSc
Brian T. Kelly, MD, MA • Lisa J. Kobrinsky, MD, MPH • Kevin P. McGrath, MD • John J. Oppenheimer, MD
David R. Stukus, MD • Janna M. Tuck, MD • Tammy Peng, MD, FIT Representative
Workshop Liaison: Todd A. Mahr, MD • Meet the Professor Breakfast Liaison: Michael E. Manning, MD
Literature Review Liaison: David Khan, MD

2017 Allied Health Committee
Jodi A. Shroba, MSN, APRN, CPNP, Chair • Charlotte M. Jacobsen, MSN, RN, Vice chair
Cheryl K. Bernstein, RN, BSN • B. Gwen Carlton, RN, DNP, FNP-BC, AE-C • Kimberly G. Clay, RN, MSN, APRN, FNP-BC
Maureen George, PhD, RN, AE-C • Mary Lou Hayden, RN, MSN, FNP-BC, AE-C • Marc L. Rubin, BSPharm, RPh
Christine W. Wagner, RN, MSN, CPNP, AE-C
REALITIES OF ASTHMA CARE
BECAUSE PATIENTS CAN BE HARD TO READ

Thursday, October 26, 2017
Registration & Check-in
6:00 PM – 6:10 PM
Dinner & Presentation
6:10 PM – 8:00 PM

SHERATON BOSTON HOTEL
Independence Room
Boston, MA

RANDALL W. BROWN, MD, MPH, AE-C
Pulmonologist & Pediatrician
Director, Asthma Programs
Center for Managing Chronic Disease
University of Michigan
Ann Arbor, Michigan

DESCRIPTION
- Discuss how patient perception about asthma and its treatment impacts clinical outcomes
- Review the benefits and challenges that different types of inhaler technologies present for patients
- Understand how device technologies may affect inhalation technique
- Examine how a patient-centric approach to asthma management, treatment selection, and medication dosing
  may help improve adherence and outcomes for patients with asthma

If you are licensed in any state or other jurisdiction or are an employee
or contractor of any organization or governmental entity that limits or
prohibits meals from pharmaceutical companies, please identify
yourself so that you (and we) are able to comply with such requirements.
Your name, the value, and the purpose of any educational item, meal, or
other items of value you receive may be reported as required by state or
federal law. Once reported, this information may be publicly accessible.
Thank you for your cooperation.

This is a promotional event. CME/CE credit will not be available
for this session.

In compliance with PhRMA guidelines, spouses or other guests are not
permitted to attend company-sponsored programs. This promotional
activity is brought to you by Teva Respiratory and is not certified for
continuing medical education. The speakers are presenting on behalf
of Teva Respiratory and must present information in compliance with
FDA requirements.

The Non-CME Corporate Forum content and views expressed therein do
not necessarily reflect the views, policies or position of the American
College of Allergy, Asthma & Immunology.

Please visit www.regonline.com/AsthmaCareBoston
to register for this Teva Respiratory-Supported Program.
Our allergy and immunology community is grounded in a rich history – and together, we can build on what we know to create a strong future. With precision medicine helping you to take the best science available and put it into practice every day, the future of allergy looks bright. This year, the College has created an Annual Meeting that is all about that bright future.

Welcome to Boston! We’re bringing you cutting-edge research from around the globe, and access to the newest treatments and technologies. The program is perfect for whatever stage you are at in your journey – whether you are a veteran allergist or a Fellow-in-Training. From our Thursday program on food allergy and atopic dermatitis to in-depth practice management sessions, the College is covering all the topics you want. See speakers who will inspire you and while you’re here, connect with colleagues at fun networking events.

This year’s meeting is all about keeping up with what’s new in our field and applying evidenced-based medicine to our daily practices. The track structure from the 2016 meeting is back, and the sub-committees have reviewed submissions from you – the College members – and made their recommendations to the Program Committee. This way, the meeting is created by and for you on the topics that matter most to you. The committee has worked hard to build a program tailored to your needs.

This year’s Thursday program on Oct. 26 will focus on two hot topics – atopic dermatitis and food allergy. The Thursday morning session is focused on atopic dermatitis, covering infectious complications, the role of contact allergy, pathophysiology, epidemiology, and the newest treatments. If you’ve been wondering about the new guidelines that have been issued involving food allergy, make sure you attend the Thursday afternoon session. Mechanisms, prevention, epidemiology and more will be discussed. One ticket to the Thursday program lets you attend both – you can get all the info you need on the many changes in recommendations for these diseases.

The College turned 75 this year. At the opening plenary on Saturday, Oct. 28, we’re going to be remembering our past, exploring the present and looking forward to the future of both the College and health care. It’s a great place to be if you’re looking to find what the College can do for you or how to get more involved. We’ll be talking about how the College is uniquely positioned to serve, grow and lead the specialty.

Ever since the College added “asthma” to our name in 1994, we’ve been striving to educate the public that allergists are the experts in asthma treatment. At this year’s Annual Meeting, we’re going to give you more skills for your toolbox than ever before. What can you do about difficult-to-treat asthma? How do you “step up” when patients fail one of the steps? What are the latest treatments? We’ll cover it all. Plus, stay until Monday, Oct. 30 to catch a special session debating current approaches to the treatment of obstructive lung disease and many other fantastic sessions. Your interventions improve patient outcomes – and these sessions are going to give you an extra edge.

We have a lot of sessions this year on specific diseases that you encounter in practice. On Friday, join us for a symposium on chronic rhinosinusitis. We’re covering host microbial interactions, inflammatory endotypes and treatment paradigms for patients. On Oct. 30, come to a plenary on mastocytosis and mast cell activation syndrome – we want to demystify these conditions and offer you ways to develop a treatment plan. Plus, you can get an update on techniques for immunotherapy – the cornerstone of your practice. You’ll get the most up-to-date, evidence-based guidelines for diagnosis and therapy for these diseases, so you can develop a treatment plan that is directed toward precision medicine.

Be ready to learn and ready for surprises. We’re focusing in on taking your practice into the future.
Thank you to the 2017 ACAAI Corporate Council Members

BENEFACTOR MEMBERSHIP

AstraZeneca
Boston Scientific
Sanofi Genzyme
Regeneron

PATRON MEMBERSHIP

Aimmune Therapeutics
ALK
Boehringer Ingelheim
Circassia
Genentech
Novartis
GSK
Kaléo
Mylan
Teva Respiratory
The College is proud to honor the following individuals for their service to the College and the specialty of allergy/immunology. These awards will be presented during the ACAAI Awards Ceremony at 7:00 pm, Saturday, in the Constitution Ballroom Salon B (2nd Floor) of the Sheraton Boston Hotel.

**Distinguished Fellow Award**

**Gary N. Gross, MD, FACAAI**  
*Dallas, TX*  
Clinical Professor of Internal Medicine, UT Southwestern Medical School.

**Distinguished Service Award**

**Stephen A. Imbeau, MD, FACAAI**  
*Florence, SC*  
Co-founder, Allergy, Asthma & Sinus Center; Assistant Clinical Professor, Medical University of South Carolina, Charleston.

**International Distinguished Fellow Award**

**Tak Hong Lee, MD, FACAAI**  
*Hong Kong, China*  
Head of the Allergy Centre of Hong Kong Sanatorium and Hospital.

**Woman in Allergy Award**

**Sandra M. Gawchik, DO, FACAAI**  
*Upland, PA*  
Clinical Associate Professor of Pediatrics, Thomas Jefferson Medical College, Philadelphia; Co-director of Allergy and Clinical Immunology, Crozer-Chester Medical Center; President of Asthma and Allergy Research Associates.

**Young Faculty Support Awards**

**Kuan-Hsiang Gary Huang, MD, PhD**  
Albert Einstein Medical Center, Philadelphia, PA  
**Anjeni Keswani, MD**  
George Washington University School of Medicine and Health Sciences, Washington, DC

**Clemens von Pirquet Awards**

**First Place – Alliance Memorial Award**  
**Brian P. Peppers, DO, PhD**  
Case Western Reserve University, Richmond Heights, OH

**Second Place**  
**Karina Shah Gobin, MD**  
Medical College of Wisconsin, Milwaukee, WI

**Third Place**  
**David A. Hill, MD**  
The Children’s Hospital of Philadelphia, Philadelphia, PA
SAVE THE DATE!

PRACTICE EMPOWERMENT

PATIENTS • COMMUNITY • PARTNERS

American College of Allergy, Asthma & Immunology
2018 Annual Scientific Meeting
SEATTLE | NOV 15-19
Washington State Convention Center
Gold Headed Cane Award

Dr. Gailen D. Marshall to Receive Gold Headed Cane Award

The College is proud to honor Gailen D. Marshall, MD, PhD, FACAAI as recipient of the 17th Annual Gold Headed Cane Award for demonstrating the highest standards of scientific excellence and integrity. The Award will be presented during the ACAAI Awards Ceremony scheduled at 7:00 pm, Saturday, in the Constitution Ballroom Salon B (2nd Floor) of the Sheraton Boston Hotel.

The Gold Headed Cane Award is annually given to a College Fellow who has demonstrated the highest standards of scientific excellence and integrity. The Gold Headed Cane Committee, consisting of past award recipients, selects qualified nominees for election of one by voting Fellows of the College. The award serves as an inspiration to young doctors and encourages them in family, social, civic, religious and professional life to cultivate character that earns the respect and goodwill of colleagues and the profession at large.

Dr. Gailen D. Marshall joined the College in 1988 and became a Fellow in 1993. He has been extensively involved with the College for the past 29 years and has served on multiple committees, presented numerous lectureships, and been honored with the Distinguished Service Award and recognized as a Distinguished Fellow of the College.

Dr. Marshall has served the College’s publications for the past 16 years; he was appointed associate editor of the Annals of Allergy, Asthma and Immunology in 2005 and became editor-in-chief (EIC) in 2006. “The experience of developing the journal to meet the needs of our membership as well as others around the world has been and remains one of the great highlights of my professional career,” said Dr. Marshall.

Dr. Marshall serves as the R. Faser Triplett, Sr., MD, Chair of Allergy and Immunology, Professor of Medicine, Pediatrics and Pathology, Vice Chair for Research, Director of the Division of Clinical Immunology and Allergy and Chief of the Laboratory of Behavioral Immunology Research at UMMC. His major research interests are the effects of psychological stress and environmental factors on immunoregulatory pathways involved in various diseases including allergic rhinitis, asthma, cancer and diabetes; the immunomodulatory effects of stress management; and the effectiveness of the integrative approach to clinical care, particularly in patients with allergy, asthma- or immune-based diseases. Dr. Marshall has published over 250 peer-reviewed articles, reviews and book chapters, and has received extensive research funding from the NIH, industry, HRSA and several philanthropic sources during his career.

“To receive the Golden Headed Cane award is an honor for which I am so very humbled and grateful. It has been an ongoing joy for me to be able to contribute to our specialty in teaching, research and service – and I cannot imagine a better venue than the College to invest whatever talent and time I have for the practicing allergist-immunologist community and the patients we all serve,” said Dr. Marshall.

Gold Headed Cane Recipients

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>Harold S. Nelson, MD</td>
</tr>
<tr>
<td>2002</td>
<td>Joseph A. Bellanti, MD</td>
</tr>
<tr>
<td>2003</td>
<td>Edward J. O’Connell, MD</td>
</tr>
<tr>
<td>2004</td>
<td>Elliot F. Ellis, MD</td>
</tr>
<tr>
<td>2005</td>
<td>John C. Selner, MD</td>
</tr>
<tr>
<td>2006</td>
<td>Phillip L. Lieberman, MD</td>
</tr>
<tr>
<td>2007</td>
<td>Betty B. Wray, MD</td>
</tr>
<tr>
<td>2008</td>
<td>Donald W. Aaronson, MD, JD, MPH</td>
</tr>
<tr>
<td>2009</td>
<td>Emil J. Bardana, Jr., MD</td>
</tr>
<tr>
<td>2010</td>
<td>Raymond Slavin, MD</td>
</tr>
<tr>
<td>2011</td>
<td>Ira Finegold, MD</td>
</tr>
<tr>
<td>2012</td>
<td>Rufus E. Lee, Jr., MD</td>
</tr>
<tr>
<td>2013</td>
<td>Michael S. Blaiss, MD</td>
</tr>
<tr>
<td>2014</td>
<td>Peter B. Boggs, MD</td>
</tr>
<tr>
<td>2015</td>
<td>Eli O. Meltzer, MD</td>
</tr>
<tr>
<td>2016</td>
<td>Bobby Q. Lanier, MD</td>
</tr>
<tr>
<td>2017</td>
<td>Gailen D. Marshall, MD, PhD</td>
</tr>
</tbody>
</table>
ACAAI appreciates the following promotional contributions from its corporate supporters.

**Aimmune Therapeutics**
Supporter of the ACAAI Corporate Council…a Non-CME Corporate Forum…and the Saturday afternoon refreshment break.

**ALK, Inc.**
Supporter of the ACAAI Corporate Council…a Non-CME Corporate Forum…the Immunotherapy Shared Decision-making Tool…and the Immunotherapy Shared Decision-making Allergist Instructional Video.

**AstraZeneca**
Supporter of the ACAAI Corporate Council…a Product Theater…hotel elevator clings…window clings…and co-supporter of AllergyWatch.

**Boehringer Ingelheim Pharmaceuticals, Inc.**
Supporter of the ACAAI Corporate Council…and a Product Theater.

**Boston Scientific**
Supporter of the ACAAI Corporate Council…and FIT Travel Scholarships.

**Circassia Pharmaceuticals, Inc.**
Supporter of the ACAAI Corporate Council…and a Product Theater…and the webinar on *The Role of Biomarkers in Asthma Management*.

**CSL Behring**
Supporter of a Product Theater…a Non-CME Corporate Forum…hand sanitizer stations…Daily Schedule Board…signage in the convention center…Advance Registrant Brochure…mobile app…column wraps…banners in the convention center…hotel room door hangers…and advertisements in the Final Program Guide.

**DBV Technologies**
Supporter of a Non-CME Corporate Forum…badge lanyards…hotel tent card…Allied Health Professionals Networking Reception…and an advertisement in the Final Program Guide.

**Genentech, Inc. and Novartis Pharmaceuticals Corporation**
Supporter of the ACAAI Corporate Council…Welcome Reception…a Product Theater…and two tables at the fundraising dinner.

**GlaxoSmithKline**
Supporter of the ACAAI Corporate Council.

**Johnson & Johnson Consumer Inc.**
Supporter of the Internet Café…and FIT Travel Scholarships.

**kaléo®**
Supporter of the ACAAI Corporate Council…exhibit aisle markers…signage in the convention center…and the Anaphylaxis Station.

**Lincoln Diagnostics, Inc.**
Supporter of two tables at the fundraising dinner.

**Mylan**
Supporter of the ACAAI Corporate Council…hotel key card…ACAAI Awards Ceremony…FIT and Program Directors Breakfast…*College Insider…College Advantage*...and the Anaphylaxis Station.

**Nestlé Nutrition Institute**
Supporter of FIT Travel Scholarships.

**Pfizer, Inc.**
Supporter of a Product Theater.

**Sanofi Genzyme and Regeneron Pharmaceuticals**
Supporter of the ACAAI Corporate Council…two Product Theaters…hotel escalator banister clings…branded floor clings in the convention center…banner in the hotel…gobo lasers in the convention center and hotel…digital signage at the hotel…Eczema Page on the ACAAI Website…the Practice Management Center website…the Atopic Dermatitis Patient Education Brochure…and the Atopic Dermatitis E-yardstick Educational Tool.

**Shire**
Supporter of two Non-CME Corporate Forums…a Product Theater…ACAAI Media Wall…and the convention center light boxes.

**Stallergenes Greer**
Supporter of Friday’s Fellow-in-Training Welcome Reception.

**Sunovion Pharmaceuticals Inc.**
Supporter of the Board of Regents dinner.

**Teva Respiratory**
Supporter of the Nationwide Asthma Screening Program…ACAAI Corporate Council…one table at the fundraising dinner…and an advertisement in the Final Program Guide…two Non-CME Corporate Forums…banners in the convention center and hotel…escalator clings…Wi-Fi in the convention center and hotel…charging cards…FIT Bowl…FIT and Training Directors Luncheon…FIT Travel Scholarships…Allergy Payor Toolkit…and co-supporter of AllergyWatch.
This activity is supported by independent educational grants from the following commercial supporters:

**Aimmune Therapeutics**  
Supporter of the Thursday Program on New Horizons in Food Allergy.

**Boehringer Ingelheim Pharmaceuticals, Inc.**  
Supporter of the Sunday Symposium on The Asthmatic Who Does Not Qualify for a $T_2$ Biologic: What Is Next?

**GlaxoSmithKline**  
Supporter of the Sunday Symposium on Which $T_2$ Biologic is Best Suited for GINA 4-5 Non-responders?... and Workshop W11 on PBL: Burden of Non-Adherence In Asthma and Role Of Shared Decision-Making.

**KARL STORZ Endoscopy-America, Inc.**  
In-kind support consisting of loaned durable equipment for the Hands-on Session in Rhinolaryngoscopy.

**Micro Direct, Inc.**  
In-kind support consisting of loaned durable equipment for the Allied Health Workshop on Beyond FEV1: Improve Your Spirometry Skills.

**Mylan**  
Supporter of the Sunday Breakfast Symposium on Anaphylaxis: Causes, Diagnosis and Management.

**Pharming NV**  
Supporter of the Friday Luncheon Symposium on Current Management of Hereditary Angioedema: Considerations to Optimize Individualized Care.

**Sanofi Genzyme and Regeneron Pharmaceuticals**  
Partial Support of the Thursday Program on Moving Toward Precision Medicine in Atopic Dermatitis and Food Allergy.

**Stallergenes Greer**  
Supporter of Workshop W27 on Immunotherapy 2017: SCIT, SLIT and More!
A FUN, MUSICAL EVENING OF TIMELESS AMERICAN CLASSICS MADE FAMOUS BY FRANK SINATRA, DEAN MARTIN AND NAT KING COLE IN LANDAU’S OWN UNIQUE STYLE

LANDAU EUGENE MURPHY, JR.

Reception with cocktails, plated dinner, and concert

>>> Plus a special live auction >>>

Tickets still available! Purchase at the Registration Desk in the Hall C Lobby (2nd Floor) of the Hynes Convention Center.

Tickets
$250

Tables
$2,300

Corporate Tables
$10,000

Show Only Tickets $55 with cash bar

Net proceeds donated to the ACAAI Foundation
General Information

Net proceeds donated to the ACAAI Foundation

Tickets still available!
Purchase at the Registration Desk in the Hall C Lobby (2nd Floor) of the Hynes Convention Center.

Reception with cocktails, plated dinner, and concert

Plus a special live auction

Tickets
$250

Tables
$2,300

Corporate Tables
$10,000

Show Only Tickets
$55 with cash bar

2017 ANNUAL SCIENTIFIC MEETING
Boston, MA
Oct. 26 – 30

Special Announcements

Admission by Badge Only
Admission to all meeting rooms and the exhibit area will be by badge only. This rule will be strictly enforced by security guards at all entrances. Note: Children under 12 are not admitted to the Scientific Sessions or the exhibit area.

Anaphylaxis Station
The Anaphylaxis Station, located in the Exhibit Hall in Booth #1901, gives health care providers the opportunity to try out various epinephrine auto-injectors and discuss the unique features of each delivery device. Medical affairs staff from the manufacturers, along with representatives from the College’s Anaphylaxis Committee, will be available to answer questions and provide assistance.

Hours:
3:00 – 4:00 pm, Friday
10:30 – 11:00 am, 12:30 – 1:30 pm,
3:00 – 3:30 pm, Saturday
10:00 – 10:30 am, 12:30 – 1:30 pm, Sunday

Supported by Kaléo and Mylan

Alliance Hospitality Suite
The Alliance Hospitality Suite – located in the Republic Ballroom (2nd Floor) of the Sheraton Boston Hotel – will be open to registered spouses and guests only from 8:00 – 10:30 am, Friday through Monday.

Annual Meeting Website
Maximize your time at the meeting! Find schedules, download handouts and access all the information you need at annualmeeting.acaai.org.

Awards Ceremony
The College invites all registrants to the ACAAI Awards Ceremony on Saturday at the Sheraton Boston Hotel. The Awards Ceremony will begin at 7:00 pm and will be held in the Constitution Ballroom Salon B (2nd Floor) of the Sheraton Boston Hotel. The College will formally welcome our newly approved Fellows and recognize the recipients of the College’s Distinguished Fellow, International Distinguished Fellow, Distinguished Service, Clemens von Pirquet, Woman in Allergy, and Young Faculty Support Awards. Finally, we’ll award this year’s recipient of the College’s prestigious Gold Headed Cane Award.

Supported by Mylan

Badge Designations
Blue Member/Fellow Physicians
Purple Non-member Physicians
Green Nurses/Allied Health
Lime Fellows-in-Training/Residents
Orange Non-Physicians
Red Technical Exhibitors
Teal Spouses/Guests
Lt Orange Press
Fuschia Staff
Gray Meeting Technicians

Replacement badges – $10.00 each

Boston City Information Desk
For information regarding Boston, visit the Boston City Information Desk located on Level 1 of the Hynes Convention Center (across from Hall A). While the desk will be available for maps and brochures throughout the meeting, it will be staffed during the following hours to assist with making restaurant reservations and providing city information.

Hours:
Noon – 4:00 pm, Thursday
9:00 am – 5:00 pm, Friday
9:00 am – 5:00 pm, Saturday
9:00 am – 5:00 pm, Sunday
9:00 am – 2:00 pm, Monday

Capturing of NPI Numbers
As part of the health care reform legislation signed into law in March 2010, the Physician Payment Sunshine Act requires medical device, biologic and drug companies to publicly disclose gifts and payments made to physicians.

To help our ACAAI Annual Scientific Meeting exhibitors and industry partners in fulfilling the mandatory reporting provisions of the Sunshine Act, the College is requesting U.S. health care provider attendees supply their 10-digit NPI (National Provider Identifier) number when registering for the Annual Scientific Meeting. The NPI will be embedded in the bar code data on the attendee’s badge – it will NOT be printed on the badge. Exhibitors can download the NPI information by scanning the badge through a lead retrieval system so that they can record and track any reportable transactions.

Child Care Services
Please contact the concierge at the hotel at which you are staying for a list of bonded independent babysitters and babysitting agencies. Note: Children under 12 are not admitted to the Scientific Sessions or the exhibit area.
Coat/Luggage Check
A complimentary coat/luggage check is located in the Level 1 Lobby of the Hynes Convention Center and will be available:

Hours: 7:30 am – 5:00 pm, Thursday
       7:00 am – 7:00 pm, Friday
       7:30 am – 7:30 pm, Saturday
       6:00 am – 6:30 pm, Sunday
       6:00 am – 5:30 pm, Monday

College Resource Center
Stop by the College Resource Center, located in the Hall C Lobby (2nd Floor) of the Hynes Convention Center, to get connected and learn more about ongoing College programs, Vision 2020 and more. Test drive the College Learning Connection (CLC) – your home for professional development and resources.

Hours: 3:00 – 6:00 pm, Friday
       9:45 am – 4:00 pm, Saturday
       9:45 am – 2:00 pm, Sunday

Credit Claiming
For your convenience, the College will be using an online evaluation and credit claiming system for the 2017 Annual Scientific Meeting. This system will allow you to complete evaluations and claim credit for sessions attended. After completing an annual meeting evaluation, you will be able to save and/or print your certificate. Complete details can be found on page 19.

Disclaimer
The primary purpose of the ACAAI Annual Scientific Meeting is educational. Information, as well as technologies, products and/or services discussed, is intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and the views of the College disclaim any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.

Doctors’ Job Fair
Looking for new opportunities, an associate for your group, or a buyer for your practice? The Doctors’ Job Fair brings together all interested parties seeking or offering professional opportunities.

This unique program is scheduled from 12:30 – 3:30 pm, Saturday, in Hall A (1st Floor) of the Hynes Convention Center. Representatives of clinics, groups and physicians’ offices looking for associates will be among those conducting interviews, which will be held in private draped booths.

E-poster Presentations
The College is excited to continue to offer electronic posters to its program this year with expanded poster viewing times. E-posters provide a more engaging and interactive visual presentation of abstracts and allow for online access with full search capabilities. Each presenting author has a 10-minute presentation slot. View all poster presentation times on pages 84-108. E-posters are also accessible at college.acaai.org/eposters and via the mobile app during the conference. The e-posters will be on display in Halls C & D (2nd Floor) of the Hynes Convention Center and will be assigned to monitors by category. When posters are not being presented, the monitors are self-service for searching and viewing posters.

Hours: 3:30 – 6:00 pm, Friday
       10:30 – 11:00 am; 12:30 – 1:30 pm;
       3:00 – 3:30 pm, Saturday
       9:45 – 10:30 am; 12:30 – 1:45 pm, Sunday

Exhibit Hall
More than 70 technical and scientific exhibitors in over 200 booths are displaying their latest products in Halls C & D (2nd Floor) of the Hynes Convention Center during the convention. The College appreciates the support of its exhibitors and urges all registrants to visit the displays.

Hours: 3:00 – 6:00 pm, Friday
       9:45 am – 4:00 pm, Saturday
       9:45 am – 2:00 pm, Sunday

First Aid
A First Aid station is located in the Level 1 Lobby of the Hynes Convention Center during the following hours:

Hours: 8:00 am – 5:00 pm, Thursday
       8:00 am – 6:00 pm, Friday
       8:00 am – 5:30 pm, Saturday
       8:00 am – 6:00 pm, Sunday
       8:00 am – 5:00 pm, Monday

Foundation Display
The Foundation of the ACAAI is proud to recognize those individuals who have generously contributed to the Foundation. A list of donors can be found on the Foundation Honor Display located on Level 2 of the Hynes Convention Center.
**Internet Café**
Visit the “Internet Café” to access the internet and send and retrieve email. The Internet Café is located on Level 3 of the Hynes Convention Center and is complimentary to all meeting registrants.

*Supported by Johnson & Johnson Consumer Inc.*

**Handouts**
Session handouts are available for download online at annaulmeeting.aacaai.org or through the mobile app.

**Meeting on Demand**
The recorded educational sessions from the 2017 Annual Meeting will be hosted on the College Learning Connection (CLC). We no longer offer DVDs. Instead, we provide a variety of online packages designed to meet your particular needs, from the entire set of recordings to topical collections. Go to education.aacaai.org/ondemand.

**Mobile App**
Maximize your time at the meeting with the free ACAAI Annual Scientific Meeting mobile app. To download, visit acaai.org/apps or search for ACAAI in your app store.

*Supported by CSL Behring*

**MOC Designated Sessions**
Eight sessions have been designated for MOC this year. For details please see the Education Information on page 18.

**Networking Goes Viral: #ACAAI**
Be a part of the Annual Meeting conversation! Use hashtag #ACAAI17 in your meeting-related tweets and follow the College @ACAAI. Also, share Facebook posts from facebook.com/TheACAAI.

**Non-CME Corporate Forums**
Following the close of Thursday, Friday, Saturday and Sunday’s scientific sessions, all registrants are invited to attend the special Corporate Forums at the Sheraton Boston Hotel. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your educational experience. Please see pages 81-83 for additional info.

**Photography/Video Recordings**
By registering for this meeting, attendees acknowledge and agree that ACAAI or its agents may take photographs during events and may freely use those photographs in any media for College purposes, including, but not limited to, news and promotional purposes.

The presentations, slides, and materials provided in this program are the property of the College or are used with permission of the owner. You may not photograph, videotape, audiotape or otherwise record or reproduce any of the presentations without express written permission from the College. Any attendee believed to be violating this restriction will be removed from the session and may be prohibited from participating in future College meetings.

**President’s Welcome Reception**
All attendees are encouraged to attend the President’s Welcome Reception on Saturday, held in the Grand Ballroom (2nd Floor) of the Sheraton Boston Hotel from 7:45 – 9:00 pm. It’s the perfect place to catch up with old friends, make new acquaintances and meet the College President, President-Elect and the Alliance President.

*Supported by Genentech, Inc. and Novartis Pharmaceuticals Corporation*

**Registration Desk Hours**
The Registration Desk is located in the Hall C Lobby (2nd Floor) of the Hynes Convention Center and will be open:

- **Wednesday:** 3:30 – 6:30 pm
- **Thursday:** 7:00 am – 6:00 pm
- **Friday:** 6:30 am – 6:00 pm
- **Saturday:** 6:30 am – 4:00 pm
- **Sunday:** 6:00 am – 5:00 pm

**Speaker Ready Room**
The Speaker Ready Room is located in Room 201 of the Hynes Convention Center and will be open:

- **Wednesday:** 3:00 – 7:00 pm
- **Thursday:** 7:00 am – 7:00 pm
- **Friday:** 6:30 am – 7:00 pm
- **Saturday:** 6:00 am – 6:00 pm
- **Sunday:** 6:00 am – 6:00 pm

All presenters must check into the Speaker Ready Room at least 6 hours before the start of their presentation.
Special Announcements

Special Needs
In compliance with the Americans with Disabilities Act, ACAAI requests that participants in need of special accommodation submit a written request to the College well in advance.

Virtual Meeting
Select sessions from Saturday and Sunday’s program will be webcast live. Meeting registrants will have free access to this content after the meeting. Details will be available on the College Learning Connection at education.acaai.org/virtualarchive.

Wireless Internet
Free Wi-Fi is provided to all College attendees at the Hynes Convention Center, the Sheraton Boston Hotel, and the Westin Copley Place Hotel.

Hynes Convention Center
- Open your wireless network connections
- Connect to the “ACAAI” wireless network
- Enter password: acaai2017

Sheraton Boston Hotel (guest rooms, lobby and meeting space)
- Open your wireless network connections
- Connect to the “ACAAI” wireless network
- Open your web browser, and when prompted enter password: acaai2017

Westin Copley Place Hotel (guest rooms only)
- Open your wireless network connections
- Connect to the “ACAAI” wireless network
- Open a web browser and any webpage to access portal page
- Enter access code: acaai2017
- Press “next”
- Agree to the terms & conditions

Supported by Teva Respiratory

SPARK Program
The ACAAI SPARK program was developed by Paul Dowling, MD and the Program Director’s Committee to help “spark” an interest in residents who might be considering a career in allergy-immunology (A/I). The SPARK program provides $1,500 to help cover the expenses for residents (Pediatric, Internal Medicine, or Med-Peds) to spend 3 days at the ACAAI Annual Meeting. Recipients of the award will participate in a special Fellows-in-Training (FIT) symposium. There will also be time for the resident to attend a wide variety of sessions covering all aspects of allergy-immunology. With the leadership of the FIT Representatives, Tammy Peng, MD and Amar Dixit, MD, each SPARK recipient will have a FIT mentor while they are in Boston and beyond. You might recognize them by their yellow SPARK ribbon, so please say hello and welcome to our 2017 SPARK recipients:

Justine Ade, MD • Rainbow Babies & Children’s Hospital/University Hospitals
Andrea Aguilera, MD • Indiana University
Omolola Alakija, MD • Northwestern Internal Medicine
Jasmine Alsukhon, MD • Western Michigan University
Seemal Awan, MD • George Washington University
Ahmed Hamed, MD • East Carolina University
Stephanie Hudey, MD • University of South Florida
Christine Panganiban, MD • Kaiser Permanente
Alexander Patterson, MD • University of Kentucky
Matthew Perez, MD • Baylor College of Medicine
Luke Pittman, MD • Madigan Army Medical Center
Cheryl Rozario, DO • University of Rochester
Denise Sanchez Tejera, MD • Rochester General Hospital
Ashley Stoner, MD • University of Arkansas
Mohamed Warsame, MD • University of Missouri at Kansas City
This activity is supported by independent educational grants from:

• Aimmune Therapeutics
• Boehringer Ingelheim Pharmaceuticals, Inc.
• GlaxoSmithKline
• Mylan
• Pharming NV
• Sanofi Genzyme and Regeneron Pharmaceuticals
• Stallergenes Greer

This activity is also supported by KARL STORZ Endoscopy-America, Inc. and Micro Direct, Inc. through in-kind educational grants consisting of loaned durable equipment and disposable supplies.

Target Audience
Medical professionals who treat patients with allergic and/or immunological conditions:

• Practicing allergist/immunologists
• Allergy/immunology Fellows-in-Training
• Physician assistants
• Nurses and advanced practice nurses
• Allied health professionals
• Primary care physicians
• Other medical professionals

Overall Educational Objectives
At the conclusion of this activity, participants should be able to:

• Identify major advances in key areas of cutting edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract.
• Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
• Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
• Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
• Explain the impact of environmental exposures and external influences on patients with allergic disorders.
• Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
• Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
• Discuss processes, tools and technologies for the efficient allergy and immunology practice.

Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Specific disclosure information for the 2017 Annual Meeting is conveniently located online at college.acaai.org/disclosures. There is a link to this information in the Annual Meeting app under Disclosures.

Accreditation and Credit Statements
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 42 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics (AAP) and is acceptable for maximum of 42 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the AAP.

Advanced Practice Health Care Providers
1-Day Course:
This education activity is pending approval by the American Association of Nurse Practitioners for approval of up to 7.25 contact hours of accredited education.

Allied Health Professionals 1.5-Day Course:
This education activity is pending approval by the American Association of Nurse Practitioners for approval of up to 11.0 contact hours of accredited education.
The American Board of Allergy and Immunology’s (ABAI) Maintenance of Certification (MOC) program offers evidence of highly qualified physicians who use best practices and evidence-based standards for care. Linking the educational content of the ACAAI Annual Scientific Meetings to the MOC program is one way the College helps its members provide ABAI with evidence of their commitment to lifelong learning.

**IMPORTANT:** ABAI’s MOC program requires diplomates to obtain a minimum of 25 CME credits in allergy and immunology each year. CME credits for the Annual Meeting can be used to satisfy this requirement. Additionally, the ABAI recommends that 6 of the 25 credits be designated as self-assessment (MOC Part II) credit. With the approval of ABAI, the College has designated eight sessions at the meeting for MOC self-assessment credit.

In order to earn MOC self-assessment credit at designated sessions:
- You must be currently enrolled in the ABAI’s MOC program.
- You must attend the entire designated session.
- You must fully complete a paper form, including answering all pre- and post-test questions, providing a full name and ACAAI badge ID number.
- Forms must be legible in order to receive credit. ACAAI will submit the required reports that include MOC self-assessment credits to the ABAI. ABAI will enter the MOC self-assessment credits onto the ABAI web portal page (portal.abai.org/session/new). The amount of MOC self-assessment credit earned is always equal to the amount of AMA PRA Category 1 Credit™ claimed for the session. (Partial self-assessment credit is not available.) Faculty cannot earn CME or MOC self-assessment credit for their own presentations.

Ultimately, CME activities for which MOC self-assessment credit is awarded may be cross-referenced to the ABAI examination content outline, available on the ABAI website (www.abai.org/Overview.asp). Details of the six Core Competencies are also located on the ABAI website. The six Core Competencies are: Patient Care and Procedural Skills; Medical Knowledge; Practice-based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; and System-based Practice.

### MOC/CME Sessions:

#### Friday

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 – 3:00 pm</td>
<td>Rooms 302-304</td>
<td>Plenary Mastocytosis / Mast Cell Activation Syndrome: Demystifying MCAS – Clearing the Muddy Waters</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>Rooms 302-304</td>
<td>Symposium Childhood Asthma</td>
</tr>
</tbody>
</table>

#### Saturday

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am – 12:30 pm</td>
<td>Auditorium (2nd Floor)</td>
<td>Plenary Demystifying Early Introduction of Food to Prevent Food Allergy</td>
</tr>
<tr>
<td>3:30 – 5:30 pm</td>
<td>Auditorium (2nd Floor)</td>
<td>Symposium Sleep-disordered Breathing in Patients With Allergy and Asthma</td>
</tr>
</tbody>
</table>

#### Sunday

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 10:00 am</td>
<td>Auditorium (2nd Floor)</td>
<td>Symposium Which T2 Biologic is Best Suited for GINA 4-5 Non-responders?</td>
</tr>
<tr>
<td>4:00 – 5:00 pm</td>
<td>Room 306</td>
<td>Current Controversies Alternative Therapies in Asthma &amp; Allergy Management: Vitamin D, Fish Oil and Prebiotics/Probiotics</td>
</tr>
</tbody>
</table>

#### Monday

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 9:30 am</td>
<td>Auditorium (2nd Floor)</td>
<td>Plenary Current Approaches for Treatment of Obstructive Lung Disease</td>
</tr>
<tr>
<td>3:30 – 5:00 pm</td>
<td>Auditorium (2nd Floor)</td>
<td>Plenary What We Know: Non-infectious Complications of PID</td>
</tr>
</tbody>
</table>
For your convenience, the College will be using an online evaluation and credit claiming system for the 2017 Annual Scientific Meeting. This system will allow you to complete evaluations and claim credit for sessions attended. After completing an overall meeting evaluation, you will be able to save and/or print your certificate.

Where to access the evaluation and credit claiming system:

At the meeting:
• Hynes Convention Center:
  Level 2 (Auditorium Foyer) – CME Kiosk Stations
  Level 3 – Internet Café computers
• Personal laptops, tablets, and other mobile devices (recommended) at annualmeeting.acaai.org

After the meeting:
• Office or home computers at annualmeeting.acaai.org

How to log into the evaluation and credit claiming system:
1) Go to annualmeeting.acaai.org.
2) Click the “Claim Credit” button.
3) Log in using your last name and badge ID number.
4) Complete the evaluations and claim your credit for the sessions you attended.
5) Complete the overall meeting evaluation.
6) Save and/or print your certificate.

The evaluation and credit claiming site will remain open until December 31, 2017.

Certificates:
• CME Certificates will be awarded to physicians only, per the American Medical Association (AMA PRA Handbook, p. 8).
• Certificates of Attendance will be awarded to all non-physician participants.

Visit annualmeeting.acaai.org for additional information.

Replacement Certificates:
Once you have claimed credit for the 2017 Annual Meeting, your certificate will always be available on the College Learning Connection (education.acaai.org). Log in using your College username/password, and click “My Account,” then “My Learning” to find your learning transcript.
## Daily Events

### Wednesday, October 25th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 – 7:00 pm</td>
<td>Speaker Ready Room</td>
<td>201</td>
</tr>
<tr>
<td>3:30 – 6:30 pm</td>
<td>Registration</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
</tbody>
</table>

### Thursday, October 26th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 6:00 pm</td>
<td>Registration</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>7:00 am – 7:00 pm</td>
<td>Speaker Ready Room</td>
<td>201</td>
</tr>
<tr>
<td>7:30 am – 5:00 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 1</td>
</tr>
<tr>
<td>7:45 am – 4:30 pm</td>
<td>Board of Regents Meeting</td>
<td>Fairfax (3rd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:00 – 11:00 am</td>
<td>Moving Toward Precision Medicine in Atopic Dermatitis and Food Allergy</td>
<td>Ballroom A (3rd Floor)</td>
</tr>
<tr>
<td>9:10 – 9:25 am</td>
<td>Refreshment Break</td>
<td>Ballroom A Foyer (3rd Floor)</td>
</tr>
<tr>
<td>11:00 am – noon</td>
<td>Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>Noon – 4:00 pm</td>
<td>New Horizons in Food Allergy</td>
<td>Ballroom A (3rd Floor)</td>
</tr>
<tr>
<td>2:05 – 2:20 pm</td>
<td>Refreshment Break</td>
<td>Ballroom A Foyer (3rd Floor)</td>
</tr>
<tr>
<td>6:00 – 8:00 pm</td>
<td>Non-CME Corporate Forum: Shire</td>
<td>Liberty Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:00 – 8:00 pm</td>
<td>Non-CME Corporate Forum: Teva Respiratory</td>
<td>Independence Ballroom (2nd Floor / Sheraton)</td>
</tr>
</tbody>
</table>

### Friday, October 27th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am – 6:00 pm</td>
<td>Registration</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>6:30 am – 7:00 pm</td>
<td>Speaker Ready Room</td>
<td>201</td>
</tr>
<tr>
<td>7:00 am – 7:00 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 1</td>
</tr>
<tr>
<td>7:30 – 11:30 am</td>
<td>Annual Literature Review</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>7:45 – 8:45 am</td>
<td>SPARK Program</td>
<td>101</td>
</tr>
<tr>
<td>8:00 – 10:30 am</td>
<td>Alliance Hospitality Suite</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:00 – 11:30 am</td>
<td>Office Administrators Practice Management Course</td>
<td>311</td>
</tr>
<tr>
<td>8:00 am – noon</td>
<td>Advanced Practice Health Care Providers Course</td>
<td>312</td>
</tr>
<tr>
<td>8:30 – 9:30 am</td>
<td>Alliance: Mindfulness Meditation for Stress Relief and Relaxation</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:30 – 10:30 am</td>
<td>Breakfast Symposium: Chronic Rhinosinusitis: Translating Studies of Innate Immunity/Barrier Function and Inflammatory Endotypes to Treatment Paradigms for Patients.</td>
<td>Ballroom BC (3rd Floor)</td>
</tr>
<tr>
<td>9:15 – 9:30 am</td>
<td>Office Administrators Practice Management Course Refreshment Break</td>
<td>311 Foyer</td>
</tr>
<tr>
<td>9:30 – 9:45 am</td>
<td>Literature Review Refreshment Break</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>9:55 – 10:10 am</td>
<td>Advanced Practice Health Care Providers Course Refreshment Break</td>
<td>312 Foyer</td>
</tr>
<tr>
<td>10:15 – 11:15 am</td>
<td>Special Seminar: What’s New in Health Care</td>
<td>302-304</td>
</tr>
<tr>
<td>11:30 am – 12:30 pm</td>
<td>AACA Board of Governor’s Meeting</td>
<td>107</td>
</tr>
<tr>
<td>11:30 am – 12:45 pm</td>
<td>Literature Review Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Office Administrators Practice Management Course Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>11:30 am – 1:30 pm</td>
<td>Luncheon Symposium: Current Management of Hereditary Angioedema: Considerations to Optimize Individualized Care</td>
<td>Ballroom BC (3rd Floor)</td>
</tr>
<tr>
<td>Noon – 1:00 pm</td>
<td>Advanced Practice Health Care Providers Course Lunch Break</td>
<td>On Own</td>
</tr>
</tbody>
</table>

---

*All programs held at the Hynes Convention Center unless otherwise noted.*
**Friday, October 27th (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noon – 2:00 pm</td>
<td>Corporate Council Meeting</td>
<td>200</td>
</tr>
<tr>
<td>Noon – 2:00 pm</td>
<td>FIT Bowl Subcommittee</td>
<td>108</td>
</tr>
<tr>
<td>12:45 – 3:45 pm</td>
<td>Annual Literature Review</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td>Advanced Practice Health Care Providers Course</td>
<td>312</td>
</tr>
<tr>
<td>1:00 – 4:00 pm</td>
<td>Office Administrators Practice Management Course</td>
<td>311</td>
</tr>
<tr>
<td>1:30 – 3:00 pm</td>
<td>Plenary Session: Mastocytosis / Mast Cell Activation Syndrome: Demystifying MCAS – Clearing the Muddy Waters</td>
<td>302-304</td>
</tr>
<tr>
<td>2:00 – 3:15 pm</td>
<td>Advanced Practice Health Care Providers Interactive Concurrent Workshops</td>
<td></td>
</tr>
<tr>
<td>2:15 – 2:30 pm</td>
<td>Literature Review Refreshment Break</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>2:30 – 2:45 pm</td>
<td>Office Administrators Practice Management Course Refreshment Break</td>
<td>311 Foyer</td>
</tr>
<tr>
<td>3:00 – 4:00 pm</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>3:00 – 4:15 pm</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td>Alliance Pre-Board Meeting</td>
<td>Gardner (3rd Floor / Sheraton)</td>
</tr>
<tr>
<td>3:00 – 6:00 pm</td>
<td>College Resource Center</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>3:00 – 6:00 pm</td>
<td>Exhibit Hours</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>3:15 – 3:30 pm</td>
<td>Advanced Practice Health Care Providers Course Refreshment Break</td>
<td>103 Foyer</td>
</tr>
<tr>
<td>3:30 – 4:45 pm</td>
<td>Advanced Practice Health Care Providers Interactive Concurrent Workshops</td>
<td></td>
</tr>
<tr>
<td>3:30 – 5:30 pm</td>
<td>FIT Educational Program</td>
<td>Ballroom A (3rd Floor)</td>
</tr>
<tr>
<td>3:30 – 6:00 pm</td>
<td>E-poster Presentations</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>Symposium: Childhood Asthma</td>
<td>302-304</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>WAO / ACAAI International Forum: World Allergy Forum: State of the Art on the Management of Atopic Dermatitis</td>
<td>312</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>Town Hall Meeting Hosted by ACAAI House of Delegates</td>
<td>210</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>Workshops</td>
<td></td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>W1 PBL: Child With a Chronic Cough</td>
<td>204</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>W2 How to Improve Your Patients’ Satisfaction: Improving Practice Operations – Which Pearls Really Work</td>
<td>202</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>W3 Essentials of Sterile Compounding for the Allergy Practice</td>
<td>203</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>W4 Nuts and Bolts of Rush and Cluster Immunotherapy</td>
<td>206</td>
</tr>
</tbody>
</table>

All programs held at the Hynes Convention Center unless otherwise noted.
Daily Events

All programs held at the Hynes Convention Center unless otherwise noted.

**Friday, October 27th (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 – 6:00 pm</td>
<td>Workshops (continued)</td>
<td>Back Bay Ballroom Salon A (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>4:45 – 6:00 pm</td>
<td>Advanced Practice, Allied Health and Office Administrators</td>
<td>Back Bay Ballroom Salons BCD (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>5:30 – 6:30 pm</td>
<td>FIT General Meeting</td>
<td>Ballroom A (3rd Floor)</td>
</tr>
<tr>
<td>6:30 – 7:30 pm</td>
<td>FIT Welcome Reception</td>
<td>Back Bay Ballroom Salons BCD (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:30 – 8:30 pm</td>
<td>Non-CME Corporate Forum: Aimmune Therapeutics</td>
<td>Constitution Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:30 – 8:30 pm</td>
<td>Non-CME Corporate Forum: DBV Technologies</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:30 – 8:30 pm</td>
<td>Non-CME Corporate Forum: Teva Respiratory</td>
<td>Independence Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:30 – 9:30 pm</td>
<td>American Association of Allergists and Immunologists of Indian Origin (AAAII) Annual Meeting and Dinner Symposium</td>
<td>Liberty Ballroom (2nd Floor / Sheraton)</td>
</tr>
</tbody>
</table>

**Saturday, October 28th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 – 6:00 pm</td>
<td>Speaker Ready Room</td>
<td>201</td>
</tr>
<tr>
<td>6:30 – 7:45 am</td>
<td>Fellows-in-Training / Allergy-Immunology Program Directors’ Breakfast</td>
<td>Back Bay Ballroom Salons BCD (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:30 am – 4:00 pm</td>
<td>Registration</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>6:45 – 7:45 am</td>
<td>Committee Chair and Vice Chair Breakfast</td>
<td>200</td>
</tr>
<tr>
<td>7:30 am – 7:30 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 1</td>
</tr>
<tr>
<td>8:00 – 8:30 am</td>
<td>Opening Ceremony and Welcome Announcements</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>8:00 – 10:30 am</td>
<td>Allied Health Professionals Course</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:00 am – 12:15 pm</td>
<td>Alliance: Abstract Art with Barbara Leiner Greenstein and Mary Hughes</td>
<td>302-304</td>
</tr>
<tr>
<td>8:30 – 10:30 am</td>
<td>Plenary Session: The College: Celebrating 75 Years of Excellence</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>9:45 am – 4:00 pm</td>
<td>College Resource Center</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>9:45 am – 4:00 pm</td>
<td>Exhibit Hours</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>9:55 – 10:10 am</td>
<td>Allied Health Professionals Course Refreshment Break</td>
<td>302-304 Foyer</td>
</tr>
<tr>
<td>10:30 – 11:00 am</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>10:30 – 11:00 am</td>
<td>E-poster Presentations</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Anaphylaxis Committee</td>
<td>107</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Billing and Coding Committee</td>
<td>305</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Clinical Programs/Patient Safety and Quality Committee</td>
<td>105</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Government Relations Committee</td>
<td>301</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Payer/Managed Care Committee</td>
<td>303</td>
</tr>
</tbody>
</table>
Daily Events

Saturday, October 28th (continued)

10:30 am – noon  Therapeutic Regulations Committee ........................................................ 109
10:35 – 11:00 am Product Theater 1: CSL Behring .......................................................... Halls C & D (2nd Floor)
10:35 – 11:00 am Product Theater 2: Pfizer, Inc. .............................................................. Halls C & D (2nd Floor)
11:00 am – 12:30 pm  Plenary Session: Demystifying Early Introduction of Food to Prevent Food Allergy Auditorium (2nd Floor)
Noon – 1:30 pm  GME Program Directors’ Committee ........................................................ 101
12:15 – 1:30 pm Allied Health Professionals Course Lunch Break ........................................... On Own
12:30 – 1:30 pm Lunch Concessions / Visit Exhibits .............................................................. Halls C & D (2nd Floor)
12:30 – 1:30 pm E-poster Presentations .......................................................... Halls C & D (2nd Floor)
12:30 – 1:30 pm ABAI Forum ....................................................................................... 206
12:30 – 3:30 pm Product Theater 1: Boehringer Ingelheim Pharmaceuticals, Inc. ........... Halls C & D (2nd Floor)
12:35 – 1:30 pm Product Theater 2: AstraZeneca .............................................................. Halls C & D (2nd Floor)
1:30 – 2:30 pm  Dermatology Committee .............................................................................. 301
1:30 – 2:30 pm Food Allergy Committee .............................................................................. 109
1:30 – 2:30 pm Integrative Medicine Committee .............................................................. 105
1:30 – 2:30 pm Member Relations Committee ...................................................................... 303
1:30 – 2:30 pm Rhinitis/Sinusitis/Ocular Committee .............................................................. 305
1:30 – 3:00 pm ACAAI Foundation Board of Trustees Meeting ........................................... 107
1:30 – 3:00 pm Telehealth Task Force .................................................................................. 108
1:30 – 3:00 pm  Plenary Session: Emerging Concepts in Chronic Cough .......................... Auditorium (2nd Floor)
1:30 – 3:00 pm Allied Health Professionals Interactive Concurrent Workshops
AHP1 Beyond FEV1: Improve Your Spirometry Skills ...................................................... 102
AHP2 Immunotherapy Guideline Update: Compliance With USP 797 and Office Compounding ...................................................... 103
AHP3 Patient Education in a Fast-paced Allergy Office: Pearls From 60 Years of Practice ...................................................... 104
3:00 – 3:15 pm Allied Health Professionals Course Refreshment Break .............................. 102-104 Foyer
3:00 – 3:30 pm Ice Cream & Refreshment Break / Visit Exhibits ........................................ Halls C & D (2nd Floor)
3:00 – 3:30 pm E-poster Presentations .................................................................................. Halls C & D (2nd Floor)
3:05 – 3:30 pm Product Theater 1: Shire ............................................................................. Halls C & D (2nd Floor)
3:05 – 3:30 pm Product Theater 2: Genentech Inc. and Novartis Pharmaceuticals Corporation ...................................................... Halls C & D (2nd Floor)
3:15 – 4:45 pm Allied Health Professionals Interactive Concurrent Workshops
AHP4 Beyond FEV1: Improve Your Spirometry Skills ...................................................... 102
AHP5 Immunotherapy Guideline Update: Compliance With USP 797 and Office Compounding ...................................................... 103
AHP6 Patient Education in a Fast-paced Allergy Office: Pearls From 60 Years of Practice ...................................................... 104
3:30 – 4:30 pm Pro/Con Debate: Should FeNO Be Used in All Asthma Patients? .................. 306
3:30 – 5:30 pm Symposium: Sleep-disordered Breathing in Patients With Allergy and Asthma Auditorium (2nd Floor)
3:30 – 5:30 pm Conflict Resolution in Your GME Environment ........................................... 302-304
3:30 – 5:30 pm Workshops
W8 Living With an Itch: Approach to Diagnosis and Treatment ........................................ 206
W9 PBL: Masqueraders of Atopic Dermatitis ................................................................. 200
W10 Managing Severe Asthma in Adults and Children ...................................................... 210
W11 PBL: Burden of Non-adherence in Asthma and Role of Shared Decision-making .......... 204
W12 Advocacy Council 2017 Update on Coding: What You Need to Know ...................... 312
W13 PBL: Difficult Cases in Primary Immunodeficiency ...................................................... 300
W14 FPIES, EoE and Other GI Disorders: Gastroenterology and Allergy Viewpoint ........... 311
## Daily Events

All programs held at the Hynes Convention Center unless otherwise noted.

### Saturday, October 28th (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 – 7:00 pm</td>
<td>26th Annual FIT Bowl Competition</td>
<td>Ballroom BC (3rd Floor)</td>
</tr>
<tr>
<td>6:00 – 7:00 pm</td>
<td>Alliance International Reception</td>
<td>Constitution Ballroom Salon A (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>7:00 – 7:45 pm</td>
<td>ACAAI Awards Ceremony</td>
<td>Constitution Ballroom Salon B (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>7:45 – 9:00 pm</td>
<td>President’s Welcome Reception</td>
<td>Grand Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:30 – 10:30 pm</td>
<td>Non-CME Corporate Forum: CSL Behring</td>
<td>Back Bay Ballroom Salons AB (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:30 – 10:30 pm</td>
<td>Non-CME Corporate Forum: ALK, Inc.</td>
<td>Back Bay Ballroom Salons CD (2nd Floor / Sheraton)</td>
</tr>
</tbody>
</table>

### Sunday, October 29th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 am – 6:00 pm</td>
<td>Speaker Ready Room</td>
<td>201</td>
</tr>
<tr>
<td>6:00 am – 6:30 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 1</td>
</tr>
<tr>
<td>6:30 – 8:15 am</td>
<td>Breakfast Symposium: Anaphylaxis: Causes, Diagnosis and Management</td>
<td>Ballroom BC (3rd Floor)</td>
</tr>
<tr>
<td>6:30 – 8:30 am</td>
<td>International Committee</td>
<td>Fairfax (3rd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:30 am – 4:00 pm</td>
<td>W15 Hands-on Session in Rhinolaryngoscopy</td>
<td>207</td>
</tr>
<tr>
<td>6:45 – 7:45 am</td>
<td>Committee Meetings</td>
<td>Constitution Ballroom Salon A (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>7:00 – 8:15 am</td>
<td>Meet the Professor Breakfasts</td>
<td>101</td>
</tr>
<tr>
<td>7:30 am – noon</td>
<td>Advocacy Council Meeting</td>
<td>300</td>
</tr>
<tr>
<td>8:00 – 9:00 am</td>
<td>Exhibitors Advisory Meeting</td>
<td>205</td>
</tr>
<tr>
<td>8:00 – 10:30 am</td>
<td>Alliance Hospitality Suite</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:00 am – 12:15 pm</td>
<td>Allied Health Professionals Course</td>
<td>302-304</td>
</tr>
<tr>
<td>8:30 – 9:30 am</td>
<td>Allience: Wine Blind Tasting Experience</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>8:30 – 10:00 am</td>
<td>Plenary Session: Which T, Biologic is Best Suited for GINA 4-5 Non-responders?</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>9:00 – 10:00 am</td>
<td>Publications Committee</td>
<td>301</td>
</tr>
<tr>
<td>9:45 – 10:30 am</td>
<td>E-poster Presentations</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>9:45 am – 2:00 pm</td>
<td>College Resource Center</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>9:45 am – 2:00 pm</td>
<td>Exhibit Hours</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>9:55 – 10:10 am</td>
<td>Allied Health Professionals Course Refreshment Break</td>
<td>302-304 Foyer</td>
</tr>
<tr>
<td>10:00 – 10:30 am</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
</tbody>
</table>
### Sunday, October 29th (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:05 – 10:30 am</td>
<td>Product Theater 1: Sanofi Genzyme and Regeneron Pharmaceuticals</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>10:30 – 11:00 am</td>
<td>Plenary Session: Bela Schick Lecture</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Respiratory and Sleep-related Breathing Disorders Committee</td>
<td>Room 303</td>
</tr>
<tr>
<td>11:00 am – 12:30 pm</td>
<td>Plenary Session: Regulatory Changes That Affect Allergists: USP 797; FDA Guidance, Etc. – What You Need to Do</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>11:30 am – 1:30 pm</td>
<td>Annals Editorial Board Meeting</td>
<td>Room 102</td>
</tr>
<tr>
<td>Noon – 2:30 pm</td>
<td>Alliance Annual Business Meeting and Brunch</td>
<td>Off-Site (Top of the Hub)</td>
</tr>
<tr>
<td>12:30 – 1:30 pm</td>
<td>Lunch Concessions / Visit Exhibits</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>12:30 – 1:30 pm</td>
<td>2018 Annual Meeting Program Committee</td>
<td>Room 103</td>
</tr>
<tr>
<td>12:30 – 1:30 pm</td>
<td>Past Presidents’ Committee</td>
<td>Room 205</td>
</tr>
<tr>
<td>12:30 – 1:30 pm</td>
<td>Fellows-in-Training / Allergy-Immunology Program Directors’ Luncheon</td>
<td>Back Bay Ballroom Salons BCD (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>12:30 – 1:45 pm</td>
<td>E-poster Presentations</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>12:35 – 1:30 pm</td>
<td>Product Theater 1: Sanofi Genzyme and Regeneron Pharmaceuticals</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>12:35 – 1:30 pm</td>
<td>Product Theater 2: Circassia Pharmaceuticals, Inc.</td>
<td>Halls C &amp; D (2nd Floor)</td>
</tr>
<tr>
<td>1:30 – 3:30 pm</td>
<td>Symposium: Can We Predict Severity Risk for Food Allergy?</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>1:30 – 3:30 pm</td>
<td>Oral Abstract Session A: Adverse Drug Reactions, Insect Reactions, Anaphylaxis</td>
<td>Room 306-304</td>
</tr>
<tr>
<td>1:30 – 3:30 pm</td>
<td>Oral Abstract Session B: Allergy Diagnostics, Immunotherapy and Angioedema, Urticaria</td>
<td>Room 306</td>
</tr>
<tr>
<td>1:30 – 3:30 pm</td>
<td>Oral Abstract Session C: Asthma, Other Lower Airway Disorders</td>
<td>Ballroom A (3rd Floor)</td>
</tr>
<tr>
<td>3:30 – 4:00 pm</td>
<td>Refreshment Break</td>
<td>Level 2 &amp; 3 Lobbies</td>
</tr>
<tr>
<td>4:00 – 5:00 pm</td>
<td>Symposium: The Asthmatic Who Does Not Qualify for a T&lt;sub&gt;2&lt;/sub&gt; Biologic: What Is Next?</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>4:00 – 6:00 pm</td>
<td>Workshops</td>
<td>Room 202, 203, 206, 300-304</td>
</tr>
<tr>
<td>6:30 – 8:30 pm</td>
<td>Non-CME Corporate Forum: Shire</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:45 – 7:45 pm</td>
<td>Fundraiser Reception</td>
<td>Grand Ballroom Foyer (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>7:45 – 10:30 pm</td>
<td>Fundraiser Dinner &amp; Entertainment</td>
<td>Grand Ballroom (2nd Floor / Sheraton)</td>
</tr>
</tbody>
</table>
## Daily Events

**Monday, October 30th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 am – 5:00 pm</td>
<td>Speaker Ready Room</td>
<td>201</td>
</tr>
<tr>
<td>6:00 am – 5:30 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 1</td>
</tr>
<tr>
<td>6:30 am – 4:00 pm</td>
<td>Registration</td>
<td>Hall C Lobby (2nd Floor)</td>
</tr>
<tr>
<td>6:30 – 7:45 am</td>
<td>Meet the Professor Breakfasts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M1  Phenotype-based Approach for the Management of Preschool Episodic Wheezing and Asthma</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>M2  Immunodeficiency in Patients With COPD</td>
<td>102</td>
</tr>
<tr>
<td></td>
<td>M3  It Must Be Immunodeficiency, but the Immunoglobulins Are Normal!</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>M4  How to Deal With Orthopedic Implants</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>M5  Rush/Cluster IT: How to Implement in Your Practice</td>
<td>107</td>
</tr>
<tr>
<td></td>
<td>M6  Drug Allergy for the Practicing Allergist</td>
<td>108</td>
</tr>
<tr>
<td></td>
<td>M7  Eosinophilic Gastrointestinal Disease</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td>M8  How to Start a Center of Excellence: The Cough Center Experience</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>M9  Mast Cell Activation Syndrome</td>
<td>111</td>
</tr>
<tr>
<td></td>
<td>M10 Eosinophilic Conditions and the Allergist</td>
<td>200</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td>Plenary Session: Current Approaches for Treatment of Obstructive Lung Disease</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>8:00 – 10:30 am</td>
<td>Alliance Hospitality Suite</td>
<td>Republic Ballroom (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>9:30 – 10:30 am</td>
<td>Annual Business Meeting</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>10:30 am – noon</td>
<td>Alliance Post-Board Meeting</td>
<td>Fairfax (3rd Floor / Sheraton)</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>Symposium: Immunology of Eczema: How to Best Address the Itch That Rashes Cause</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>Accreditation and Certification Committee</td>
<td>205</td>
</tr>
<tr>
<td>12:30 – 1:00 pm</td>
<td>Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>1:00 – 3:00 pm</td>
<td>Oral Abstract Session A: Clinical Immunology, Immunodeficiency and Other</td>
<td>Auditorium (2nd Floor)</td>
</tr>
<tr>
<td>1:00 – 3:00 pm</td>
<td>Oral Abstract Session B: Food Allergy</td>
<td>302-304</td>
</tr>
<tr>
<td>1:00 – 3:15 pm</td>
<td>Oral Abstract Session C: Pharmacology/Pharmacotherapeutics, Rhinitis and Other Upper Airway Disorders, and Skin Disorders</td>
<td>Ballroom A (3rd Floor)</td>
</tr>
<tr>
<td>1:00 – 3:00 pm</td>
<td>Workshops</td>
<td></td>
</tr>
<tr>
<td></td>
<td>W27  Immunotherapy 2017: SCIT, SLIT and More!</td>
<td>202</td>
</tr>
<tr>
<td></td>
<td>W28  Treating Asthma and Allergic Disease in the Elderly Utilizing Precision Medicine</td>
<td>203</td>
</tr>
<tr>
<td></td>
<td>W29  Food Challenges in Practice: Safe and Simplified</td>
<td>206</td>
</tr>
<tr>
<td></td>
<td>W30  The Spectrum of COPD: The Disease and Comorbidities</td>
<td>210</td>
</tr>
<tr>
<td></td>
<td>W31  Biologics in Atopic Dermatitis</td>
<td>310</td>
</tr>
<tr>
<td></td>
<td>W32  Anaphylaxis: A Spectrum of Cases</td>
<td>311</td>
</tr>
<tr>
<td></td>
<td>W33  Facial Swelling: Lips &amp; More</td>
<td>312</td>
</tr>
<tr>
<td></td>
<td>W34  Insect Allergy Update in Today’s Complicated Beehive</td>
<td>313</td>
</tr>
<tr>
<td>3:00 – 3:30 pm</td>
<td>Refreshment Break</td>
<td>Auditorium Foyer (2nd Floor)</td>
</tr>
<tr>
<td>3:30 – 5:00 pm</td>
<td>Plenary Session: What We Know: Non-infectious Complications of PID</td>
<td>Auditorium (2nd Floor)</td>
</tr>
</tbody>
</table>

All programs held at the Hynes Convention Center unless otherwise noted.
## Committee Meetings

*All programs held at the Hynes Convention Center unless otherwise noted.*

### HOURS

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noon – 2:00 pm</td>
<td>FIT Bowl Subcommittee</td>
<td>108</td>
</tr>
<tr>
<td>3:00 – 4:15 pm</td>
<td>Annual Meeting Program Subcommittees</td>
<td>207</td>
</tr>
</tbody>
</table>

### Friday, October 27th

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 – 7:45 am</td>
<td>Committee Chair and Vice Chair Breakfast*</td>
<td>200</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Anaphylaxis Committee</td>
<td>107</td>
</tr>
<tr>
<td></td>
<td>Billing and Coding Committee</td>
<td>305</td>
</tr>
<tr>
<td></td>
<td>Clinical Programs/Patient Safety and Quality Committee</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>Government Relations Committee</td>
<td>301</td>
</tr>
<tr>
<td></td>
<td>Payer/Managed Care Committee</td>
<td>303</td>
</tr>
<tr>
<td>10:30 am – noon</td>
<td>Therapeutic Regulations Committee</td>
<td>109</td>
</tr>
<tr>
<td>Noon – 1:30 pm</td>
<td>GME Program Directors' Committee</td>
<td>101</td>
</tr>
<tr>
<td>1:30 – 2:30 pm</td>
<td>Dermatology Committee</td>
<td>301</td>
</tr>
<tr>
<td></td>
<td>Food Allergy Committee</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td>Integrative Medicine Committee</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>Member Relations Committee</td>
<td>303</td>
</tr>
<tr>
<td></td>
<td>Rhinitis/Sinusitis/Ocular Committee</td>
<td>305</td>
</tr>
<tr>
<td>1:30 – 3:00 pm</td>
<td>ACAAI Foundation Board of Trustees</td>
<td>107</td>
</tr>
<tr>
<td></td>
<td>Telehealth Task Force</td>
<td>108</td>
</tr>
</tbody>
</table>

### Saturday, October 28th

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 – 7:45 am</td>
<td>International Committee*</td>
<td>Fairfax (3rd Floor / Sheraton)</td>
</tr>
<tr>
<td>6:45 – 7:45 am</td>
<td>Allied Health Professionals Committee*</td>
<td>Constitution Ballroom Salon A (2nd Floor / Sheraton)</td>
</tr>
<tr>
<td>9:00 – 10:00 am</td>
<td>Publications Committee</td>
<td>301</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Respiratory and Sleep-related Breathing Disorders Committee</td>
<td>303</td>
</tr>
<tr>
<td>11:30 am – 1:30 pm</td>
<td>Annals Editorial Board</td>
<td>102</td>
</tr>
<tr>
<td>12:30 – 1:30 pm</td>
<td>2018 Annual Meeting Program Committee</td>
<td>103</td>
</tr>
<tr>
<td></td>
<td>Past Presidents' Committee</td>
<td>205</td>
</tr>
</tbody>
</table>

### Sunday, October 29th

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>Accreditation and Certification Committee</td>
<td>205</td>
</tr>
</tbody>
</table>

### Monday, October 30th

*A complimentary breakfast will be served at these meetings.*
Each year, the American College of Allergy, Asthma & Immunology presents several named lectures during the Annual Scientific Meeting. The “Bela Schick,” “John P. McGovern” and “Bernard Berman” lectures are presented annually. The “Daniel J. Goodman” and “Lester Mittelstaedt” lectures are presented in alternate years and the “Luisa Businco Lecture” is presented during the International Food Allergy Symposium.

The allergists selected to present named lectures embody the high standards and achievements of the physicians for whom the lectures are named. The College is proud to present the following named lectures at its 2017 Annual Scientific Meeting. All lectures will be held at the Hynes Convention Center.

**Bernard Berman Memorial Lecture**

**The College and the Future of Health Care**
Saturday, October 28, 9:35 – 10:15 am
Susan Rudd Bailey, MD, FACAAI

The annual Bernard Berman Memorial Lecture recognizes a kind, caring clinician-allergist with interests in the various aspects of allergy and a passion for teaching. The Memorial Lecture is a testament to Dr. Berman’s caring nature, unique skills as a gifted teacher and unselfish compassion for his patients. He was a past president of the College and one of the founders of the American Board of Allergy and Immunology.

**Bela Schick Lecture**

**The Future of Medicine and Allergy – Is It FINALLY a Brave New World?**
Sunday, October 29, 10:30 – 11:00 am
J. Allen Meadows, MD, FACAAI

The annual Bela Schick Lecture is named in honor of one of medicine’s most respected scientists. Bela Schick was born in Hungary and attended medical school in Austria. After serving as an Extraordinary Professor of Children’s Diseases at the University of Vienna, he immigrated to the United States in 1923. He was a pediatrician at Mt. Sinai in New York for many years, loved by his patients and respected by his fellows. Dr. Schick is best known for his work with Clemens von Pirquet on anaphylaxis and for the test he developed to assess immunity in diphtheria.

**Lester Mittelstaedt Lecture**

**The Evolution of the Child “At Risk” for the Development of Food Allergy**
Sunday, October 29, 2:35 – 3:05 pm
David M. Fleischer, MD, FACAAI

The biennial Mittelstaedt Lecture recognizes outstanding contributions in the specialty of allergy, asthma and immunology. A leader in the field of allergy and immunology, Dr. Mittelstaedt played a key role in gaining the certification of qualified allergists. Known for his educational programs, Dr. Mittelstaedt is a past president of the American Association for Clinical Immunology & Allergy (AACIA).

**John P. McGovern Lecture**

**GINA 2017: How Will This Change My Practice?**
Monday, October 30, 8:05 – 8:30 am
Paul O’Byrne, MD

This annual lectureship is supported by a grant from the John P. McGovern Foundation. The Foundation sought to establish a lectureship that would recognize eminent physicians and scientists, both clinicians and researchers, who have contributed meritoriously to the advancement of knowledge in the specialty of allergy-immunology. Lecturers receive the prized John P. McGovern medallion, created especially for the lectureship. Dr. McGovern was a past president of the College and a strong leader in the field of patient care.
To make it easier for participants to identify Annual Meeting sessions that are relevant to their practice, the College has identified 9 critical areas for allergy and immunology. These 9 areas make up the Annual Meeting Track System.

### Tracks

- **BSL** Bela Schick Lecture
- **CC** Current Controversies
- **MTP** Meet the Professor Breakfast
- **PCD** Pro/Con Debate
- **PLN** Plenary
- **SEM** Seminar
- **SYM** Symposium
- **THR** Thursday Program
- **TPD** Training Program Directors
- **WAO** World Allergy Organization Forum
- **WKS** Workshop

### Asthma and Respiratory/Sleep Disorders

<table>
<thead>
<tr>
<th>Session Title</th>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternative Therapies in Asthma &amp; Allergy Management: Vitamin D, Fish Oil and Prebiotics/Probiotics</td>
<td>CC</td>
<td>63</td>
</tr>
<tr>
<td>The Asthmatic Who Does Not Qualify for a T_{h} Biologic: What Is Next?</td>
<td>SYM</td>
<td>63</td>
</tr>
<tr>
<td>Breaking News: Assessing Fracture Risk and Preventing Fractures in the Steroid-treated Patient</td>
<td>MTP</td>
<td>55</td>
</tr>
<tr>
<td>Childhood Asthma</td>
<td>SYM</td>
<td>47</td>
</tr>
<tr>
<td>Current Approaches for Treatment of Obstructive Lung Disease</td>
<td>PLN</td>
<td>66</td>
</tr>
<tr>
<td>Emerging Concepts in Chronic Cough</td>
<td>PLN</td>
<td>52</td>
</tr>
<tr>
<td>Immunodeficiency in Patients With COPD</td>
<td>MTP</td>
<td>64</td>
</tr>
<tr>
<td>Managing Severe Asthma in Adults and Children</td>
<td>WKS</td>
<td>35</td>
</tr>
<tr>
<td>New Approaches to Chronic Cough in Children and Adults</td>
<td>MTP</td>
<td>55</td>
</tr>
<tr>
<td>PBL: Burden of Non-adherence in Asthma and Role of Shared Decision-making</td>
<td>WKS</td>
<td>35</td>
</tr>
<tr>
<td>PBL: Child With a Chronic Cough</td>
<td>WKS</td>
<td>33</td>
</tr>
<tr>
<td>Phenotype-based Approach for the Management of Preschool Episodic Wheezing and Asthma</td>
<td>MTP</td>
<td>64</td>
</tr>
<tr>
<td>Severe Asthma: Where Biologics Fit</td>
<td>MTP</td>
<td>55</td>
</tr>
<tr>
<td>Should FeNO Be Used in All Asthma Patients?</td>
<td>PCD</td>
<td>52</td>
</tr>
<tr>
<td>Sleep-disordered Breathing in Patients With Allergy and Asthma</td>
<td>SYM</td>
<td>53</td>
</tr>
<tr>
<td>The Spectrum of COPD: The Disease and Comorbidities</td>
<td>WKS</td>
<td>40</td>
</tr>
<tr>
<td>Treating Asthma and Allergic Diseases in the Elderly Utilizing Precision Medicine</td>
<td>WKS</td>
<td>39</td>
</tr>
<tr>
<td>Which T_{h} Biologic Is Best Suited for GINA 4-5 Non-responders?</td>
<td>SYM</td>
<td>57</td>
</tr>
</tbody>
</table>
### Clinical Immunology and Autoimmune and Biologicals

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Great Masqueraders: Alternate Presentations of Primary Immunodeficiencies</td>
<td>WKS 37</td>
</tr>
<tr>
<td>Hypereosinophilic Syndrome: Evaluation and Management</td>
<td>MTP 55</td>
</tr>
<tr>
<td>Immunology of Eczema: How to Best Address the Itch That Rashes Cause</td>
<td>SYM 67</td>
</tr>
<tr>
<td>It Must Be Immunodeficiency, but the Immunoglobulins Are Normal!</td>
<td>MTP 64</td>
</tr>
<tr>
<td>Mastocytosis/Mast Cell Activation Syndrome: Demystifying MCAS – Clearing the Muddy Waters</td>
<td>PLN 47</td>
</tr>
<tr>
<td>PBL: Difficult Cases in Primary Immunodeficiency</td>
<td>WKS 36</td>
</tr>
<tr>
<td>What We Know: Non-infectious Complications of PID</td>
<td>PLN 71</td>
</tr>
<tr>
<td>Workup of the Patient With Recurrent Infections: Laboratory Evaluation of Immunodeficiency and What to Do With Normal IgG Levels</td>
<td>MTP 55</td>
</tr>
<tr>
<td>World Allergy Forum: State of the Art on the Management of Atopic Dermatitis</td>
<td>WAO 48</td>
</tr>
</tbody>
</table>

### Dermatology

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologics in Atopic Dermatitis</td>
<td>WKS 40</td>
</tr>
<tr>
<td>Current Management of Hereditary Angioedema: Considerations to Optimize Individualized Care</td>
<td>SYM 46</td>
</tr>
<tr>
<td>Diagnostic Problems in Dermatology: Bring a Case and Ask the Experts</td>
<td>MTP 55</td>
</tr>
<tr>
<td>Facial Swelling: Lips and More</td>
<td>WKS 41</td>
</tr>
<tr>
<td>How to Deal With Orthopedic Implants</td>
<td>MTP 64</td>
</tr>
<tr>
<td>Living With an Itch: Approach to Diagnosis and Treatment</td>
<td>WKS 34</td>
</tr>
<tr>
<td>Office Procedures for Allergic Skin Diseases</td>
<td>WKS 34</td>
</tr>
<tr>
<td>PBL: Detailed Workup and Treatment of Chronic Urticaria</td>
<td>WKS 39</td>
</tr>
<tr>
<td>PBL: Masqueraders of Atopic Dermatitis</td>
<td>WKS 35</td>
</tr>
<tr>
<td>Skin Biopsy and Patch Testing for the Allergist: How to Perform and Interpret</td>
<td>WKS 37</td>
</tr>
<tr>
<td>Thursday Morning Program: Moving Toward Precision Medicine in Atopic Dermatitis and Food Allergy</td>
<td>THR 42</td>
</tr>
</tbody>
</table>

### Environmental and Integrative Medicine

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental Allergy: Indoor/Outdoor</td>
<td>WKS 38</td>
</tr>
<tr>
<td>Integrative Allergy: Tools for Taking an Integrative Medicine History and Resources</td>
<td>MTP 56</td>
</tr>
<tr>
<td>Marijuana, Hookah, Vaping and Asthmatics</td>
<td>MTP 56</td>
</tr>
</tbody>
</table>
### Food & Drug Allergy and GI Disorders

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Can We Predict Severity Risk for Food Allergy?</td>
<td>SYM 59</td>
</tr>
<tr>
<td>Demystifying Early Introduction of Food to Prevent Food Allergy</td>
<td>PLN 51</td>
</tr>
<tr>
<td>Drug Allergy for the Practicing Allergist</td>
<td>MTP 65</td>
</tr>
<tr>
<td>Drugs Gone Wild: Cutaneous Manifestations of Drug Allergy</td>
<td>WKS 37</td>
</tr>
<tr>
<td>Eosinophilic Conditions and the Allergist</td>
<td>MTP 65</td>
</tr>
<tr>
<td>Eosinophilic Gastrointestinal Disease</td>
<td>MTP 65</td>
</tr>
<tr>
<td>Food Challenges in Practice: Safe and Simplified</td>
<td>WKS 40</td>
</tr>
<tr>
<td>FPIES, EoE and Other GI Disorders: Gastroenterology and Allergy Viewpoint</td>
<td>WKS 36</td>
</tr>
<tr>
<td>Going Nuts: The Complexities of Diagnosis and Management in Nut Allergy Patients</td>
<td>WKS 34</td>
</tr>
<tr>
<td>PBL: A Patient With Severe Eczema?</td>
<td>MTP 56</td>
</tr>
<tr>
<td>Thursday Afternoon Session: New Horizons in Food Allergy</td>
<td>THR 43</td>
</tr>
</tbody>
</table>

### Immunotherapy and Diagnostics

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunotherapy 2017: SCIT, SLIT and More!</td>
<td>WKS 39</td>
</tr>
<tr>
<td>Nuts and Bolts of Rush and Cluster Immunotherapy</td>
<td>WKS 33</td>
</tr>
<tr>
<td>Rush/Cluster IT: How to Implement in Your Practice</td>
<td>MTP 64</td>
</tr>
</tbody>
</table>

### Population Health and Infectious Diseases / International Travel

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hot Topics in Pediatric Allergy: AAP/SOAI</td>
<td>WKS 39</td>
</tr>
<tr>
<td>Smoking Cessation in an Allergy Practice: What’s New and How To</td>
<td>WKS 37</td>
</tr>
</tbody>
</table>

### Practice Management / Professional Issues

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy Council 2017 Update on Coding: What You Need to Know</td>
<td>WKS 35</td>
</tr>
<tr>
<td>Advocacy Council Update on Legal/Regulatory Issues: The Alphabet Soup (USP, DASH, MACRA, MIPS and APMs)</td>
<td>WKS 38</td>
</tr>
<tr>
<td>Bela Schick Lecture: The Future of Medicine and Allergy – Is It FINALLY a Brave New World?</td>
<td>BSL 58</td>
</tr>
<tr>
<td>Competing With Dr. Google: How Allergists Can Combat Misinformation &amp; Misperceptions</td>
<td>MTP 56</td>
</tr>
<tr>
<td>Conflict Resolution in Your GME Environment</td>
<td>TPD 53</td>
</tr>
<tr>
<td>Essentials in Becoming a Leader in Your Office</td>
<td>WKS 38</td>
</tr>
</tbody>
</table>
### Practice Management / Professional Issues (continued)

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Essentials of Sterile Compounding for the Allergy Practice</td>
<td>WKS 33</td>
</tr>
<tr>
<td>How to Improve Your Patients’ Satisfaction: Improving Practice Operations – Which Pearls Really Work</td>
<td>WKS 33</td>
</tr>
<tr>
<td>How to Start a Center of Excellence: The Cough Center Experience</td>
<td>MTP 65</td>
</tr>
<tr>
<td>Regulatory Changes That Affect Allergists: USP 797; FDA Guidance, Etc. – What You Need to Do</td>
<td>PLN 58</td>
</tr>
<tr>
<td>Special Seminar: What’s New in Health Care</td>
<td>SEM 45</td>
</tr>
<tr>
<td>Telehealth/Telemedicine</td>
<td>WKS 36</td>
</tr>
</tbody>
</table>

### Rhinitis / Sinusitis / Ocular and Anaphylaxis

<table>
<thead>
<tr>
<th>Session Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis: A Spectrum of Cases</td>
<td>WKS 40</td>
</tr>
<tr>
<td>Anaphylaxis: Causes, Diagnosis and Management</td>
<td>SYM 57</td>
</tr>
<tr>
<td>Chronic Rhinosinusitis: Translating Studies of Innate Immunity/Barrier Function and Inflammatory Endotypes to Treatment Paradigms for Patients</td>
<td>SYM 45</td>
</tr>
<tr>
<td>Hands-on Session in Rhinolaryngoscopy</td>
<td>WKS 36</td>
</tr>
<tr>
<td>Hands-on Session in Rhinolaryngoscopy – Intermediate/Advanced</td>
<td>WKS 38</td>
</tr>
<tr>
<td>Insect Allergy Update in Today’s Complicated Beehive</td>
<td>WKS 41</td>
</tr>
<tr>
<td>Introductory Course in Rhinolaryngoscopy</td>
<td>WKS 34</td>
</tr>
<tr>
<td>Mast Cell Activation Syndrome</td>
<td>MTP 65</td>
</tr>
</tbody>
</table>
Friday, October 27

W1  PBL: Child With a Chronic Cough
4:00 – 6:00 pm
Fee: $80 (FITs: $35). Limit 25.
Ray S. Davis, MD, FACAAI and
Kevin R. Murphy, MD, FACAAI (SC)
This is one of the most common complaints in an allergist’s office. The case will engage the audience in a real-time needs assessment. Evaluation will focus on cutting-edge diagnostics, including FeNO.

Objectives: Discuss the differential diagnosis of one of the most common complaints to an allergist’s office – chronic cough; and understand an appropriate diagnostic evaluation for a child with a chronic cough.

Track: Asthma and Respiratory/Sleep Disorders; Rhinitis/Sinusitis/Ocular and Anaphylaxis

W2  How to Improve Your Patients’ Satisfaction: Improving Practice Operations – Which Pearls Really Work
4:00 – 6:00 pm
Fee: $80 (FITs: $35). Limit 50.
Stanley Fineman, MD, MBA, FACAAI and
Kay Tyler, BS, BA, MBA
At this session, we plan to discuss practice management techniques that help improve patients’ satisfaction, including improved patient communication with staff and physicians and monitoring patient feedback with satisfaction surveys. We will also present techniques that help improve practice operations, including customer service training, office flow and HR hiring and management.

Objectives: Institute LEAN for allergists in their practice; discuss use of technology in practice to help reduce no-shows; and discuss importance of staff training.

Track: Practice Management/Professional Issues

W3  Essentials of Sterile Compounding for the Allergy Practice
4:00 – 6:00 pm
Fee: $80 (FITs: $35). Limit 50.
Bryan L. Martin, DO, FACAAI and
Michael R. Nelson, MD, FACAAI
Allergists who compound immunotherapy extracts must comply with applicable current guidelines (such as USP 797) mandated by national legislation. This session walks participants step-by-step through applicable guidelines, office requirements, techniques and the media fill test and quiz to achieve compliance.

Objectives: Describe the requirements of USP 797 and relevant guidelines for allergen extract compounding; and demonstrate the technique of sterile compounding required in office-based practice.

Track: Practice Management/Professional Issues

W4  Nuts and Bolts of Rush and Cluster Immunotherapy
4:00 – 6:00 pm
Fee: $80 (FITs: $35). Limit 50.
David B. Engler, MD, FACAAI and
Mike Tankersley, MD, FACAAI
Immunotherapy (IT) is highly effective in certain allergic ailments, but many patients have difficulty building up to the high, effective doses necessary to achieve relief; rush and cluster IT allow for accelerated forms of building up the dose.

Objectives: Demonstrate competence in allergen selection and administration in successful rush and cluster immunotherapy regimens; and identify patient indications, immunologic mechanisms and special considerations related to rush and cluster immunotherapy delivery.

Track: Immunotherapy and Diagnostics; Practice Management/Professional Issues
Workshops

Separate Registration Fee • Admission by Ticket Only
All Workshops Will Be Held at the Hynes Convention Center

**Friday, October 27 (continued)**

**W5** Office Procedures for Allergic Skin Diseases
4:00 – 6:00 pm
Room 310
Luz S. Fonacier, MD, FACAAI and Peter A. Lio, MD

Atopic dermatitis and contact dermatitis are allergic skin diseases often seen in the allergist’s practice. There are office procedures that can be done for dermatologic allergic disorders, and patch testing is increasingly used in the allergist’s office. This workshop will cover clinical evaluation of disease severity in patients with atopic dermatitis, response to treatment for atopic dermatitis and use of wet wraps, bleach bath, KOH smear and Wood’s lamp. We will also discuss the indication and interpretation of the standard patch testing. Cases will be presented to demonstrate and self-assess skill at the interpretation of patch tests. Hands-on patch testing will be demonstrated.

**Objectives:** Describe a physician-friendly method of determining severity and response to treatment for atopic dermatitis and use of wet wraps, bleach bath, KOH smear and Wood’s lamp; demonstrate the application of epicutaneous patch test; and discuss the indications and interpretation of the standard patch testing.

**Track:** Dermatology

**W6** Going Nuts: The Complexities of Diagnosis and Management in Nut Allergy Patients
4:00 – 6:00 pm
Room 313
Matthew Greenhawt, MD, MSc, MBA, FACAAI and David R. Stukus, MD, FACAAI

This will be an interactive, case-based session that will review the utility of SPT, IgE, component testing, OFCs and interpretation of results with consideration of cross-reactivities and co-sensitization. We will also discuss tailoring management to individual needs and desires, such as when general avoidance versus targeted avoidance would be beneficial.

**Objectives:** Describe the utility of various diagnostic tests for nut allergies; discuss interpretation of test results given cross-reactivities and co-sensitizations; and explain individualized management strategies to meet the needs and desires of patients and their families.

**Track:** Food & Drug Allergy and GI Disorders

**Saturday, October 28**

**W7** Introductory Course in Rhinolaryngoscopy
6:00 – 8:00 am
Room 210
Jerald W. Koepeke, MD, FACAAI and Seong H. Cho, MD, FACAAI

This workshop will provide attendees with the ability to discuss the surgical anatomy of the upper airway, including the nasal cavity, pharynx and larynx; identify normal and abnormal anatomy, as well as disease presentations and post-operative changes found with endoscopic examination of the upper airway; and identify the indications for, and the use of, the fiber-optic rhinoscope in the allergist’s office.

**Objectives:** Describe the major anatomical findings in the upper airway; identify normal and abnormal anatomy, disease presentations and post-op findings; and identify indications for use of the rhinoscope in the allergist’s office.

**Track:** Rhinitis/Sinusitis/Ocular and Anaphylaxis

**W8** Living With an Itch: Approach to Diagnosis and Treatment
3:30 – 5:30 pm
Room 206
Peter A. Lio, MD and Gil Yosipovitch, MD

This presentation will include discussion of the causes of pruritis with and without a rash, systemic diseases that need to be considered, and the use of systemic agents, phototherapy, and “alternative” and “natural” medications for itch.

**Objectives:** Develop strategies for allergist and dermatologist co-management of patients with itch; and outline an evidence-based therapeutic ladder for management of itch.

**Track:** Dermatology
### Saturday, October 28 (continued)

**W9  PBL: Masqueraders of Atopic Dermatitis**
- **Time:** 3:30 – 5:30 pm
- **Room:** 200
- **Fee:** $80 (FITs: $35). Limit 25.
- **Speakers:** Ray S. Davis, MD, FACAAI and Howard I. Maibach, MD

A problem-based learning (PBL) interactive case discussion will challenge the participants to discuss a case of a chronic rash, followed by an expert lecture, with photos of masqueraders of atopic dermatitis and the latest cutting-edge therapy.

**Objectives:** Interactively discuss the differential diagnosis and proposed therapy for a challenging case of a patient with a chronic rash; and view multiple pictures of various masqueraders of atopic dermatitis and review the best practices for therapy.

**Track:** Dermatology

**W10  Managing Severe Asthma in Adults and Children**
- **Time:** 3:30 – 5:30 pm
- **Room:** 210
- **Fee:** $80 (FITs: $35). Limit 50.
- **Speakers:** Leonard B. Bacharier, MD, FACAAI and David M. Lang, MD, FACAAI

This workshop will examine newer therapies and their appropriate use in treating severe asthma in adults and children. We will look at the endotypic and phenotypic characterization of severe asthma in children and adults and discuss appropriate therapy based on these classifications. Newer administration techniques, including intravenous treatment, will also be covered.

**Objectives:** Recognize how basic science and clinical research has identified distinct pathophysiology endotypes in severe asthma; describe which patients are candidates for therapy with new biologic agents approved for use in asthma; and discuss differences in presentation and treatment of children and adults with severe asthma.

**Track:** Asthma and Respiratory/Sleep Disorders

**W11  PBL: Burden of Non-adherence in Asthma and Role of Shared Decision-making**
- **Time:** 3:30 – 5:30 pm
- **Room:** 204
- **Fee:** $80 (FITs: $35). Limit 25.
- **Speakers:** Don A. Bukstein, MD, FACAAI and Gary Steven, MD, FACAAI

The interactivity of the PBL case during the first hour allows for everyone to pick up pearls from each other on non-adherence. Content experts will summarize their expert knowledge with regard to the case using references and reinforce the most current guidelines/practice parameters for use in shared decision-making.

**Objectives:** Examine the factors that contribute to non-adherence; discuss the burdens of non-adherence in children and adults; and recognize the role of shared decision-making in improving non-adherence.

**Track:** Asthma and Respiratory/Sleep Disorders; Practice Management/Professional Issues

**Supported by an independent educational grant from GlaxoSmithKline**

**W12  Advocacy Council 2017 Update on Coding: What You Need to Know**
- **Time:** 3:30 – 5:30 pm
- **Room:** 312
- **Fee:** $80 (FITs: $35). Limit 50.
- **Speakers:** Gary N. Gross, MD, FACAAI and Stephen A. Imbeau, MD, FACAAI

Coding is complex and errors can lead to underpayments or, worse, penalties. The Advocacy Council of the ACAAI team will review coding issues important to allergists.

**Objectives:** Review changes that have taken place and those pending for 2018; and learn how to code correctly and earn payments to which you are entitled.

**Track:** Practice Management/Professional Issues

---

**Separate Registration Fee • Admission by Ticket Only**

All Workshops Will Be Held at the Hynes Convention Center
Workshops

Saturday, October 28 (continued)

W13  PBL: Difficult Cases in Primary Immunodeficiency
3:30 – 5:30 pm  Room 300
Fee: $80 (FITs: $35). Limit 25.
Lisa J. Kobrynski, MD, MPH, FACAAI and
John M. Routes, MD, FACAAI

Primary immunodeficiencies may present with more than frequent infections, thus presenting a diagnostic dilemma for clinicians. We will discuss cases of primary immunodeficiency with various presentations. In addition, patients frequently experience complications, such as autoimmunity. We will highlight some management strategies for some of these complications.

Objectives: Discuss the evaluation of a complex patient with suspected immunodeficiency; and manage common complications of primary immunodeficiency diseases.

Track: Clinical Immunology and Autoimmune and Biologicals

W14  FPIES, EoE and Other GI Disorders:
Gastroenterology and Allergy Viewpoint
3:30 – 5:30 pm  Room 311
Fee: $80 (FITs: $35). Limit 50.
Jen Lightdale, MD and
Terri Brown-Whitehorn, MD

This session will review common non-IgE-mediated food allergen conditions with gastrointestinal manifestations, including food protein induced enterocolitis syndrome (FPIES) and eosinophilic esophagitis (EoE).

Objectives: Discuss typical gastrointestinal presentations of FPIES; review international consensus guidelines for diagnosis and management of FPIES; and describe current evidence-based approaches to the diagnosis and management of EoE.

Track: Food & Drug Allergy and GI Disorders

Sunday, October 29

W15  Hands-on Session in Rhinolaryngoscopy
6:30 – 8:30 am  Room 207
Fee: $150 (FITs: $50). Limit 30.
Jerald W. Koepke, MD, FACAAI;
Seong H. Cho, MD, FACAAI;
Kevin R. Murphy, MD, FACAAI (SC);
Grant C. Olson, MD, FACAAI;
Donald W. Pulver, MD, FACAAI and
C. Ross Westley, MD, FACAAI

This workshop will provide attendees with the ability to describe the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope; describe variations of normal seen when participants examine one another in this hands-on session; and demonstrate the proper handling and initial skills needed to perform a comprehensive upper airway examination with a fiber-optic endoscope.

Objectives: Describe the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope; describe variations of normal seen in this hands-on session; and demonstrate the proper handling and initial skills needed to perform a comprehensive upper airway examination with a fiber-optic endoscope.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

Supported by KARL STORZ Endoscopy-America, Inc.

through an independent educational grant consisting of loaned durable equipment

W16  Telehealth/Telemedicine
4:00 – 6:00 pm  Room 202
Fee: $80 (FITs: $35). Limit 50.
Tania Elliott, MD, FACAAI;
Jay M. Portnoy, MD, FACAAI and
Jennifer Shih, MD

The presentation will describe the appeal of on-demand visits and how practicing allergists can participate. In addition, the use of facilitated teledem visits will be described and demonstrated.

Objectives: Describe the difference between facilitated and non-facilitated teledem visits; describe how to do a facilitated visit; and discuss current on-demand telemedicine models.

Track: Practice Management/Professional Issues

Separate Registration Fee • Admission by Ticket Only
All Workshops Will Be Held at the Hynes Convention Center
Sunday, October 29 (continued)

**W17  Smoking Cessation in an Allergy Practice:**
What’s New and How To
4:00 – 6:00 pm  Room 203
Fee: $80 (FITs: $35). Limit 50.
Chitra Dinakar, MD, FACAAI and
Mark Sands, MD

Allergists see numerous patients who have tobacco cessation needs. Learn what you can provide in your office.

**Objectives:** Describe adverse effects of tobacco smoke (active and passive) and risk of asthma; describe available smoking cessation aids; and devise a smoking cessation plan based on personalized risks/benefits.

**Track:** Population Health and Infectious Diseases/International Travel

**W18  Skin Biopsy and Patch Testing for the Allergist:**
How to Perform and Interpret
4:00 – 6:00 pm  Room 206
Fee: $150 (FITs: $50). Limit 50.
Marcella R. Aquino, MD, FACAAI and
Mark A. Davis-Lorton, MD, FACAAI

Participants in this session will learn to perform a skin biopsy, including which materials are needed and the optimal place to perform the biopsy. They will also learn how to load patch test chambers, and where and how to apply them to a patient’s back.

**Objectives:** Perform a skin biopsy with proper technique and tools, considering optimal location and potential adverse effects/complications; and learn to prepare and apply a patch test to a patient with suspected allergic contact dermatitis.

**Track:** Dermatology; Clinical Immunology and Autoimmune and Biologicals

**W19  Great Masqueraders: Alternate Presentations of Primary Immunodeficiencies**
4:00 – 6:00 pm  Room 200
Fee: $80 (FITs: $35). Limit 50.
Dominique Pichard, MD and
Kathleen Sullivan, MD

Immune deficiency and immune dysregulation may affect various organ systems; frequently, affected patients do not present with non-infectious manifestations. The clinician should be aware of these great masqueraders to recognize immunodeficiency states and treat them appropriately.

**Objectives:** Recognize primary immunodeficiencies presenting with inflammatory bowel disease; and recognize various skin manifestations of primary immunodeficiencies.

**Track:** Clinical Immunology and Autoimmune and Biologicals

**W20  Drugs Gone Wild: Cutaneous Manifestations of Drug Allergy**
4:00 – 6:00 pm  Room 210
Fee: $80 (FITs: $35). Limit 50.
Aleena Banerji, MD and
Aidan Long, MD

Cutaneous reactions are a common presentation of drug hypersensitivity reactions. This session will focus on key points in the recognition, evaluation and management of these reactions, using a case-based approach.

**Objectives:** Recognize common cutaneous manifestations of drug hypersensitivity reactions.

**Track:** Food & Drug Allergy and GI Disorders
Sunday, October 29 (continued)

W21 Environmental Allergy: Indoor/Outdoor
4:00 – 6:00 pm Room 310
Fee: $80 (FITs: $35). Limit 50.
Elizabeth Matsui, MD and
David Peden, MD, FACAAI

Environmental allergens are a significant driver of airway disease. Environmental pollutants modify the response to allergens and vice versa, leading to increased airway morbidity. Environmental factors also modify levels of allergens to which individuals are exposed. This session will describe the allergen/pollutant interactions in both indoor and outdoor settings, with attention to practical and policy measures which may mitigate environmentally-driven allergic disease.

Objectives: Gain appreciation of the sources of important indoor allergens and interventions that can lower these exposures; develop an appreciation of indoor environmental factors (biomass/tobacco smoke, humidity, pest infestation) which augment allergic disease; and discuss the impact of regional environment on outdoor allergen levels and how to advise patients to prepare for these events, and learn to appreciate the impact of ambient pollutants on allergic disease, with practical intervention strategies.

Track: Environmental and Integrative Medicine

W22 Essentials in Becoming a Leader in Your Office
4:00 – 6:00 pm Room 311
Fee: $80 (FITs: $35). Limit 50.
Taylor Banks, MD and
Maureen Petersen, MD, FACAAI

This leadership workshop is designed to help physicians get ready to be leaders in their medical practice. Attendees will learn true leadership through role-playing, self-assessment tests and other leadership training scenarios. They will explore leadership roles as a manager, communicator, mentor and team member and develop individual leadership style for maximum impact. Attendees will learn practical techniques to shape their leadership messages to achieve results.

Objectives: Describe leadership styles and understand how your own style impacts those you lead; identify the key elements of effective leadership; and develop a toolbox of effective management strategies.

Track: Practice Management/Professional Issues

W23 Hands-on Session in Rhinolaryngoscopy: Intermediate/Advanced
4:00 – 6:00 pm Room 207
Fee: $150 (FITs: $50). Limit 30.
Jerald W. Koepke, MD, FACAAI;
Seong H. Cho, MD, FACAAI;
Kevin R. Murphy, MD, FACAAI (SC);
Donald W. Pulver, MD, FACAAI and
C. Ross Westley, MD, FACAAI

PREREQUISITES REQUIRED FOR THIS WORKSHOP
Participants must meet the following criteria:
1. Have taken the Introductory Hands-on Rhinolaryngoscopy Course at a previous meeting or have received similar training.
2. Have a working knowledge of the nasal and laryngeal anatomy.
3. Possess basic skills in the use of flexible fiber-optic rhinoscope.
4. Have performed at least 15 examinations with a fiber-optic rhinoscope.
5. Be willing to be examined by course participants.

Objectives: Provide an opportunity to learn how to better navigate the recesses of the nasal airway and larynx with the rhinolaryngoscope by acquiring more advanced skills needed to perform a comprehensive upper airway examination using a fiber-optic endoscope; learn to more confidently identify the major structures of the nasal, pharyngeal and glottic areas as visualized during a rhinoscopic examination and describe variations from normal, if seen, when participants examine one another; and have the opportunity to discuss challenging cases or problems they have encountered when performing this procedure.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

Supported by KARL STORZ Endoscopy-America, Inc.
through an independent educational grant consisting of loaned durable equipment
Sunday, October 29 (continued)

**W24 Advocacy Council Update on Legal/Regulatory Issues and the Alphabet Soup (USP, DASH, MACRA, MIPS and APMs)**
*4:00 – 6:00 pm* Room 312
Fee: $80 (FITs: $35). Limit 50.
J. Allen Meadows, MD, FACAAI and James M. Tracy, DO, FACAAI

We will offer an up-to-date review of the latest developments regarding implementation of health care reform, as well as review strategies for the new quality reporting programs so that you can thrive, and not just survive, in 2018.

**Objectives:** Discuss the new payment models and understand how other regulatory changes are impacting allergy practice; list options to avoid Medicare penalties in 2019; and define an APM.

**Track:** Practice Management/Professional Issues

**W25 PBL: Detailed Workup and Treatment of Chronic Urticaria**
*4:00 – 6:00 pm* Room 204
Fee: $80 (FITs: $35). Limit 25.
Thomas B. Casale, MD, FACAAI and Russell Settipane, MD, FACAAI

Through the presentation of selected cases of chronic urticaria, participants will understand the appropriate evaluation of patients, the stepwise approach to the management and the utility of biologics. Active participation will be encouraged.

**Objectives:** Describe the management of chronic urticaria; discuss the use of immunosuppressants in chronic urticaria; and review the evaluation of patients with chronic urticaria.

**Track:** Dermatology

**W26 Hot Topics in Pediatric Allergy: AAP/SOAI**
*4:00 – 6:00 pm* Room 313
Fee: $80 (FITs: $35). Limit 50.
Anne-Marie Irani, MD and Todd A. Mahr, MD, FACAAI

This workshop will review the areas of pediatric asthma and allergic diseases, focusing on recent hot topics.

**Objectives:** Review and update knowledge of recent advances in pediatric asthma and allergic rhinitis; and review and update knowledge of recent advances in pediatric allergic diseases (food allergy, atopic dermatitis, urticaria).

**Track:** Population Health and Infectious Diseases/International Travel

---

Monday, October 30

**W27 Immunotherapy 2017: SCIT, SLIT and More!**
*1:00 – 3:00 pm* Room 202
Fee: $80 (FITs: $35). Limit 50.
John J. Oppenheimer, MD, FACAAI and Jay M. Portnoy, MD, FACAAI

This workshop will cover the differences in therapeutic extracts and prescribing practices.

**Objectives:** Explain the differences between subcutaneous, sublingual and other forms of allergy immunotherapy for the purpose of therapeutic extracts related to patient care, including health care outcomes research which involves benefits related to the optimal dosing and use of immunotherapy; and write prescriptions for immunotherapy which contain safe and effective doses of each component according to current guidelines and best clinical practice for the benefit of patient care.

**Track:** Immunotherapy and Diagnostics

**Supported by an independent educational grant from Stallergenes Greer**

**W28 Treating Asthma and Allergic Disease in the Elderly Utilizing Precision Medicine**
*1:00 – 3:00 pm* Room 203
Fee: $80 (FITs: $35). Limit 50.
Paula Busse, MD and Mauli Desai, MD, FACAAI

This session will identify the particular allergic conditions and describe the specific challenges in elderly care, and enable the audience to prescribe more clinically-effective treatment options for this population. This activity will also discuss practical and everyday tips for delivering health care to this growing and important segment of the population.

**Objectives:** Categorize the distinct issues in health care facing the elderly, as it relates to the allergy/immunology physician; demonstrate the ability to summarize the current scientific literature involving allergic conditions in the elderly; and compare and contrast the current and potential future therapeutic options for allergic conditions, specifically with regards to the elderly.

**Track:** Asthma and Respiratory/Sleep Disorders

---

Separate Registration Fee • Admission by Ticket Only
All Workshops Will Be Held at the Hynes Convention Center
Monday, October 30 (continued)

**W29 Food Challenges in Practice: Safe and Simplified**

1:00 – 3:00 pm  
Room 206  
Fee: $80 (FITs: $35). Limit 50.  
*Michael Pistiner, MD* and  
*Rima Rachid, MD*

This workshop will cover the methods of food challenge tests and the advantages and limitations of each, along with discussion of the preparation, administration and implementation of the oral food challenge results and specific issues in infants and adults.

**Objectives:** Describe how to perform an oral food challenge; and review indications for an oral food challenge and reasons for deferment.

**Track:** Food & Drug Allergy and GI Disorders

**W30 The Spectrum of COPD: The Disease and Comorbidities**

1:00 – 3:00 pm  
Room 210  
Fee: $80 (FITs: $35). Limit 50.  
*Bartolome R. Celli, MD*

This session will compare differences in the diagnosis and treatment of COPD versus asthma and examine the many comorbid conditions associated with COPD.

**Objectives:** Compare differences in diagnosis of COPD versus asthma; differentiate therapies for COPD versus asthma; and distinguish comorbid conditions associated with COPD.

**Track:** Asthma and Respiratory/Sleep Disorders

**W31 Biologics in Atopic Dermatitis**

1:00 – 3:00 pm  
Room 310  
Fee: $80 (FITs: $35). Limit 50.  
*Luz S. Fonacier, MD, FACAAI* and  
*Lynda Schneider, MD, FACAAI*

Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease that affects children and adults. Current therapies used to achieve disease control include moisturization and/or topical corticosteroids and topical calcineurin inhibitors. Patients with moderate-to-severe AD often receive little benefit from these treatments. The only FDA-approved systemic treatment option for these patients is systemic steroids, due to its anti-inflammatory indication. Second line therapy, not approved by the FDA for AD yet, used by physicians for moderate to severe AD includes a host of immunosuppressants, which are not indicated for AD and may have serious adverse effects; or patients go untreated. New research on the immune pathogenesis of AD has paved the way for new, targeted, systemic therapies for AD. There is a need in the field to help clinicians understand how these new therapies might fit into the current treatment paradigm, as well as to provide them with practical recommendations for assessing AD severity, treatment response, and treatment failure.

**Objectives:** Describe methods for assessing AD severity, treatment response and treatment failure and identify patients who fail current standard of care and could be candidates for targeted therapies; and discuss the pathophysiology of AD and newly-approved targeted therapies and those in development for atopic dermatitis.

**Track:** Dermatology

**W32 Anaphylaxis: A Spectrum of Cases**

1:00 – 3:00 pm  
Room 311  
Fee: $80 (FITs: $35). Limit 50.  
*Aleena Banerji, MD* and  
*Mariana C. Castells, MD, PhD, FACAAI*

This session will address the best evidence currently available to guide best practice and review unusual presentations, as well as cases of anaphylaxis that may prove more difficult to treat (e.g., concomitant beta-blocker use, pregnancy, etc.).

**Objectives:** Describe management of severe anaphylaxis; recognize risk factors for more severe cases of anaphylaxis; and describe a detailed differential diagnosis for anaphylaxis.

**Track:** Rhinitis/Sinusitis/Ocular and Anaphylaxis
Monday, October 30 (continued)

**W33  Facial Swelling: Lips & More**

1:00 – 3:00 pm  
Room 312

Fee: $80 (FITs: $35). Limit 50.
Timothy J. Craig, DO, FACAAI and William R. Lumry, MD, FACAAI

The allergist will be updated on current guideline approaches and therapies for angioedema. The evaluation and treatment of angioedema is changing. New treatments are available and allergists need to stay current in this area. Allergists need to be able to diagnose, evaluate and develop a treatment plan for patients with various types of angioedema.

**Objectives:** Discuss the workup and treatment approaches to patients with types I and II hereditary angioedema (HAE); and discuss the pathophysiology, workup and treatment of histamine-mediated urticaria/angioedema and distinguishing features from type 3 HAE.

**Track:** Dermatology

---

**W34  Insect Allergy Update in Today’s Complicated Beehive**

1:00 – 3:00 pm  
Room 313

Fee: $80 (FITs: $35). Limit 50.
Theodore M. Freeman, MD, FACAAI and James M. Tracy, DO, FACAAI

This workshop will review the most recent practice parameters, update the parameters with recently published material, cover the diagnosis and treatment of insect sting allergy and emphasize any new information available.

**Objectives:** Recognize the most common insects that cause reaction in humans, as well as the reactions these insects cause; develop an evaluation and treatment plan, as well as evaluate how to work with local emergency departments for aftercare of patients seen; and review management of insect allergy with emphasis on the What’s New section of the Insect Practice Parameters.

**Track:** Rhinitis/Sinusitis/Ocular and Anaphylaxis
Moving Toward Precision Medicine in Atopic Dermatitis and Food Allergy

Moderator: Mark Boguniewicz, MD, FACAAI

Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

This session will cover the epidemiology of atopic dermatitis, adult atopic dermatitis and systemic aspects of atopic dermatitis; the pathophysiology of atopic dermatitis; infectious complications of atopic dermatitis; the role of contact allergy in contact dermatitis; and new treatments in atopic dermatitis.

**Track:** Dermatology

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Welcome and Introductions</td>
<td>Mark Boguniewicz, MD, FACAAI</td>
</tr>
<tr>
<td>8:05 am</td>
<td>Epidemiology of Atopic Dermatitis, Adult Atopic Dermatitis, Systemic Aspects of Atopic Dermatitis</td>
<td>Jonathan Silverberg, MD, PhD, MPH</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Pathophysiology of Atopic Dermatitis</td>
<td>Emma Guttman-Yassky, MD</td>
</tr>
<tr>
<td>8:55 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>9:10 am</td>
<td>Refreshment Break</td>
<td></td>
</tr>
<tr>
<td>9:25 am</td>
<td>Infectious Complications of Atopic Dermatitis</td>
<td>Peck Y. Ong, MD, FACAAI</td>
</tr>
<tr>
<td>9:50 am</td>
<td>Role of Contact Allergy in Eczematous Dermatitis</td>
<td>Luz S. Fonacier, MD, FACAAI</td>
</tr>
<tr>
<td>10:15 am</td>
<td>New Treatments in Atopic Dermatitis</td>
<td>Lynda Schneider, MD, FACAAI</td>
</tr>
<tr>
<td>10:40 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Recognize specific etiologies of atopic dermatitis (AD) patients and unique systemic issues related to the disorder.
- Discuss the development and specific pathophysiology of AD.
- Recognize and initiate treatment of infectious complications of AD.
Noon – 4:00 pm

**New Horizons in Food Allergy**  
_Moderator: Robert A. Wood, MD_

_Supported by an independent educational grant from Aimmune Therapeutics_

This session will explore new treatments that may be approved by the FDA for food allergy in the near future and examine the latest techniques in prevention of food allergy.

**Track: Food & Drug Allergy and GI Disorders**

- **Noon**  
  - **Oral Immunotherapy**  
    A. Wesley Burks, MD, FACAAI

- **12:25 pm**  
  - **Epicutaneous Immunotherapy**  
    J. Andrew Bird, MD, FACAAI

- **12:50 pm**  
  - **Other Approaches to Treatment**  
    Robert A. Wood, MD

- **1:15 pm**  
  - **Mechanisms of Food Allergy (Development and Treatment)**  
    Wayne G. Shreffler, MD, PhD

- **1:40 pm**  
  - **Non-IgE Mediated Food Allergy**  
    Antonella Cianferoni, MD, PhD

- **2:05 pm**  
  - **Refreshment Break**

- **2:20 pm**  
  - **Prevention of Food Allergy**  
    Aikaterini Anagnostou, MD, PhD, FACAAI

- **2:45 pm**  
  - **Epidemiology of Food Allergy**  
    Corinne Keet, MD

- **3:10 pm**  
  - **FARE: Update on Clinical Network and Tools**  
    Luis Garcia

- **3:35 pm**  
  - **Questions and Discussion**

- **4:00 pm**  
  - **Adjourn**

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Assess the use of OIT, EPIT and other approaches in the treatment of food allergy.
- Review the mechanisms of food allergy and examine the cause of non-IgE mediated food allergy.
- Recognize the role of early food introduction in preventing allergic disease; and utilize the updated infant feeding guidelines.
- Use prevention mechanisms and integrate the epidemiology of food allergy into their practice.

---

6:00 – 8:00 pm  
**Non-CME Corporate Forums**  
(See page 81 for details.)
Friday Annual Literature Review

7:30 am – 3:45 pm • Auditorium (2nd Floor) • Hynes Convention Center
Separate Registration Fee • Admission by Ticket Only
(You must be registered for the Annual Scientific Meeting to register for the Annual Literature Review)

Everything You Should Have Read Last Year, but Didn’t!

Moderator: David A. Khan, MD, FACAAI

To help you keep abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful Literature Review program. It’s a review of the most important, clinically focused literature of our specialty published between October 2016 and August 2017, with emphasis on clinical relevance. Faculty includes allergy-immunology training program directors and specialists in practice.

Moderator: James T. Li, MD, PhD, FACAAI

7:30 am  Basic Immunology
Mitchell H. Grayson, MD, FACAAI

8:00 am  Rhinitis and Sinusitis
Anju T. Peters, MD

8:30 am  Update in Clinical Immunology
John M. Routes, MD, FACAAI

9:00 am  Asthma and Lower Respiratory Diseases
James T. Li, MD, PhD, FACAAI

9:30 am  Refreshment Break

9:45 am  Update on Skin Diseases, Urticaria, Angioedema and Other Skin Disorders
Marc A. Riedl, MD, MS

10:15 am  Update in Pediatric Allergy
John M. Kelso, MD, FACAAI

10:45 am  Anaphylaxis, Drug Allergy and Stinging Insect Hypersensitivity
Anthony Montanaro, MD, FACAAI

11:15 am  Questions and Discussion

11:30 am  Lunch Break (on own)

12:45 pm  Immunotherapy
Harold S. Nelson, MD, FACAAI

1:15 pm  Food Allergy
Matthew Greenhawt, MD, MSc, MBA, FACAAI

1:45 pm  Occupational and Environmental Allergy
Mark S. Dykewicz, MD, FACAAI

2:15 pm  Refreshment Break

2:30 pm  E-health
Chitra Dinakar, MD, FACAAI

3:00 pm  The Year’s Best Articles
David A. Khan, MD, FACAAI

3:30 pm  Questions and Discussion

3:45 pm  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

- Discuss recent advances in basic science that are relevant to allergy and immunology.
- Describe recent developments in rhinitis and sinusitis.
- Recognize the clinical presentation of activated phosphoinositide 3-kinase delta syndrome and distinguish it from common variable immunodeficiency.
- Better diagnose and manage asthma and COPD.
- Discuss important scientific and clinical advances in the pathophysiology and treatment of urticaria, angioedema and other skin disorders.
- Apply practical lessons learned from recent literature in pediatric allergy, asthma and immunology.
- Identify new concepts in anaphylaxis, drug allergy and stinging insect hypersensitivity, as well as utilize clinically relevant findings in these areas.

- Describe recent developments in immunotherapy.
- Discuss recent developments in food allergy.
- Better counsel patients on environmental factors that may impact respiratory and allergic disease; and better recognize, diagnose and manage occupational allergic diseases.
- Be aware of and apply advances in electronic processes and communication that impact and improve allergy and immunology health care practice.
- Apply practical lessons learned from recent literature in allergy, asthma and immunology.
Friday General Sessions

8:30 – 10:30 am • Ballroom BC (3rd Floor) • Hynes Convention Center

Breakfast Symposium

Chronic Rhinosinusitis: Translating Studies of Innate Immunity/Barrier Function and Inflammatory Endotypes to Treatment Paradigms for Patients

Moderator: Eli O. Meltzer, MD, FACAAI

Allergy and immunology specialists will receive the most up-to-date information regarding the immunologic basis and therapeutic targets of the newest treatment options for chronic hyperplastic sinusitis.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

8:30 am  Welcome and Introductions
Eli O. Meltzer, MD, FACAAI

8:35 am  Unraveling Innate Immunity/Barrier Function and Inflammatory Endotypes in Chronic Rhinosinusitis
Robert Schleimer, MD, PhD

9:05 am  Identifying Inflammatory Therapeutic Targets in Chronic Rhinosinusitis and Nasal Polyps
Tanya M. Laidlaw, MD

9:35 am  Chronic Rhinosinusitis: Translating Studies of Innate Immunity/Barrier Function and Inflammatory Endotypes to Treatment Paradigms for Patients
Daniel L. Hamilos, MD

10:05 am  Questions and Discussion
10:30 am  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

• Examine basic immunology of innate, adaptive and mucosal host defense mechanisms.
• Apply these facts to identify targets for new, novel treatment strategies.
• Design appropriate history, physical, laboratory and imaging studies to allow precision medicine therapeutic plans to be developed for chronic hyperplastic sinusitis.

10:15 – 11:15 am • Rooms 302-304 • Hynes Convention Center

Special Seminar: What’s New in Health Care

Moderator: Bryan L. Martin, DO, FACAAI

“"The trouble with the future is that it usually arrives before we’re ready for it." —Arnold H. Glasgow

Track: Practice Management/Professional Issues

10:15 am  Update From the Center for Drugs at the FDA: Precision Medicine and Targeted Therapy
Badrul A. Chowdhury, MD, PhD

10:45 am  The Transition to Value-based Health Care: Why It’s Important and How Best to Prepare
David M. Lang, MD, FACAAI

11:15 am  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

• Describe the emerging roles of transparency and patient-centered medical decisions in health care.
• Relate the association of measures development and implementation with evidence-based guidelines.
Luncheon Symposium

Current Management of Hereditary Angioedema: Considerations to Optimize Individualized Care

Moderator: Michael E. Manning, MD, FACAAI

Supported by an independent educational grant from Pharming NV

This program will utilize a case-based interactive symposium format. The program will engage health care providers by linking discussion of the latest scientific data with its application in the clinical setting. An audience response system will be used to facilitate audience participation in decision-making related to presented cases. As faculty members move through their respective presentations, the audience will be asked to make decisions related to presented patient care. In addition to the case review and audience interactivity provided by the response system, the program will include a 20-minute question and answer session.

Track: Dermatology

11:30 am  Welcome and Introductions
Michael E. Manning, MD, FACAAI

11:35 am  HAE Overview
Michael E. Manning, MD, FACAAI

11:40 am  Case Study #1: Accurate Diagnosis of HAE in a Pediatric Patient With GI Symptoms
Joshua S. Jacobs, MD

12:10 pm  Case Study #2: Treatment of Previously Undiagnosed in the ED/Evaluating the Need for Self-administration Training
Marc A. Riedl, MD, MS

12:40 pm  Case Study #3: Treatment of a Female Patient Prone to Multi-site Attacks/Considerations for Development of a Long-term Treatment Plan That Includes Prophylaxis
William R. Lumry, MD, FACAAI

1:10 pm  Questions and Discussion

1:30 pm  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• Differentiate key signs and symptoms of HAE from other common conditions and review the HAE complement profile.
• Review the role of the complement cascade in HAE attacks.
• Discuss the role of bradykinin receptors in HAE attacks and potential pathophysiologic explanations for multi-site attacks.
Friday General Sessions

1:30 – 3:00 pm • Rooms 302-304 • Hynes Convention Center

Plenary Session MOC/CME

Mastocytosis / Mast Cell Activation Syndrome: Demystifying MCAS – Clearing the Muddy Waters

Moderator: Jay Lieberman, MD, FACAAI

There remains extensive debate regarding the definition of mastocytosis and MCAS. This session will clarify the diagnostic criteria and outline treatment possibilities.

Track: Clinical Immunology and Autoimmune and Biologicals

1:30 pm Welcome and Introductions
Jay Lieberman, MD, FACAAI

1:35 pm History and Associated Diseases
Cem Akin, MD

2:00 pm Laboratory Evaluation: Develop a Diagnostic Treatment Plan
Lawrence B. Schwartz, MD, FACAAI

2:25 pm Treatment
Mariana C. Castells, MD, PhD, FACAAI

2:50 pm Questions and Discussion

3:00 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Illustrate the appropriate historical and physical manifestations of chronic sinusitis and accompanying comorbidities.
• Design the appropriate laboratory evaluation to confirm the diagnosis of mastocytosis from mast cell activation syndrome.
• Evaluate treatment options for MCAS and mastocytosis.

3:00 – 6:00 pm • Rooms 302-304 • Hynes Convention Center

Symposium MOC/CME

Childhood Asthma

Moderator: Todd A. Mahr, MD, FACAAI

Track: Asthma and Respiratory/Sleep Disorders

4:00 pm Welcome and Introductions
Todd A. Mahr, MD, FACAAI

4:05 pm What Determines the Inception of Childhood Asthma?
Leonard B. Bacharier, MD, FACAAI

4:35 pm Can Disease Modification Occur Now or in the Future?
Wanda Phipatanakul, MD, MS, FACAAI

5:05 pm Controller Therapy: How to Choose the Correct Medication
Stanley Szefler, MD

5:35 pm Questions and Discussion

6:00 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Critique new information regarding genesis of asthma in young children from RSV vs HRV.
• Relate data from long-term therapeutic trials of therapy in childhood asthma to clinical practice.
• Examine data of long-term growth in children treated with inhaled corticosteroids and apply to clinical practice.

3:30 – 6:00 pm E-poster Presentations
Halls C & D (2nd Floor) • Hynes Convention Center
(See page 84 for details.)

3:00 – 4:00 pm Refreshment Break in Exhibit Hall

3:00 – 6:00 pm Exhibit Hall Open
Friday General Sessions

4:00 – 6:00 pm • Room 312 • Hynes Convention Center

WAO/ACAAI International Forum

World Allergy Forum: State of the Art on the Management of Atopic Dermatitis

Moderators: Mario Sanchez-Borges, MD and Stephen A. Tilles, MD, FACAAI

There are new advances in understanding the pathogenesis of atopic dermatitis (AD). Physicians will learn about best management practices and therapeutic advances in severe cases of AD. Inflammatory pathways, diagnosis, standard therapies, and novel treatment methods with biological drugs and immunomodulators in severe AD will be covered.

Track: Clinical Immunology and Autoimmune and Biologicals; Immunotherapy and Diagnostics

4:00 pm  Welcome and Introductions
Mario Sanchez-Borges, MD and Stephen A. Tilles, MD, FACAAI

4:05 pm  Inflammatory Pathways Leading to Skin Damage in Patients With Atopic Dermatitis
Lanny J. Rosenwasser, MD, FACAAI

4:35 pm  Diagnostic Approach, Patch Testing and Topical Therapy
Marcella R. Aquino, MD, FACAAI

5:05 pm  The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
John J. Oppenheimer, MD, FACAAI

5:35 pm  Questions and Discussion

6:00 pm  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

- Summarize the most recent advances in the understanding of the pathogenesis of atopic eczema.
- Identify the validated diagnostic and therapeutic methods available for the management of severe atopic dermatitis.
- Describe new systemic approaches for the treatment of patients with refractory disease.
Friday General Sessions

4:00 – 6:00 pm • Room 210 • Hynes Convention Center
Town Hall Meeting Hosted by ACAAI House of Delegates

All Meeting Attendees Are Welcome!
Beer, Wine and Cheese Reception

The Town Hall Meeting, brought to you by the House of Delegates, will begin with an informal networking session, giving you the opportunity to discuss issues with colleagues, Delegates and the College leadership. The first part of the agenda will cover the business meeting, where votes will be cast for new HOD leaders. Then expert speakers will lead thought-provoking discussions on topics of interest to the practicing allergist.

**Annual Report to Delegates**
Maeve E. O’Connor, MD, FACAAI
Speaker of the ACAAI House of Delegates

**What’s the Future Look Like for Allergy?**
Susan Rudd Bailey, MD, FACAAI
Speaker of the AMA House of Delegates

**What has the Advocacy Council Done for You Lately?**
J. Allen Meadows, MD, FACAAI
Chair of the Advocacy Council

**Have Our Advocacy Efforts Had an Impact in Washington?**
Bill Finerfrock

**Telehealth/Telemedicine: How to Use It in Your Office**
Jay M. Portnoy, MD, FACAAI

**The New Practice Parameter Format: A Look to the Future – Where Are We Headed Next?**
Dana V. Wallace, MD, FACAAI

---

**4:45 – 6:00 pm**
Advanced Practice, Allied Health and Office Administrators Networking Reception
Back Bay Ballroom Salon A (2nd Floor)
Sheraton Boston Hotel
Supported by DBV Technologies

**6:30 – 8:30 pm**
Non-CME Corporate Forums
(See page 82 for details.)

**6:30 – 9:30 pm**
American Association of Allergists and Immunologists of Indian Origin (AAAI)
Semi-annual Dinner Symposium
Liberty Ballroom (2nd Floor) • Sheraton Boston Hotel
Saturday General Sessions

Opening Ceremony and Welcome Announcements
8:00 – 8:30 am • Auditorium (2nd Floor) • Hynes Convention Center

Opening Ceremonies and Welcome Announcements
Stephen A. Tilles, MD, FACAAI
Presdent
Bradley E. Chipps, MD, FACAAI
President-elect and Program Chair
Mrs. Charlotte Meadows
Alliance President

8:30 – 10:30 am • Auditorium (2nd Floor) • Hynes Convention Center

Plenary Session
The College: Celebrating 75 Years of Excellence
Moderator: Bradley E. Chipps, MD, FACAAI

This session will highlight the contributions of the College over the last 75 years as a foundation for current activities and include planning for the future.

8:30 am Welcome and Introductions
Bradley E. Chipps, MD, FACAAI

8:35 am The ACAAI: A Dream Realized
Bobby Q. Lanier, MD, FACAAI

9:05 am ACAAI in Today’s Health Care Environment
Gailen D. Marshall, MD, PhD, FACAAI

9:35 am Bernard Berman Memorial Lecture
The College and the Future of Health Care
Susan Rudd Bailey, MD, FACAAI

10:15 am Questions and Discussion

10:30 am Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Recognize the historical presence of the College in allergy practice.
• Describe the current presence and mission of the College.
• Discuss the future role of the College in A/I practice and patient care.

9:45 am – 4:00 pm Exhibit Hall Open

10:30 – 11:00 am Refreshment Break in Exhibit Hall

10:30 – 11:00 am E-poster Presentations
Halls C & D (2nd Floor) • Hynes Convention Center
(See page 84 for details.)
Saturday General Sessions

11:00 am – 12:30 pm • Auditorium (2nd Floor) • Hynes Convention Center

**Plenary Session**

Demystifying Early Introduction of Food to Prevent Food Allergy

*Moderator: Matthew Greenhawt, MD, MSc, MBA, FAAAAI*

Data and guidelines supporting early allergen (specifically peanut) introduction are new. These recommendations evolve from former practice that supported either delay in peanut introduction (AAP 2000), and then equipoise/no benefit in delay in the timing (AAP, 2008 and AAAAI 2013). Because the guidelines are new, there are no practical recommendations as to how to implement the new policy nor how to integrate an anticipated influx of referrals of high-risk infants requiring in-office peanut introduction into the office-based practice.

**Track: Food & Drug Allergy and GI Disorders**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am</td>
<td>Welcome and Introductions</td>
<td>Matthew Greenhawt, MD, MSc, MBA, FAAAAI</td>
</tr>
<tr>
<td>11:05 am</td>
<td>The Scope of Dietary and Health Benefits Related to Early Peanut Introduction</td>
<td>Carina Venter, PhD, RD</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Implementation 101: Convincing Wary Caregivers, Colleagues and Staff of Why Early Introduction Works</td>
<td>David R. Stukus, MD, FAAAAI</td>
</tr>
<tr>
<td>11:55 am</td>
<td>How to Work With Primary Care Providers to Identify High-risk Children for Referral</td>
<td>Ruchi Gupta, MD, MPH</td>
</tr>
<tr>
<td>12:20 pm</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Review the dietary and health benefits associated with early peanut introduction.
- Discuss the approach to facilitate and set up office-based implementation of early peanut introduction.
- Review strategies to partner with primary care providers to enhance referrals of high-risk children for early peanut introduction.

12:30 – 1:30 pm • Room 206 • Hynes Convention Center

**ABAI Forum**

*Moderator: Stephen I. Wasserman, MD, FAAAAI*

The leadership of ABAI will present the Maintenance of Certification (MOC) Continuous Assessment Program (CAP) pilot, which will begin January 1, 2018. The MOC program will remain a 10-year program with two five-year cycles. This is “open-book” and diplomates will be required to answer questions from 10 recent articles, as well as some core questions during each of the six-month cycles, for a total of 80 questions per year. Diplomates will learn the functionality of the new program and how to get credit for practice activities they are already performing.

- **Part III Continuous Assessment Program Pilot**
  Stephen A. Tilles, MD, FAAAAI

- **Part IV Practice Improvement Modules**
  Theodore M. Freeman, MD, FAAAAI

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Describe the functionality of the new program and how to get credit for practice activities they are already performing.

---

12:30 – 1:30 pm • E-poster Presentations

Halls C & D (2nd Floor) • Hynes Convention Center

(See page 84 for details.)

12:30 – 1:30 pm • Visit Exhibits (Lunch on own)

12:30 – 3:30 pm • Doctors’ Job Fair

Hall A (1st Floor) • Hynes Convention Center

12:35 – 1:30 pm • Product Theaters

Halls C & D (2nd Floor) • Hynes Convention Center

(See page 122 for details.)
Emerging Concepts in Chronic Cough

Moderator: Alan B. Goldsobel, MD, FACAAI

There is a proposed paradigm shift in the diagnosis and treatment of adults with chronic cough. This paradigm moves away from the “anatomic” approach to the concept of “cough reflex hypersensitivity,” where the main causation is a hypersensitive cough reflex with triggers from anatomic, neurogenic, and inflammatory sources.

Track: Asthma and Respiratory/Sleep Disorders

1:30 pm  The Search for the Human Cough Receptor(s)  Brendan Canning, PhD

1:55 pm  The Cough Hypersensitivity Syndrome: Diagnostic Approach to Chronic Cough in Adults  Jaclyn Smith, MB, ChB, FRCP, PhD

2:20 pm  The New Therapeutic Approach to Chronic Cough in Adults: Treating the Cough Reflex  Peter Dicpinigaitis, MD

2:45 pm  Questions and Discussion

3:00 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Discuss new concepts in cause of patients with chronic cough.
• List new therapies in development for chronic cough.
• Discuss new concepts of cough receptors in humans.

Pro/Con Debate

Should FeNO Be Used in All Asthma Patients?

Moderator: Gregory W. Bensch, MD, FACAAI

The evaluation of airway inflammation can be accomplished in office-based practice. The question of its benefit will be debated.

Track: Asthma and Respiratory/Sleep Disorders

3:30 pm  Pro: Should FeNO Be Used in All Asthma Patients?  Neal Jain, MD, FACAAI

3:30 pm  Con: Should FeNO Be Used in All Asthma Patients?  Stephen P. Peters, MD, PhD

Learning Objectives
Upon completion of this session, participants should be able to:
• Describe the importance of identifying the presence or absence of type 2 inflammation among patients with diagnosed or suspected asthma.
• Discuss the role and limitations of FeNO in identifying type 2 vs. other types of airway inflammation.
• Explain the role of using FeNO in the management of asthma.
Saturday General Sessions

Conflict Resolution in Your GME Environment

Speaker: Mike Tankersley, MD, FACAAI

This session will provide definitive steps for both the avoidance and resolution of personnel conflicts among GME colleagues and office staff in order to maximize the quality of the office environment and patient care.

Track: Practice Management/Professional Issues

Learning Objectives
Upon completion of this session, participants should be able to:

• Review the benefits and risks of conflict resolution or non-resolution, respectively.
• Supply definitive steps for both the avoidance and resolution of conflicts.
• Provide case scenarios exemplifying real-life situations which may be encountered.

Symposium MOC/CME

Sleep-disordered Breathing in Patients With Allergy and Asthma

Moderator: Todd A. Mahr, MD, FACAAI

Sleep-disordered breathing is very common in patients with allergies and asthma, and it must be considered and evaluated by allergists.

Track: Asthma and Respiratory/Sleep Disorders

3:30 pm Welcome and Introductions
Todd A. Mahr, MD, FACAAI

3:35 pm Sleep-disordered Breathing and Asthma
Samuel L. Friedlander, MD

4:05 pm Sleep-disordered Breathing and Rhinitis
Timothy J. Craig, DO, FACAAI

4:35 pm Sleep-disordered Breathing and the Allergist: New Evaluation and Treatments
James E. Mojica, MD

5:05 pm Questions and Discussion

5:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

• Explain the association of AR and upper airway disease with SDB.
• Describe the association of asthma with SDB.
• Discuss the role of the allergist in patients with SDB.

5:00 – 7:00 pm
26th Annual FIT Bowl Competition
Ballroom BC (3rd Floor) • Hynes Convention Center
Supported by Teva Respiratory
Awards Ceremony
7:00 – 7:45 pm • Constitution Ballroom Salon B (2nd Floor) • Sheraton Boston Hotel
Supported by Mylan

The College invites all registrants to the ACAAI Awards Ceremony, where we will recognize our 2017 Award recipients and formally welcome our newly-approved Fellows.

The event will begin at 7:00 pm with our new Fellows being honored for their accomplishments. We will also recognize the recipients of the College’s Distinguished Fellow, International Distinguished Fellow, Distinguished Service, Clemens von Pirquet, Woman in Allergy, and Young Faculty Support Awards. Finally, we’ll award this year’s recipient of the College’s prestigious Gold Headed Cane Award.

I. Welcome
Stephen A. Tilles, MD, FACAAI
ACAAI President

II. Recognition of Newly-Elected Fellows
Bradley E. Chipps, MD, FACAAI
ACAAI President-elect

III. Distinguished Fellow Awards
Stephen A. Tilles, MD, FACAAI
ACAAI President

IV. International Distinguished Fellow Award
Stephen A. Tilles, MD, FACAAI
ACAAI President

V. Distinguished Service Award
Stephen A. Tilles, MD, FACAAI
ACAAI President

VI. Woman in Allergy Award
Stephen A. Tilles, MD, FACAAI
ACAAI President

VII. Young Faculty Support Awards
Ira Finegold, MD, FACAAI
ACAAI Foundation President

VIII. Clemens von Pirquet Awards
Mrs. Charlotte Meadows
ACAAI Alliance President

IX. Gold Headed Cane Award
Stephen A. Tilles, MD, FACAAI
ACAAI President

President’s Welcome Reception
7:45 – 9:00 pm • Grand Ballroom (2nd Floor) • Sheraton Boston Hotel
Supported by Genentech, Inc. and Novartis Pharmaceuticals Corporation

The College invites all registrants to the ACAAI President’s Welcome Reception, which will immediately follow the Awards Ceremony. It’s the perfect place to catch up with old friends, make new acquaintances and meet the College President, President-Elect and the Alliance President.

Non-CME Corporate Forums
(See page 83 for details.)
Sunday Meet the Professor Breakfasts

7:00 – 8:15 am
Fee: $50 (FITs: $25) • Limit 30 • Admission by Ticket Only
All Meet the Professor Breakfasts Will Be Held at the Hynes Convention Center

S1  Severe Asthma: Where Biologics Fit
Room 101
Thomas B. Casale, MD, FACAAI and
Stephen P. Peters, MD, PhD

This session will review the definition of severe asthma, describe emerging biologics in the treatment algorithms surrounding severe asthma, and define the relevance of fungal infection in the lung and in severe asthma.

Objectives: Define severe asthma; describe emerging biologics in the treatment algorithms surrounding severe asthma; and define the relevance of fungal infection in the lungs and in severe asthma.

Track: Asthma and Respiratory/Sleep Disorders

S4  Hypereosinophilic Syndrome: Evaluation and Management
Room 104
Sameer Mathur, MD, PhD and
Princess Ogbogu, MD

This session will be an interactive discussion focusing on challenges of diagnosing and managing hypereosinophilic syndrome. Participants will become familiar with an algorithm for evaluation and the options for treatment. New anti-IL-5 therapies are approved for treatment of asthma; however, in clinical trials, these have also been successful for hypereosinophilic syndrome.

Objectives: Describe differential diagnosis of eosinophilia and criteria for hypereosinophilia; recognize clinical presentation of hypereosinophilic syndrome; and discuss treatment options for hypereosinophilic syndrome.

Track: Clinical Immunology and Autoimmune and Biologicals

S2  New Approaches to Chronic Cough in Children and Adults
Room 102
Alan B. Goldsobel, MD, FACAAI and
Mandel R. Sher, MD, FACAAI

This session will discuss new concepts of causation of chronic cough and compare strategies for evaluation and treatment in children versus adults.

Objectives: Describe new concepts in causes of chronic cough; evaluate new therapeutic approaches to patients with chronic cough; and compare causes of chronic cough in children versus adults.

Track: Asthma and Respiratory/Sleep Disorders

S5  Workup of the Patient With Recurrent Infections: Laboratory Evaluation of Immunodeficiency and What to Do With Normal IgG Levels
Room 107
Francisco A. Bonilla, MD, PhD and
John M. Routes, MD, FACAAI

This session will help attendees identify triggers that would prompt a primary immunodeficiency workup. It will also cover best practices for conducting a basic immune workup and interpreting the findings.

Objectives: Recognize patterns of infections that prompt a primary immunodeficiency workup; describe how to conduct a basic immune workup; discuss how to interpret the findings.

Track: Clinical Immunology and Autoimmune and Biologicals

S3  Breaking News: Assessing Fracture Risk and Preventing Fractures in the Steroid-treated Patient
Room 103
Mervat Nassef, MD, FACAAI and
Marcella Walker, MD

Oral and high-dose inhaled corticosteroids can increase the risk of fractures. Physicians who frequently prescribe these medications for the treatment of asthma should include the assessment of fracture risk in the comprehensive and personalized care of their patients. This assessment can guide patient-specific management decisions to reduce fracture risk.

Objectives: Recognize the risk factors for osteoporotic fractures; utilize available tools, including DXA and FRAX, to assess fracture risk; and develop a personalized plan for preventing fractures in the steroid-treated patient.

Track: Asthma and Respiratory/Sleep Disorders; Population Health and Infectious Diseases/International Travel

S6  Diagnostic Problems in Dermatology: Bring a Case and Ask the Experts
Room 108
Marcella R. Aquino, MD, FACAAI and
Peter A. Lio, MD

This session will review and discuss evaluation and management of common skin conditions.

Objectives: Review dermatology cases relevant to the practice of allergy; and discuss optional evaluation and management strategies regarding skin rashes.

Track: Dermatology
Sunday Meet the Professor Breakfasts

7:00 – 8:15 am
Fee: $50 (FITs: $25) • Limit 30 • Admission by Ticket Only
All Meet the Professor Breakfasts Will Be Held at the Hynes Convention Center

**S7  Marijuana, Hookah, Vaping and Asthmatics**
*Room 109*
Hannelore A. Brucker, MD, FACAAI and David R. Naimi, DO

This session will review different mechanisms of reactions to hookah, marijuana and vaping, along with the influence of vaping on asthma. It should help sharpen participants’ diagnostic skills for analyzing the reactions involved. Approaches to evaluation and management of clinical problems will be offered, including handouts and summary tables.

**Objectives:** Recognize the clinical symptoms and reactions associated with the use of waterpipe tobacco smoking/hookah and vaping, habits that are increasing in prevalence worldwide; and recognize the implications of the legalization of marijuana use and discuss the various effects on the human body.

**Track:** Environmental and Integrative Medicine; Food & Drug Allergy and GI Disorders

**S8  Integrative Allergy: Tools for Taking an Integrative Medicine History and Resources**
*Room 110*
Maeve E. O’Connor, MD, FACAAI and William S. Silvers, MD, FACAAI

Many allergists are not knowledgeable about, and therefore uncomfortable addressing and discussing, complementary and alternative medicine (CAM) approaches with their inquiring patients. This session will review relevant literature, the effects and adverse effects of CAM, clinical vignettes, references and resources, and a new template for integrative history intake.

**Objectives:** Describe and distinguish integrative, complementary, and alternative modalities in allergy and asthma and assess their evidence basis; utilize online resources for effects, adverse effects, and drug-CAM interactions; and have confidence in history-taking with a new template for integrative/CAM modalities.

**Track:** Environmental and Integrative Medicine

**S9  PBL: A Patient with Severe Eczema?**
*Room 111*
Ray S. Davis, MD, FACAAI and Donald Y. Leung, MD, PhD, FACAAI

Following a PBL discussion of a case, an expert will discuss Practice Parameters on atopic dermatitis, including food testing, wet to dry wraps, potency of topical steroids and even anti-interleukin biologicals.

**Objectives:** Differentiate the various chronic rashes in a teenager; and discuss up-to-date treatments for severe atopic dermatitis.

**Track:** Food & Drug Allergy and GI Disorders; Dermatology

**S10  Competing With Dr. Google: How Allergists Can Combat Misinformation and Misperceptions**
*Room 200*
Anne K. Ellis, MD, MSc, FACAAI and David R. Stukus, MD, FACAAI

70% of patients search online for information pertaining to their health, but misinformation is prevalent. In order to prepare themselves for these conversations, allergists need to understand the breadth of misconceptions their patients encounter, as well as develop strategies for having productive discussions in the office setting.

**Objectives:** Recognize the various online resources patients use to search for information; and develop a strategy to have productive discussions with patients surrounding non-evidence-based information they receive online.

**Track:** Practice Management/Professional Issues; Population Health and Infectious Diseases/International Travel
Sunday General Sessions

6:30 – 8:15 am • Ballroom BC (3rd Floor) • Hynes Convention Center

Breakfast Symposium
Anaphylaxis: Causes, Diagnosis and Management
Moderator: Mitchell R. Lester, MD, FACAAI

Supported by an independent educational grant from Mylan

This session will address best evidence as currently available to guide best practice. This session will also review available action plans and tools that can be utilized in the therapeutic plan for the patient.

Track: Immunotherapy and Diagnostics

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Welcome and Introductions</td>
<td>Mitchell R. Lester, MD, FACAAI</td>
</tr>
<tr>
<td>6:35 am</td>
<td>Non-IgE Causes of Anaphylaxis</td>
<td>Larry Borish, MD, FACAAI</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Case Presentations: Diagnosis and Treatment of Anaphylaxis</td>
<td>Jay Lieberman, MD, FACAAI</td>
</tr>
<tr>
<td>7:50 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>8:15 am</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Learning Objectives

Upon completion of this session, participants should be able to:

• Differentiate the non-IgE causes of anaphylaxis.
• Recognize typical and atypical presentations of anaphylaxis; discuss current controversies in anaphylaxis management; and debate when epinephrine should be administered in cases of possible anaphylaxis.
• Discuss the pros and cons of available anaphylaxis outpatient action plans; and consider using a patient-oriented anaphylaxis preparedness questionnaire as an educational tool for patients at risk of anaphylaxis.

8:30 – 10:00 am • Auditorium (2nd Floor) • Hynes Convention Center

Symposium MOC/CME
Which T2 Biologic is Best Suited for GINA 4-5 Non-responders?
Moderator: John J. Oppenheimer, MD, FACAAI

Supported by an independent educational grant from GlaxoSmithKline

There are multiple biologics that have been approved for asthma. This session will explore the patient profiles that may predict a response to each agent.

Track: Asthma and Respiratory/Sleep Disorders; Immunotherapy and Diagnostics

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 am</td>
<td>Welcome and Introductions</td>
<td>John J. Oppenheimer, MD, FACAAI</td>
</tr>
<tr>
<td>8:35 am</td>
<td>Anti-IgE</td>
<td>Thomas B. Casale, MD, FACAAI</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Anti-IL-5</td>
<td>Paul O’Byrne, MD</td>
</tr>
<tr>
<td>9:25 am</td>
<td>Anti-IL-4-13</td>
<td>Elliot Israel, MD</td>
</tr>
<tr>
<td>9:50 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00 am</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Learning Objectives

Upon completion of this session, participants should be able to:

• Describe what biomarkers may be indicative of good response to treatment with anti-IgE.
• Discuss differences in outcomes of pivotal trials for the two approved anti-IL5 agents.
• Determine whether treatment failure with one biologic dictates lack of response to other agents.

9:45 – 10:30 am E-poster Presentations
Halls C & D (2nd Floor) • Hynes Convention Center
(See page 84 for details.)

9:45 am – 2:00 pm Exhibit Hall Open

10:00 – 10:30 am Refreshment Break in Exhibit Hall

10:05 – 10:30 am Product Theaters
Halls C & D (2nd Floor) • Hynes Convention Center
(See page 123 for details.)
10:30 am  

**Bela Schick Lecture**

**The Future of Medicine and Allergy – Is It FINALLY a Brave New World?**

J. Allen Meadows, MD, FACAAI

For years, we have been promised that changes in the way health care was delivered would revolutionize the way we practice medicine. We will review past promises and analyze if the “good old days” were really so good. We will look at lessons from the past to temper our expectations for the future. We will analyze challenges that allergists will face in implementing changes in the health care system including Alternative Payment Models and Accountable Care Organizations.

**Learning Objectives**

Upon completion of this session, participants should be able to:

- List similarities and differences between an ACO, an APM and an HMO.
- List challenges that may prevent fundamental changes in health care delivery systems.
- List past changes that were proposed to improve health care delivery.

**Track:** Practice Management/Professional Issues

---

11:00 am – 12:30 pm  

**Plenary Session**

Regulatory Changes That Affect Allergists: USP 797; FDA Guidance, Etc. – What You Need to Do

*Moderator: Kevin P. McGrath, MD, FACAAI*

This session is designed to help allergists understand how the regulatory changes impact their practices and what they need to do to comply.

**Track:** Practice Management/Professional Issues

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>11:05 am</td>
<td>Regulatory Changes That Affect Allergists: USP 797; FDA Guidance – What You Need to Do</td>
</tr>
<tr>
<td>11:10 am</td>
<td>J. Allen Meadows, MD, FACAAI and James L. Sublett, MD, FACAAI</td>
</tr>
<tr>
<td>11:30 am</td>
<td>Revision of the Affordable Care Act</td>
</tr>
<tr>
<td>11:35 am</td>
<td>MACRA, MIPS, APMs</td>
</tr>
<tr>
<td>11:40 am</td>
<td>Stephen A. Imbeau, MD, FACAAI</td>
</tr>
<tr>
<td>12:20 pm</td>
<td>Questions and Discussion</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Explain why changes to USP 797 will affect the way they practice.
- Adapt new regulatory requirements to their practices.

---

12:30 – 1:30 pm  

Visit Exhibits *(Lunch on own)*

12:30 – 1:45 pm  

E-poster Presentations

Halls C & D (2nd Floor) • Hynes Convention Center

*(See page 84 for details.)*

---

12:35 – 1:30 pm  

**Product Theaters**

Halls C & D (2nd Floor) • Hynes Convention Center

*(See page 123 for details.)*
Sunday General Sessions

1:30 – 3:30 pm • Auditorium (2nd Floor) • Hynes Convention Center

Symposium

Can We Predict Severity Risk for Food Allergy?

Moderator: Matthew Greenhawt, MD, MSc, MBA, FACAAI

This session will review biological and behavioral factors that may influence the risk for severe reactions and the evolution of the risk factors for developing allergy. Participants will discuss which factors may be modifiable and how this may affect management decisions.

Track: Food & Drug Allergy and GI Disorders

1:30 pm Welcome and Introductions
Matthew Greenhawt, MD, MSc, MBA, FACAAI

1:35 pm Severity in Food Allergy: Allergen and Host Factors
Julie Wang, MD, FACAAI

2:05 pm Identifying Biological Markers of Severe Allergy
Wayne Shreffler, MD

2:35 pm Lester Mittelstaedt Lecture
The Evolution of the Child “At Risk” for the Development of Food Allergy
David M. Fleischer, MD, FACAAI

3:05 pm Questions and Discussion

3:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Explore the meaning and risk factors of “severe” food allergy.
• Discuss biomarkers that may be associated with severity of food-allergic reactions.
• Discuss the evolution of what constitutes the infant at “high risk” for developing allergic disease.

1:30 – 3:30 pm
Oral Abstracts
(See pages 60-62 for details.)

3:30 – 4:00 pm
Refreshment Break on 2nd and 3rd Floors
Sunday Oral Abstracts

1:30 – 3:30 pm • Rooms 302-304 • Hynes Convention Center

Session A
Adverse Drug Reactions, Insect Reactions, Anaphylaxis

1:30 pm OR01 – Drug Rash Eosinophilia and Systemic Symptoms DRESS Syndrome Identified in Electronic Health Record Allergy Module

1:45 pm OR02 – Testing Strategies for Immediate and Delayed Reactions to Cephalosporins
C. Stone*, E. Phillips; Nashville, TN.

2:00 pm OR03 – Common Misconceptions in the Recognition and Treatment of Anaphylaxis in Community Hospital-based Medical Professionals

2:15 pm OR04 – Safe and Effective Implementation of Chemotherapy Outpatient Desensitizations
S. Barmettler*, A. Wolfson2, B. Slawski1, J. Jordan1, K. Blumenthal1, A. Banerji1; 1. Boston, MA, 2. Somerville, MA.

2:30 pm OR05 – A Penicillin Skin Testing Initiative in an Outpatient Allergy Practice

2:45 pm OR06 – Usability and Comprehension of an Illustrated Canadian Anaphylaxis Action Plan for Kids (Kids’ CAP study)
W. Alqurashi*, Ottowa, ON, Canada.

3:00 pm OR11 – Safety of Multi-dose Immunotherapy Vials After Routine Use
P. Nath*, J. Freiler; San Antonio, TX.

3:15 pm OR12 – Simultaneous Aerosolization of Two Perennial Allergens in a Novel, Naturalistic Environmental Exposure Chamber EEC Model
V. Nelson1, E. Beattie2, P. Couroux2, A. Salapatek3; 1. Philadelphia, PA, 2. Mississauga, ON, Canada.

3:30 pm Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to: OR01) describe the epidemiology of drug rash eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module of a large integrated health system; OR02) increase awareness of cephalosporin side chain families and specific testing protocols as a crucial element of cephalosporin allergy management, and formulate strategies that utilize these techniques; OR03) improve the knowledge of community hospital medical staff in both the recognition and treatment of anaphylaxis; OR04) understand key facets of implementing chemotherapy outpatient desensitization in a safe and effective manner; OR05) describe the potential impact of a penicillin skin testing initiative in an outpatient office; OR06) recognize the impact of implementing an innovative anaphylaxis action plan tool in the quality of care of pediatric anaphylaxis; OR11) discuss the safety of routinely used immunotherapy allergen extracts; and OR12) discuss the importance of creating an indoor allergen model that parallels normal household perennial allergen exposure.
1:30 pm  OR21 – Immunotherapy of Shellfish Allergy: Differential Regulatory T Cell Induction in Immunoprophylactic Therapy Using Hypoallergen-DNA Vaccines
K. Chu*, C. Wai1, N. Leung1, P. Leung2; 1. Shatin, Hong Kong, 2. Davis, CA.

1:45 pm  OR22 – Tolerance of Needleless Subcutaneous Immunotherapy in Children
A. Fiocchi*, G. Traina2, A. Martelli2, V. Fierro1, R. Valluzzi1, M. Mennini1; 1. Rome, Italy, 2. Milan, Italy.

2:00 pm  OR23 – Safe and Effective Rush Immunotherapy: A Cumulative Experience of 5530 Patients

2:30 pm  OR31 – Preventive Effect of Subcutaneous C1 Inhibitor in Patients With Very Frequent Attacks of Hereditary Angioedema

2:45 pm  OR32 – Hereditary Angioedema Prophylaxis: Effect of an Online Educational Intervention Among Allergist Learners

3:00 pm  OR33 – Evaluating Hereditary Angioedema Patients’ Satisfaction With Their Past and Present Treatments – Implications for Future Therapies
J. Jose*, T. Craig2, E. Lehman3; 1. Freehold, NJ, 2. Hershey, PA.

3:15 pm  OR34 – Lanadelumab for Prevention of Attacks in Hereditary Angioedema: Results From the Phase 3 HELP Study

3:30 pm  Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to: OR21) discern new strategies in preventing shellfish allergy and discuss the induction of different regulatory T cell subsets in hypoallergen DNA vaccine-based immunotherapy; OR22) consider the future use of needle-free SCIT for their practice; OR23) perform a rapid desensitization (rush immunotherapy) safely, and reducing the frequency of systemic reactions compared to previously described literature when utilizing both premedication and a lower targeted end-point dose; OR31) identify subcutaneous C1-Inhibitor prophylaxis as an effective option for severely affected patients with type I or II HAE; OR32) discuss the effectiveness of online medical education in improving knowledge of hereditary angioedema prophylaxis options; OR33) recognize patients’ impression and confidence in their past and present treatments for Hereditary Angioedema; and OR34) describe the results of the HELP Study and Reg., a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of lanadelumab for the prevention of attacks in hereditary angioedema.
### Session C
#### Asthma, Other Lower Airway Disorders

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm</td>
<td><strong>OR41</strong> – Epigenetic Biomarkers for Childhood Asthma</td>
<td>I. Wang*, J. Hsu; Taipei, Taiwan.</td>
<td></td>
</tr>
<tr>
<td>1:45 pm</td>
<td><strong>OR42</strong> – Seasonality for Asthma Admissions by Time-Series Analysis</td>
<td>I. Wang*, J. Hsu; Taipei, Taiwan.</td>
<td></td>
</tr>
<tr>
<td>2:00 pm</td>
<td><strong>OR43</strong> – Obesity Disrupts Tissue-protective Macrophage Populations in the Adipose and Lung</td>
<td>H. Hill*, H. Lim, Y. Foong, V. Nelson, K. Won, M. Lazar; Philadelphia, PA.</td>
<td></td>
</tr>
<tr>
<td>2:15 pm</td>
<td><strong>OR44</strong> – The Impact of Traditional Literacy and Education on Health Literacy in Adolescents with Asthma</td>
<td>D. Jordan*, J. Bush², D. Ownby¹, J. Waller¹, M. Tingen¹; 1. Augusta, GA, 2. Macon, GA.</td>
<td></td>
</tr>
<tr>
<td>2:30 pm</td>
<td><strong>OR45</strong> – Evaluations of Inflammatory Cell Markers in Aspirin-exacerbated Respiratory Disease Patients During Aspirin Challenge Test</td>
<td>C. Mitsui*; Sagamihara, Japan.</td>
<td></td>
</tr>
<tr>
<td>2:45 pm</td>
<td><strong>OR46</strong> – History of Eczema is Associated with More Severe Hospital Course in Children Hospitalized for Asthma</td>
<td>M. Liu*, J. Patel², P. Ong¹; 1. Los Angeles, CA, 2. Seattle, WA.</td>
<td></td>
</tr>
<tr>
<td>3:00 pm</td>
<td><strong>OR47</strong> – Seasonal and Regional Variation of Asthma-related Hospitalization and Mortality in the United States</td>
<td>P. Shrestha*, D. Poudel¹, R. Dhital¹, P. Karmacharya²; 1. Wyomissing, PA, 2. Rochester, MN.</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives:**
Upon completion of this session, participants should be able to: OR41) identify epigenetic biomarkers for childhood asthma and the mechanisms underlying these effects; OR42) identify the seasonal effect of air pollution and other risk factors for asthma exacerbations; OR43) recognize the role of functional heterogeneity among innate immune cells in disease; OR44) identify major factors influencing health literacy in adolescents with asthma; OR45) discuss the mechanism of cysLT overproduction after aspirin-induced reaction; OR46) discuss allergic sensitization, eczema and whether they play a role in effecting asthma course and severity; OR47) discuss seasonal variation in asthma related hospitalization and mortality to have better understanding of its management during peak months; and OR48) recognize the impact of team-based care on improving asthma control.

3:30 – 4:00 pm
*****
Refreshment Break on 2nd and 3rd Floors
Sunday General Sessions

4:00 – 5:00 pm • Room 306 • Hynes Convention Center

Current Controversies MOC/CME

Alternative Therapies in Asthma & Allergy Management: Vitamin D, Fish Oil and Prebiotics/Probiotics

Moderator: Don A. Bukstein, MD, FACAAI

This new format will provide information regarding expected outcomes when alternative non-pharmacologic compounds are used and will explore the positive and negative effects of these supplements.

Track: Asthma and Respiratory/Sleep Disorders

Speakers:
Christina E. Ciaccio, MD, MSc, FACAAI and
Gailen D. Marshall, MD, PhD, FACAAI

Learning Objective
Upon completion of this session, participants should be able to:
• Describe evidence that supports or refutes the use of vitamin D, fish oil and/or prebiotics/probiotics as primary versus supplemental therapy for various allergy and asthma conditions.

4:00 – 6:00 pm • Auditorium (2nd Floor) • Hynes Convention Center

Symposium

The Asthmatic Who Does Not Qualify for a T2 Biologic: What Is Next?

Moderator: Bryan L. Martin, DO, FACAAI

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This session is designed to educate participants about issues that arise in managing patients with non-eosinophilic severe asthma and about different and newer therapeutic options. Issues regarding adherence are significant in all patients with asthma and particularly problematic in patients with severe asthma.

Track: Asthma and Respiratory/Sleep Disorders

4:00 pm Welcome and Introductions
Bryan L. Martin, DO, FACAAI

4:05 pm Treat Comorbidities and Address Adherence
Richard J. Martin, MD

4:35 pm Current Therapy and Future Targets
Peter Barnes, MD

5:05 pm Bronchial Thermoplasty
Reynold A. Panettieri, MD

5:35 pm Questions and Discussion

6:00 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Describe comorbidities that contribute to symptoms and exacerbations in patients with severe asthma.
• Discuss other therapies used in severe asthmatics who have failed high-dose ICS therapy.
• Demonstrate the ideal characteristics of the asthmatic patient who would respond to bronchial thermoplasty.

6:30 – 8:30 pm Non-CME Corporate Forums
(See page 83 for details.)

6:45 – 10:30 pm Fundraising Event
Grand Ballroom (2nd Floor) • Sheraton Boston Hotel
(See page 120 for details.)
Monday Meet the Professor Breakfasts

6:30 – 7:45 am
Fee: $50 (FITs: $25) • Limit 30 • Admission by Ticket Only
All Meet the Professor Breakfasts Will Be Held at the Hynes Convention Center

M1 Phenotype-based Approach for the Management of Preschool Episodic Wheezing and Asthma
Room 101
Avraham Beigelman, MD, MSCI and
Stanley Szeftler, MD

Preschool children with episodic wheezing and asthma experience significant morbidity, mainly due to acute exacerbations. This seminar will review the results of recent clinical trials that investigated phenotype-based approaches for preschool asthma management. We will conclude with a suggested phenotype-based approach for the management of preschool episodic wheezing and asthma.

Objectives: Discuss the results of recent clinical trials that investigated therapeutic approaches for preschool asthma; and propose a phenotype-based approach for the management of preschool asthma.

Track: Asthma and Respiratory/Sleep Disorders

M2 Immunodeficiency in Patients With COPD
Room 102
Antoine E. Azar, MD and
Anil Nanda, MD, FACAAI

This session will discuss immunodeficiency in patients with COPD, including antibody deficiency. The role of immunoglobulin replacement therapy and prophylactic antibiotics will be examined. Practical aspects of treating patients with COPD in an allergy medical practice will also be reviewed.

Objectives: Perform immunodeficiency workup of patients with COPD; identify COPD patients who may benefit from immunodeficiency treatment; and categorize the treatment of COPD in an allergy practice.

Track: Asthma and Respiratory/Sleep Disorders

M3 It Must Be Immunodeficiency, but the Immunoglobulins Are Normal!
Room 103
Vivian P. Hernandez-Trujillo, MD, FACAAI and
Richard L. Wasserman, MD, PhD, FACAAI

Although antibody deficiencies are the most common primary immunodeficiency, there is a wide variety of additional defects that may present in a similar fashion. We will discuss the evaluation of patients with suspected immune deficiency in whom the serum immunoglobulins are normal.

Objectives: Evaluate patients with suspected immunodeficiency whose serum immunoglobulins are normal.

Track: Clinical Immunology and Autoimmune and Biologicals

M4 How to Deal With Orthopedic Implants
Room 104
Jonathan A. Bernstein, MD, FACAAI and
Howard I. Maibach, MD

This session will focus on the common contact allergens that are encountered by medical devices and prostheses.

Objectives: Describe the top allergens found in orthopedics, along with associated devices and prosthesis categories (such as surgical preparation, metals, plastics and post-operative care products).

Track: Dermatology

M5 Rush/Cluster IT: How to Implement in Your Practice
Room 107
Michael E. Manning, MD, FACAAI and
James W. Sublett, MD, MPH, FACAAI

Rush and cluster immunotherapy buildup schedules are a treatment option to help patients achieve maintenance dosage sooner than traditional buildup schedules. This course will discuss the logistics of implementing rush/cluster immunotherapy schedules into your clinical practice.

Objectives: Discuss the risk and benefits of rush/cluster immunotherapy schedules; and become familiar with rush/cluster immunotherapy schedules and develop a strategy to implement these schedules in clinical practice.

Track: Immunotherapy and Diagnostics
Monday Meet the Professor Breakfasts

6:30 – 7:45 am
Fee: $50 (FITs: $25) • Limit 30 • Admission by Ticket Only
All Meet the Professor Breakfasts Will Be Held at the Hynes Convention Center

M6  Drug Allergy for the Practicing Allergist
Room 108
Aleena Banerji, MD and
Aidan A. Long, MD

We will review optimal strategies to evaluate patients presenting with drug allergies, including antibiotics and ASA/NSAIDs. This will include the role of skin testing using non-irritating skin test concentrations, drug challenges and desensitization. Current guidelines for management of drug allergy patients will be discussed.

Objectives: Review optimal strategies for evaluation and management of patients with drug allergies.

Track: Food & Drug Allergy and GI Disorders

M7  Eosinophilic Gastrointestinal Disease
Room 109
J. Andrew Bird, MD, FACAAI and
Julie Wang, MD, FACAAI

This interactive session will focus on the diagnosis and management of eosinophilic gastrointestinal diseases and the importance of interdisciplinary care of patients between gastroenterologists and dieticians.

Objectives: Discuss diagnostic criteria for eosinophilic gastrointestinal diseases; and explain treatment options for patients with eosinophilic gastrointestinal disease.

Track: Food & Drug Allergy and GI Disorders

M8  How to Start a Center of Excellence: The Cough Center Experience
Room 110
Mandel R. Sher, MD, FACAAI and
William W. Storms, MD, FACAAI

Learn the tools to develop a clinical center of excellence embedded in a practice, such as assessment and treatment protocols and internal and external marketing, including social media. Cough centers are the model, and we will present the concept of cough hypersensitivity in the diagnosis and treatment of chronic cough.

Objectives: Develop a clinical center of excellence embedded in an existing practice; and integrate the concept of cough hypersensitivity with the diagnosis and treatment of chronic cough.

Track: Practice Management/Professional Issues; Asthma and Respiratory/Sleep Disorders

M9  Mast Cell Activation Syndrome
Room 111
Mariana C. Castells, MD, PhD, FACAAI and
Lawrence B. Schwartz, MD, PhD, FACAAI

This session will cover the diagnosis and treatment of a variety of mast cell-related diseases, including cutaneous mastocytosis, systemic mastocytosis and mast cell activation syndrome.

Objectives: Utilize the current diagnostic criteria for mast cell activation syndrome to care for patients with possible mast cell-related disease; and implement available therapeutics to alleviate symptoms related to mast cell disease.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

M10  Eosinophilic Conditions and the Allergist
Room 200
Michael Wechsler, MD, MMSc

In this session, we will discuss various eosinophilic diseases, from eosinophilic asthma and eosinophilic pneumonia to Churg Strauss syndrome and hypereosinophilic syndrome.

Objectives: Discuss differentiating features between different eosinophilic conditions; and appreciate novel therapies for different eosinophilic conditions.

Track: Food & Drug Allergy and GI Disorders
Monday General Sessions

8:00 – 9:30 am • Auditorium (2nd Floor) • Hynes Convention Center

Plenary Session

Current Approaches for Treatment of Obstructive Lung Disease

Moderator: Michael Wechsler, MD

This session will examine the evidence for treatment of obstructive lung disease.

Track: Asthma and Respiratory/Sleep Disorders

8:00 am Welcome and Introductions
Michael Wechsler, MD

8:05 am John P. McGovern Lecture
GINA 2017: How Will This Change My Practice?
Paul O’Byrne, MD

8:30 am GOLD 2017: How Will This Change My Practice?
Peter Barnes, MD

8:55 am Data Sharing in the Context of Clinical Trials
Jeffrey Drazen, MD

9:20 am Questions and Discussion

9:30 am Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Evaluate the potential positive outcomes from GINA add-on therapy.
• Choose the patient population that will not have sufficient burden of disease to necessitate GOLD therapy.
• Evaluate all of the evidence to provide guidance for appropriate cost-effective use of these medications.

Annual Business Meeting

9:30 – 10:30 am • Auditorium (2nd Floor) • Hynes Convention Center
All Registrants Invited • Refreshments Will Be Provided

Stephen A. Tilles, MD, FACAAI Presiding

I. Call to Order
Stephen A. Tilles, MD, FACAAI

II. Approval of 2016 Minutes and Standing Rules
Stephen A. Tilles, MD, FACAAI

III. Historian’s Report
Joseph A. Bellanti, MD, FACAAI

IV. Foundation President’s Report
Ira Finegold, MD, FACAAI

V. Alliance President’s Address
Mrs. Charlotte Meadows

VI. State of the College
Stephen A. Tilles, MD, FACAAI

VII. Recognition of Outgoing Regents
Stephen A. Tilles, MD, FACAAI

VIII. Nominating Council Report and Election of Officers
James L. Sublett, MD, FACAAI

IX. Presentation of New Officers and Regents
Stephen A. Tilles, MD, FACAAI

X. Installation of New President
Stephen A. Tilles, MD, FACAAI

XI. President’s Acceptance
Bradley E. Chipps, MD, FACAAI

XII. Presentation to Outgoing President
Bradley E. Chipps, MD, FACAAI

XIII. New Business
Bradley E. Chipps, MD, FACAAI

XIV. Adjournment
Bradley E. Chipps, MD, FACAAI
Symposium

Immunology of Eczema: How to Best Address the Itch That Rashes Cause

Moderator: Lynda Schneider, MD, FACAAI

Allergists are seeing patients from a variety of age groups who present with chronic pruritic dermatitis. Often the diagnosis is not eczema. It is important to become familiar with these masqueraders, their pathophysiology and treatment options.

Track: Clinical Immunology and Autoimmune and Biologicals; Dermatology

10:30 am Welcome and Introductions
Lynda Schneider, MD, FACAAI

10:35 am Immunology of Eczematous Dermatitis: How to Best Address It
Donald Y. Leung, MD, PhD, FACAAI

11:05 am Dealing With Chronic Scratchers: How to Best Address the Problem
Gil Yosipovitch, MD

11:35 am Skin Diseases in the Elderly
Luz S. Fonacier, MD, FACAAI

12:05 pm Questions and Discussion

12:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

• Demonstrate competency in recognizing various forms of dermatitis that are not eczema.
• Apply treatment strategies to relieve symptoms of dermatitis.
• Prioritize different treatment strategies for the patient who itches from dermatitis.

12:30 – 1:00 pm Lunch (on own)

1:00 – 3:00 pm Oral Abstracts
(See pages 68-70 for details.)

3:00 – 3:30 pm Refreshment Break in Auditorium Foyer (2nd Floor)
Monday Oral Abstracts

1:00 – 3:00 pm • Auditorium (2nd Floor) • Hynes Convention Center

Session A
Clinical Immunology, Immunodeficiency and Other

1:00 pm
**OR61** – Stratification of Peanut-murine Model into Anaphylaxis Severity Risk Groups Using Intradermal Testing Read by Thermography

1:15 pm
**OR62** – Eosinophilia and an Elevated Immunoglobulin E in an Elderly Male
J. Brooks*, F. Lobo; New Haven, CT.

1:30 pm
**OR63** – A Case of Recurrent Splenic Lesions in a Patient with Vici Syndrome
S. Jain*, A. Larkin, H. Chong; Pittsburgh, PA.

1:45 pm
**OR64** – Ocular Manifestations in Primary Immunodeficiency (PID) Patients Within the US Immunodeficiency Network (USIDNET) Registry

2:00 pm
**OR81** – Associations Between Urine Naphthol Concentrations and Allergic Diseases in Children
I. Wang*, T. Lin; Taipei, Taiwan.

2:15 pm
**OR82** – Bovine Colostrum Supplementation in Respiratory Allergies According to Sensitization: Subgroup Analysis of Randomized Controlled Trial

2:30 pm
**OR83** – Medication Use and Drug Allergies Do Not Appear More Frequent Among Patients with Eosinophilic Esophagitis
L. Rothstein*, R. Miller, B. Lebwohl, P. Green, S. Lagana, R. Abdelmessih; New York, NY.

2:45 pm
**OR84** – A Novel Mutation Identified in the SATB1 Gene, Presenting as Hyper IgM Syndrome
Y. Abedi*, V. Bonagura; Great Neck, NY.

3:00 pm
Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to: OR61) learn how thermography, a nonlethal, inexpensive and minimally invasive procedure, can be used to determine allergic sensitization in the murine model prior to a challenge; OR62) discuss the evaluation of patients with eosinophilia and elevated IgE levels; OR63) discuss rare presentations of patients with Vici Syndrome; OR64) discuss ocular manifestations in patients with primary immunodeficiency; OR81) identify the effect of polycyclic aromatic hydrocarbons exposures on allergic diseases; OR82) differentiate monosensitized from polysensitized patients in terms of their response to bovine colostrum supplement; OR83) discuss whether medication use and drug allergy are more common in patients with EOE undergoing biopsy; and OR84) describe the different clinical and genetic manifestations of hyper IgM syndrome, and the utility of whole exome sequencing when hyper IgM syndrome targeted testing fails to elucidate the diagnosis.

3:00 – 3:30 pm
Refreshment Break in Auditorium Foyer (2nd Floor)
# Monday Oral Abstracts

## Session B
### Food Allergy

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm</td>
<td><strong>OR71</strong> – Prevalence of Coexisting Diagnoses in Patients With Eosinophilic Esophagitis in a Large Pediatric Population</td>
<td>P. Capucilli*, A. Cianferoni, J. Spergel; Philadelphia, PA.</td>
<td></td>
</tr>
<tr>
<td>1:15 pm</td>
<td><strong>OR72</strong> – Viscous Oral Cromolyn for the Treatment of Eosinophilic Esophagitis: A Double-blind, Placebo-controlled Trial</td>
<td>J. Lieberman*, J. Zhang, C. Cavender; Memphis, TN.</td>
<td></td>
</tr>
<tr>
<td>1:30 pm</td>
<td><strong>OR73</strong> – Cost-effectiveness of Confirmatory Oral Food Challenges in the Diagnosis of Children with Food Allergy</td>
<td>S. Leibel, A. Alsaggaf*, J. Murphy; San Diego, CA.</td>
<td></td>
</tr>
<tr>
<td>1:45 pm</td>
<td><strong>OR74</strong> – Comparison of Galactose-a-1,3-galactose Specific IgE Responses in Children From Rural Kenya and Central Virginia</td>
<td>J. Wilson*1, A. Schuyler1, L. Workman1, M. Perzanowski2, H. James1, S. Commins1, P. Heymann1, T. Platt-Mills2; 1. Charlottesville, VA, 2. Brooklyn, NY.</td>
<td></td>
</tr>
<tr>
<td>2:00 pm</td>
<td><strong>OR75</strong> – What Pediatricians Are Advising on Infant Peanut Introduction</td>
<td>B. Hoffman*1, L. Moreno2, L. Gerber1, D. D’Angelo1, E. Abramson1; 1. New York, NY, 2. Jackson Heights, NY.</td>
<td></td>
</tr>
<tr>
<td>2:30 pm</td>
<td><strong>OR77</strong> – The Prevalence of Nut and Seafood Allergies Among Adults in the United States</td>
<td>R. Gupta*1, J. Blumenstock1, C. Warren2, K. Mittal1, J. Kotowska1, B. Smith1; 1. Chicago, IL, 2. Alhambra, CA.</td>
<td></td>
</tr>
<tr>
<td>2:45 pm</td>
<td><strong>OR78</strong> – The Prevalence of Childhood Food Allergy in the United States: An Update</td>
<td>R. Gupta*1, C. Warren2, J. Blumenstock1, J. Kotowska1, K. Mittal1, B. Smith1; 1. Chicago, IL, 2. Alhambra, CA.</td>
<td></td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives:**
Upon completion of this session, participants should be able to: **OR71** identify the most common and potentially novel comorbidities seen in patients with Eosinophilic Esophagitis; **OR72** discuss results of a clinical trial of cromolyn for EoE; **OR73** discuss the cost-effectiveness of oral food challenges compared to specific food avoidance; **OR74** recognize nuances in using alpha-gal specific IgE to diagnose alpha-gal allergy; **OR75** recognize the revised guidelines on peanut introduction and how they are influencing the practice of pediatricians in the community; **OR76** discuss potential differences in adverse events during positive food challenges to peanut among peanut-allergic children, adolescents and adults; **OR77** discuss the representative estimated prevalence of allergy to shellfish, fin fish, peanut, and tree nuts in adults in the United States; and **OR78** discuss an updated representative estimate of food allergy prevalence in children in the United States.
Monday Oral Abstracts

1:00 – 3:15 pm • Ballroom A (3rd Floor) • Hynes Convention Center

Session C
Pharmacology/Pharmacotherapeutics, Rhinitis and Other Upper Airway Disorders, and Skin Disorders

1:00 pm

OR90 – Quality Improvement Survey Assessing Immunotherapy Efficacy and Barriers in an Outpatient Setting

1:15 pm

OR91 – The Disease Severity and Quality of Life of Asthmatic Children After Probiotics Supplementation
I. Wang*, J. Hsu; Taipei, Taiwan.

1:30 pm

OR92 – Utility of Inpatient Penicillin Allergy Testing at Reducing Exposure to Non-Beta Lactam Antibiotics

1:45 pm

OR93 – Evaluating Pneumococcal Vaccination Status, Patient Demographics and Disease Burden at an Internal Medicine Clinic

2:00 pm

OR101 – Outcomes of Patients With Aspirin-exacerbated Respiratory Disease on Omalizumab
T. Jean*, V. Eng, J. Sheikh, S. Samant; Los Angeles, CA.

2:15 pm

OR111 – Determining the Clinical Relevance of Positive Patch Testing to Gold
B. Yang*, B. Sundquist, M. Pasha; Albany, NY.

2:30 pm

OR112 – Effect of Prenatal Dog Exposure on Eczema Development in Early and Late Childhood

2:45 pm

OR113 – Secondary Immunodeficiency Due to Immunosuppressants for Allergic Contact Dermatitis (ACD) From Vascular Clips
S. Joshi*, D. Khan; 1. Dallas, TX, 2. Grapevine, TX.

3:00 pm

OR114 – Pilot Study Evaluating the Effects of Baby’s First Bath on Newborn Skin
D. Preston*, J. Wisniewski, A. Smith; Charlottesville, VA.

3:15 pm

Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
OR90) discuss barriers associated with immunotherapy administration in an outpatient setting along with expected time of improvement; OR91) identify the effects of probiotics on the disease severity, quality of life, and immune biomarkers of children with asthma; OR92) identify the strengths and limitations of inpatient penicillin skin testing as a component of antibiotic stewardship; OR93) evaluate the shortcomings in pneumococcal vaccine administration in order to identify and overcome barriers; OR101) discuss available treatments for aspirin-exacerbated respiratory disease; OR111) discern the clinical relevance of positive patch testing to gold; OR112) describe the effect of prenatal dog exposure on the risk for eczema in childhood; OR113) identify secondary immunodeficiency as a complicating factor in management of severe contact dermatitis due to limited treatment options; and OR114) obtain the knowledge necessary to assess transepidermal water loss in atopic dermatitis.

3:00 – 3:30 pm
 Refreshment Break in Auditorium Foyer (2nd Floor)
Monday General Sessions

3:30 – 5:00 pm • Auditorium (2nd Floor) • Hynes Convention Center

Plenary Session MOC/CME

What We Know: Non-infectious Complications of PID

Moderator: Richard L. Wasserman, MD, PhD, FACAII

Many primary immunodeficiency disorders (PID) present with signs and symptoms of immune dysregulation. We will highlight national data on non-infectious complications of PID and discuss the evaluation of patients. We will also present current information on the use of biologicals to treat specific immune deficiencies, as well as advances in this area.

**Track:** Clinical Immunology and Autoimmune and Biologicals

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30</td>
<td>Welcome and Introductions</td>
<td>Richard L. Wasserman, MD, PhD, FACAII</td>
</tr>
<tr>
<td>3:35</td>
<td>What We Know: Data From USIDNet on the Frequency of Non-infectious Complications of PID</td>
<td>Kathleen Sullivan, MD, PhD</td>
</tr>
<tr>
<td>4:00</td>
<td>What We Need to Know: Evaluation of PID Patients With Immune Dysregulation</td>
<td>Troy Torgerson, MD, PhD</td>
</tr>
<tr>
<td>4:25</td>
<td>Where Are We Going? Personalized Therapy for Monogenic Immune Deficiency With Immune Dysregulation</td>
<td>Jennifer Leiding, MD</td>
</tr>
<tr>
<td>4:50</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>5:00</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Describe the frequency of non-infectious complications of primary immunodeficiency.
- Recognize the manifestations of non-infectious complications of primary immunodeficiency and the appropriate evaluation of the patient.
- Be aware of the therapeutic options available for the treatment of monogenic immunodeficiencies, including monoclonal antibodies.

5:00 pm

2017 Annual Scientific Meeting Adjourns
Fellows-in-Training Programs

All Fellows-in-Training (FITs) are encouraged to participate in the following special activities designed to meet their unique needs and interests. Friday’s FIT General Meeting includes the presentations and election of a FIT representative to the Board of Regents. All of the activities shown on these pages, as well as plenary sessions and symposia, are complimentary.

Friday

3:30 – 5:30 pm
Ballroom A (3rd Floor) • Hynes Convention Center
FIT Educational Program

Moderators: Tammy Peng, MD and Amar Dixit, MD

During this educational program, there will be a panel discussion regarding opportunities for involvement in the College, both in fellowship and beyond. After that, speakers will discuss the diagnosis and management of stinging insect hypersensitivity and the association of autoimmunity and immune dysregulation in immune disorders.

3:30 pm  Welcome and Introductions
Tammy Peng, MD and Amar Dixit, MD

3:35 pm  Getting Involved: Starting in Fellowship and Above and Beyond
Warner W. Carr, MD, FACAAI; Bryan L. Martin, DO, FACAAI and Meagan W. Shepherd, MD, FACAAI

4:10 pm  Stinging Insect Hypersensitivity and Venom Immunotherapy
David B.K. Golden, MD, FACAAI

4:45 pm  Autoimmunity and Immune Dysregulation in Immune Deficiency Disorders
Charlotte Cunningham-Rundles, MD

5:00 pm  Questions and Discussion

5:30 pm  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:
- Identify testing and history necessary for the diagnosis of stinging insect hypersensitivity and to recognize indications for and management of venom immunotherapy.
- Describe the roles of autoimmunity and immune dysregulation in immune deficiency disorders.
- Identify opportunities for involvement in the College and acquire strategies for continued involvement throughout their careers.

5:30 – 6:30 pm
Ballroom A (3rd Floor) • Hynes Convention Center
FIT General Meeting

5:30 pm  Welcome and Introductions
Tammy Peng, MD
Senior FIT Representative

5:35 pm  FIT Section Update
Amar Dixit, MD
Junior FIT Representative

Candidate Speeches and Election of Junior FIT Representative

5:55 pm  ABAI Certification
Stephen I. Wasserman, MD, FACAAI
American Board of Allergy and Immunology

6:10 pm  ACAAI Update
Stephen A. Tilles, MD, FACAAI
ACAAI President

6:30 – 7:30 pm
Back Bay Ballroom Salons BCD (2nd Floor)
Sheraton Boston Hotel
FIT Welcome Reception

Fellows-in-Training are invited to attend the FIT Welcome Reception. It’s the perfect place to kick back and connect with FITs from other programs across the country after a day packed with learning.

Supported by Stallergenes Greer
Fellows-in-Training Programs

Saturday

Fellows-in-Training/Allergy-Immunology Program Directors’ Breakfast
6:30 – 7:45 am
Back Bay Ballroom Salons BCD (2nd Floor)
Sheraton Boston Hotel
Supported by Mylan

Doctors’ Job Fair
12:30 – 3:30 pm
Hall A (1st Floor)
Hynes Convention Center

26th Annual FIT Bowl Competition
5:00 – 7:00 pm
Ballroom BC (3rd Floor)
Hynes Convention Center
Supported by Teva Respiratory

ACAAI Awards Ceremony
7:00 – 7:45 pm
Constitution Ballroom Salon B (2nd Floor)
Sheraton Boston Hotel
Supported by Mylan

President’s Welcome Reception
7:45 – 9:00 pm
Grand Ballroom (2nd Floor)
Sheraton Boston Hotel
Supported by Genentech, Inc. and Novartis Pharmaceuticals Corporation

Clemens von Pirquet Awards

The ACAAI Alliance will present Clemens von Pirquet Awards to three Fellows-in-Training for their outstanding abstracts at the Awards Ceremony, 7:00 pm, Saturday. The recipients are:

The Alliance Memorial Award recipient is Dr. Brian P. Peppers, Case Western Reserve University, Richmond Heights, OH, who will receive a $2,500 first place award for his abstract, “Stratification of Peanut-murine Model Into Anaphylaxis Severity Risk Groups Using Intradermal Testing Read by Thermography.”

The second place award of $1,500 will be presented to Dr. Karina Shah Gobin, Medical College of Wisconsin, Milwaukee, WI, for her abstract, “Quality Improvement Survey Assessing Immunotherapy Efficacy and Barriers in an Outpatient Setting.”

Dr. David A. Hill, The Children’s Hospital of Philadelphia, Philadelphia, PA, will receive a $1,000 third place award for his abstract, “Obesity Disrupts Tissue-protective Macrophage Populations in the Adipose and Lung.”

Young Faculty Support Awards

The Foundation of ACAAI will present two $50,000 Young Faculty Support Awards at the Awards Ceremony, 7:00 pm, Saturday. The recipients of the awards are:

Kuan-Hsiang Gary Huang, MD PhD MSc, Albert Einstein Medical Center, Philadelphia, PA.

Anjeni Keswani, MD, MSCI, George Washington University School of Medicine and Health Sciences, Washington, DC.

Travel Scholarships

The ACAAI Travel Scholarship Donors awarded travel scholarships to 235 Fellows-in-Training to attend the 2017 Annual Scientific Meeting.

ACAAI Thanks Its Travel Scholarship Sponsors

The Fellows-in-Training section of the College expresses its appreciation to the following sponsors of this year’s Fellows-in-Training Travel Scholarships:

Boston Scientific
Capitol Associates*
Johnson & Johnson Consumer, Inc.
Nestlé Nutrition Institute
Teva Respiratory

*In honor of Dr. Donald Aaronson’s service to the College.

Sunday

Fellows-in-Training/Allergy-Immunology Program Directors’ Luncheon
12:30 – 1:30 pm
Back Bay Ballroom Salons BCD (2nd Floor)
Sheraton Boston Hotel
Supported by Teva Respiratory
Friday Office Administrators
Practice Management Course

8:00 am – 4:00 pm • Room 311 • Hynes Convention Center
Separate Registration Fee • Admission by Ticket Only
Moderator: Kay Tyler, BS, BA, MBA

Target Audience: Office practice administrators/managers, nurse managers and other clinical staff responsible for practice management activities, new and established allergist-immunologists in private practice, employed allergists and FITs.

Track: Practice Management/Professional Issues

8:00 am
Welcome and Introductions
Kay Tyler, BS, BA, MBA

8:05 am
Advocacy Council Update
J. Allen Meadows, MD, FACAAI, Advocacy Council Chair
This session will bring you up to date on recent Advocacy Council activities, as well as changes in regulations, payment and insurance.

8:55 am
ACAAI Resources to Help Your Practice Thrive
Jennifer Pfeifer, MBA, CMPE
Practice managers wear numerous hats and are expected to be experts in everything from HR to coding to marketing to MIPs. But where can you find reliable information on all these topics? The College website has a wealth of resources on allergy practice management and should be your first stop when looking for information.

9:15 am
Refreshment Break

9:30 am
The Changing World of Regulations and Payment: MIPS, APMs and Telehealth
Kim Alexander and Kay Tyler, BS, BA, MBA
2017 is a transition year for MIPS, but 2018 will require full participation to avoid penalties. Find out how to participate in MIPS successfully, how APMs might be a solution and what telehealth might look like for allergists.

10:00 am
Questions and Discussion

10:20 am
Human Resources in the Millennial Generation
Helen Combs
From the front desk clerk to the busy physician, we are dealing with several generational differences that affect recruiting and retention. This session will hit on trends in creative staffing, building a strong human resources arm within any size practice, and monitoring provider well-being to have a top-notch practice.

10:40 am
Lunch Break (on own)

11:00 am
Financial Services: Coding and Collecting to Maximize Revenue
Charlie Furr, MHA
As insurance reimbursement continues to shift more of the financial burden to patients, practices must also shift office policies on upfront collections, explanation of benefits to confused patients, and financing/managing potential bad debt. This session will cover how to code correctly on the front end, how to manage the patient burden and how to watch the bottom line.

Continues next page
I Dreamt I Was in the Most Awesome Doctor’s Office and I Liked It
Laura Meadows
As consumers of health care services, we absolutely know what we like, and don’t like, when going to the provider’s office. Time. Staff. Facility. Provider. Communication. This session will take a look, through a very critical eye, at what the new patient, the follow-up patient, and the shot patient honestly see in the office, and what they dream of seeing in the office.

Measurement and Benchmarks and How to Create a Management Dashboard
Shaun Kwan, MBA, BSEE
This session will discuss financial measurements (e.g. collections, write-offs) and operational measurements (e.g. no-show rates, provider scheduling) and their usefulness in managing a practice. This session will also cover quality metrics (e.g. MIPS reports, patient surveys) and how to use them to improve quality in the practice.

Learning Objectives
Upon completion of this session, participants should be able to:
• Describe important changes at the national level that impact practice management; and discuss future changes within the allergy landscape.
• Summarize the practice resources and advocacy resources section of the ACAAI website; outline the resources available to practices and the subject areas covered; and explain the benefits of becoming an ACAAI Allied Health member.
• Describe MIPS reporting requirements for 2017 and 2018; discuss how APMs might be an alternative for allergy practices; and review the requirements for telehealth and identify telehealth options for allergy practices.
• Discuss concrete samples and examples of managing the vastness of human resources in today’s environment; and identify generational differences to help to cope, address, and excel in managing resources.
• Discuss coding tips for procedures in the allergists’ office and manage the patient through the collections process; and describe trends in insurance reimbursement and how to guard against pitfalls in coding and delays in receiving payment.
• Discuss practical tips on improving patient satisfaction from the front door to the billing statement; and design operational efficiencies in clinics and shot rooms using best practices learned from other allergists’ offices.
• Design a management dashboard, encompassing various measurements and benchmarks, to improve practice outcomes.

Advanced Practice, Allied Health and Office Administrators Networking Reception
4:45 – 6:00 pm
Back Bay Ballroom Salon A (2nd Floor)
Sheraton Boston Hotel
Supported by DBV Technologies
Friday Advanced Practice
Health Care Providers Course

8:00 am – 2:00 pm • Room 312 • Hynes Convention Center
Separate Registration Fee • Admission by Ticket Only

Target Audience: Nurse practitioners, physician assistants, allergy-immunology nurses, other health care providers with extensive experience and physicians. This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 7.25 contact hours of accredited education.

Moderator: Jodi Shroba, MSN, APRN, CPNP

Track: Practice Management/Professional Issues

8:00 am  Welcome and Introductions  Jodi Shroba, MSN, APRN, CPNP
8:05 am  Anaphylaxis “Outside the Box:” Interpretation and Treatment of Those Difficult Cases  Kimberly G. Clay, RN, MSN, APRN, FNP-BC and Stanley Fineman, MD, MBA, FACAAI
8:55 am  Biologics: What We Know and Don’t Know  Gailen D. Marshall, MD, PhD, FACAAI
9:50 am  Questions and Discussion
9:55 am  Refreshment Break
10:10 am  SLIT or SCIT: That Is the Question  Mary Lou Hayden, RN, MSN, FNP-BC, AE-C
11:00 am  Questions and Discussion
11:05 am  Bumps in the Road: How Changes in the Health Care Landscape Will Affect Our Patients and Practice  Gary N. Gross, MD, FACAAI
11:55 am  Questions and Discussion

Noon  Lunch (on own)
1:00 pm  All About the Microbiome  Christina E. Ciaccio, MD, MSc, FACAAI
1:55 pm  Questions and Discussion

Learning Objectives
Upon completion of this session, participants should be able to:

- Recognize signs and symptoms of unusual causes of anaphylaxis; identify “pseudo-anaphylaxis” and understand proper management of this condition; and interpret case scenarios, including evaluation and development of management plan.
- Explain indication of biologics; and identify patients who would benefit from biologic therapy.
- Identify appropriate patients for SCIT and SLIT; discuss administration issues and controversies in SLIT; and discuss benefits and risks in SCIT and SLIT.
- Discuss how changes in national health care coverage will change our practice; and discuss how patient coverage will affect our patients.
- Review how microbiota contribute to a healthy immune system; and discuss the role of intestinal microbiota in the development of food allergy and other chronic diseases.

Continues next page
Friday Advanced Practice
Health Care Providers Course (continued)

2:00 – 4:45 pm
Admission by Ticket Only
Interactive Concurrent Workshops

2:00 – 3:15 pm

AP1 Hot Topics in Allergy and Asthma: A Review of the Literature
   Room 102 • Hynes Convention Center
   Charlotte Jacobsen, MSN, RN and
   Jodi Shroba, MSN, APRN, CPNP

AP2 Integrative Allergy: Evidence-based Integrative Medicine in Allergy Practice
   Room 103 • Hynes Convention Center
   William S. Silvers, MD, FACAAI

AP3 To the Internet and Beyond: The Use of Technology to Advance Our Practice
   Room 104 • Hynes Convention Center
   Jay M. Portnoy, MD, FACAAI and
   Jamie Wolverton, BHS, RRT-NPS, AE-C

3:15 pm Refreshment Break

3:30 – 4:45 pm

AP4 Hot Topics in Allergy and Asthma: A Review of the Literature
   Room 102 • Hynes Convention Center
   Charlotte Jacobsen, MSN, RN and
   Jodi Shroba, MSN, APRN, CPNP

AP5 Integrative Allergy: Evidence-based Integrative Medicine in Allergy Practice
   Room 103 • Hynes Convention Center
   William S. Silvers, MD, FACAAI

AP6 To the Internet and Beyond: The Use of Technology to Advance Our Practice
   Room 104 • Hynes Convention Center
   Jay M. Portnoy, MD, FACAAI and
   Jamie Wolverton, BHS, RRT-NPS, AE-C

4:45 pm Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• AP1/AP4 – Discuss evidence pertinent to advanced practice in allergy and asthma as presented in recent literature; and correlate current research findings to best practice in allergy and asthma.

• AP2/AP5 – Describe and distinguish integrative, complementary, and alternative modalities in allergy and asthma and assess their evidence basis; and access worthwhile online resources for integrative modalities, supplements and history-taking templates.

• AP3/AP6 – Describe the use of telemedicine in practice; and discuss ways to use social media and apps to enhance patient education.

4:45 – 6:00 pm
Advanced Practice, Allied Health and Office Administrators Networking Reception
Back Bay Ballroom Salon A (2nd Floor)
Sheraton Boston Hotel
Supported by DBV Technologies
Saturday Allied Health Professionals Course

8:00 am – 12:15 pm • Rooms 302-304 • Hynes Convention Center

Separate Registration Fee • Admission by Ticket Only

Target Audience: Health professionals including, but not limited to, RNs, LPNs, MAs, PAs, NPs, MDs/DOs. This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 11.0 contact hours of accredited education.

Moderator: Kimberly G. Clay, RN, MSN, APRN, FNP-BC

Track: Practice Management/Professional Issues

8:00 am Welcome and Introductions
Jodi Shroba, MSN, APRN, CPNP

8:05 am On Their Own: Transitioning Our Allergic Patients to College
David R. Stukus, MD, FACAAI
In this session, participants will be able to help transition their teenage patients with asthma and food allergies to college life. We will discuss tips for success and possible barriers that might impede successful living at college.

9:00 am What's Eating You: Dealing With Food Allergy-related Anxiety
Melissa Korenblat-Hanin, ACSW, LCSW
This presentation will explore the importance of acknowledging the thoughts and feelings associated with having and living with food allergies. We will discuss how to recognize, understand and address anxiety-related symptoms. We will address ways to build confidence and competence in navigating food allergies safely in order to minimize risk-taking behaviors. The session will assist with understanding components that enhance and build stability, security and sensibility in dealing with food allergies.

9:55 am Refreshment Break

10:10 am Eosinophilic Esophagitis Management
Megan Ott Lewis, CPNP
In this session, participants will learn about the work-up for EoE and testing and diet modification for EoE. This will include any new treatment options.

11:05 am Understanding Oral Immunotherapy and Its Application in Clinical Practice
Justin Greiwe, MD
This course will provide a detailed synopsis of oral immunotherapy (OIT), reviewing the history of OIT and examining evidence supporting its use. Identification of patients who might benefit from this therapy will be discussed, but we will also highlight the risks and limitations associated with OIT.

Noon Questions and Discussion

12:15 pm Lunch (on own)

Learning Objectives
Upon completion of this session, participants should be able to:

• Identify key components to help students transition to college; and identify dangers and barriers to transitioning patients to independent living.
• Discuss interviewing techniques that would help identify anxiety in patients and families; and describe techniques that will help patients reduce their anxiety related to food allergy diagnosis.
• Describe presenting signs and symptoms of EoE; discuss diagnostic testing in EoE; discuss elimination diets and pharmacotherapy for EoE.
• Recognize how to appropriately diagnose and evaluate patients with food allergies; summarize the various therapies currently available for food immunotherapy; and identify the dangers and limitations associated with food immunotherapy, specifically OIT.

Continues next page
Health Care Providers

Saturday Allied Health Professionals Course (continued)

1:30 – 4:45 pm

Admission by Ticket Only

Interactive Concurrent Workshops

1:30 – 3:00 pm

AHP1  Beyond FEV1: Improve Your Spirometry Skills
Room 102  •  Hynes Convention Center
Michelle R. Dickens, MSN, RN, FNP-C, AE-C and
Concettina Tolomeo, DNP, APRN, FNP-BC, AE-C

The diagnosis and management of diseases such as asthma and COPD rely on accurate interpretation of spirometry. However, many providers rely on simple FEV1 interpretation, which can be misleading. This session will explore acceptability, reproducibility, proper coaching techniques, and additional spirometry parameters to produce a more accurate and precise interpretation.

This activity is supported by Micro Direct, Inc. through an independent educational grant consisting of loaned durable equipment.

AHP2  Immunotherapy Guideline Update: Compliance With USP 797 and Office Compounding
Room 103  •  Hynes Convention Center
Cheryl K. Bernstein, BSN, RN, CCRC and J. Allen Meadows, MD, FACAAI

The program will update the participants on the current requirements for allergen extract compounding according to USP 797 and the new FDA’s “Insanitary Conditions at Compounding Facilities.” The discussion will include a practical approach to implementing the requirements in the allergy practice.

AHP3  Patient Education in a Fast-paced Allergy Office: Pearls From 60 Years of Practice
Room 104  •  Hynes Convention Center
Mary Lou Hayden, RN, MSN, FNP-BC, AE-C and Kristen Welborn, MSN, APRN, FNP-BC

Description Patient education is essential in healthcare, and particularly in allergic diseases and asthma. This workshop will present key findings from the literature on learning principles, health literacy, assessing readiness to make behavioral changes and assessing role of culture in patient education. This information will be related to typical asthma and allergy patients in our practices.

3:00 pm  Refreshment Break

3:15 – 4:45 pm

AHP4  Beyond FEV1: Improve Your Spirometry Skills
Room 102  •  Hynes Convention Center
Michelle R. Dickens, MSN, RN, FNP-C, AE-C and
Concettina Tolomeo, DNP, APRN, FNP-BC, AE-C

The diagnosis and management of diseases such as asthma and COPD rely on accurate interpretation of spirometry. However, many providers rely on simple FEV1 interpretation, which can be misleading. This session will explore acceptability, reproducibility, proper coaching techniques, and additional spirometry parameters to produce a more accurate and precise interpretation.

This activity is supported by Micro Direct, Inc. through an independent educational grant consisting of loaned durable equipment.

AHP5  Immunotherapy Guideline Update: Compliance With USP 797 and Office Compounding
Room 103  •  Hynes Convention Center
Cheryl K. Bernstein, BSN, RN, CCRC and J. Allen Meadows, MD, FACAAI

The program will update the participants on the current requirements for allergen extract compounding according to USP 797 and the new FDA’s “Insanitary Conditions at Compounding Facilities.” The discussion will include a practical approach to implementing the requirements in the allergy practice.

AHP6  Patient Education in a Fast-Paced Allergy Office: Pearls From 60 Years of Practice
Room 104  •  Hynes Convention Center
Mary Lou Hayden, RN, MSN, FNP-BC, AE-C and Kristen Welborn, MSN, APRN, FNP-BC

Patient education is essential in healthcare, and particularly in allergic diseases and asthma. This workshop will present key findings from the literature on learning principles, health literacy, assessing readiness to make behavioral changes and assessing role of culture in patient education. This information will be related to typical asthma and allergy patients in our practices.

4:45 pm  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• AHP1/AHP4 – Describe the concepts of acceptability and reproducibility as they relate to spirometry testing; demonstrate proper coaching techniques for patients performing spirometry testing; and discuss the role of the FEV1/FVC ratio as it applies to spirometry interpretation.

• AHP2/AHP5 – Describe the compliance requirements for allergen extract preparation according to USP chapter 797 and the new FDA regulations; identify practical approaches for implementation of the USP 797 compounding guidelines in the allergy office.

• AHP3/AHP6 – Discuss teaching/learning principles in health care; discuss health literacy, including identification and culturally sensitive approaches; apply teaching/learning and health literacy principles to pediatric, adult and older adult patient cases.
Sunday Allied Health Professionals Course

8:00 am – 12:15 pm • Rooms 302-304 • Hynes Convention Center
Separate Registration Fee • Admission by Ticket Only

Target Audience: Health professionals including, but not limited to, RNs, LPNs, MAs, PAs, NPs, MDs/DOs. This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 11.0 contact hours of accredited education.

Moderator: Charlotte Jacobsen, MSN, RN

Track: Practice Management/Professional Issues

8:00 am  Welcome and Introductions
Jodi Shroba, MSN, APRN, CPNP

8:05 am  Allergic Rhinitis Across the Spectrum: Presentation, Diagnostics and Treatment Options
Anne K. Ellis, MD, MSc, FACAAI

9:00 am  Medication Adherence in COPD and Adult Asthma
Maureen George, PhD, RN, AE-C, FAAN

9:55 am  Refreshment Break

10:10 am  Asthma Yardstick
Roxana Siles, MD, FACAAI

11:05 am  Adverse Reactions to Vaccines
Dana V. Wallace, MD, FACAAI

Noon  Questions and Discussion
12:15 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Discuss common and unusual presenting signs and symptoms of allergic rhinitis; compare in vivo and in vitro diagnostic testing options; plan pharmacologic and nonpharmacologic treatment approaches to cases of allergic rhinitis.
• Describe similarities and differences in medication adherence between two common adult populations.
• Describe how to personalize asthma treatments based on asthma phenotypes; and describe how to use an asthma yardstick to manage patients not responsive to standardized asthma step care.
• Discuss types of adverse reactions to vaccinations; review vaccine testing procedures and which patients need testing; and discuss excipients in vaccines.
Following the close of Thursday, Friday, Saturday and Sunday’s scientific sessions, all registrants are invited to attend the special Corporate Forums at the Sheraton Boston Hotel. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your educational experience.

Thursday, October 26

6:00 – 8:00 pm
Independence Ballroom (2nd Floor)
Sheraton Boston Hotel

Supported by Teva Respiratory

Realities of Asthma Care: Because Patients Can Be Hard to Read

Presented by:
Randall W. Brown, MD

This Teva Respiratory-supported dinner presentation will discuss how patient perception about asthma and its treatment impacts clinical outcomes, review the benefits and challenges that different types of inhaler technologies present for patients, consider how device technologies may affect inhalation technique, and examine how a patient-centric approach to asthma management, treatment selection, and medication dosing may help improve adherence and outcomes for patients with asthma.

Also visit Teva Respiratory at Booth #2408.

6:00 – 8:00 pm
Liberty Ballroom Salons ABC (2nd Floor)
Sheraton Boston Hotel

Supported by Shire

The Role of Sustained Kallikrein Inhibition: Driving Change in the Management of HAE

Presented by:
Aleena Banerji, MD
William Lumry, MD
Douglas Johnston, DO
Allen Kaplan, MD
Alvin Schmaier, MD
Raffi Tachdjian, MD

Shire invites you to a dinner program to explore the role of plasma kallikrein in the pathophysiology of HAE and how to manage this rare, potentially life-threatening disease. Optimization of current treatments for HAE will be discussed, as well as the potential of future therapies to address currently unmet needs.

Also visit Shire at Booth #2608.
Friday Non-CME Corporate Forums

Following the close of Thursday, Friday, Saturday and Sunday’s scientific sessions, all registrants are invited to attend the special Corporate Forums at the Sheraton Boston Hotel. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your educational experience.

Friday, October 27

6:30 – 8:30 pm
Constitution Ballroom (2nd Floor)
Sheraton Boston Hotel

Supported by Aimmune Therapeutics

From Diagnosis to Potential Future Oral Immunotherapeutic Options: Understanding the Burden and Risk of Avoidance in Peanut Allergy

Presented by:
Ruchi Gupta, MD
J. Andrew Bird, MD
Linda Herbert, PhD

During this case-based panel discussion, Ruchi Gupta, MD, MPH (moderator); J. Andrew Bird, MD; and Linda Herbert, PhD, will discuss the impact of peanut allergy on patients’ and caregivers’ lives, providing an allergist’s and a psychologist’s perspectives. The discussion will also cover potential oral treatments that could confer desensitization.

Also visit Aimmune Therapeutics at Booths #1909 and #2114.

6:30 – 8:30 pm
Independence Ballroom (2nd Floor)
Sheraton Boston Hotel

Supported by Teva Respiratory

Treating Adults With Severe Uncontrolled Eosinophilic Asthma

Presented by:
Gregory W. Bensch, MD
Mario Castro MD

A review of considerations in the diagnosis and management of severe eosinophilic asthma.

Also visit Teva Respiratory at Booth #2408.

6:30 – 8:30 pm
Republic Ballroom (2nd Floor)
Sheraton Boston Hotel

Supported by DBV Technologies

Is Avoidance Enough? Accidental Exposure in Peanut Allergy

Presented by:
David M. Fleischer, MD
Matthew Greenhawt, MD
Stanley M. Fineman, MD
Joseph Baumert, PhD
Ming Tsai, Chef/Owner of Blue Dragon

Studies show that accidental exposure remains a problem in peanut allergy. Despite practicing strict avoidance, individuals experience reactions – including anaphylaxis – to as little as trace amounts of peanut. Join experts for a discussion on addressing accidental exposure through awareness, food industry practices, and investigational therapeutic approaches, including epicutaneous immunotherapy.

Also visit DBV Technologies at Booth #2620.
Following the close of Thursday, Friday, Saturday and Sunday’s scientific sessions, all registrants are invited to attend the special Corporate Forums at the Sheraton Boston Hotel. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your educational experience.

Saturday, October 28

8:30 – 10:30 pm
Back Bay Ballroom Salons AB (2nd Floor)
Sheraton Boston Hotel

Supported by CSL Behring

Be the P.I. in Your Practice – Identifying and Effectively Managing Patients with Primary Immunodeficiency

This unique 4-Corners™ presentation will take you through “4 corners” of primary immunodeficiency, including differential diagnosis, treatment options, and management with subcutaneous immunoglobulin. Attendees will have an opportunity to participate in small groups and interact with each of the presenters. Complimentary desserts and drinks will be served.

Also visit CSL Behring at Booth #2420.

8:30 – 10:30 pm
Back Bay Ballroom Salons CD (2nd Floor)
Sheraton Boston Hotel

Supported by ALK, Inc.

New Advances in House Dust Mite Allergy Treatment: Expanding use of Immunotherapy

Presented by:
Eli Meltzer, MD
Travis Miller, MD
Harold Nelson, MD
Hendrik Nolte, MD
Ellen Sher, MD
David Skoner, MD

ALK Pharmaceuticals will host a dessert reception which includes three mini presentations on new advances in house dust mite immunotherapy. $25 donations will be made to the Foundation of the ACAAI and the Allergy & Asthma Network for each participant attending all 3 mini presentations.

Also visit ALK, Inc. at Booth #2120.

Sunday, October 29

6:30 – 8:30 pm
Republic Ballroom (2nd Floor)
Sheraton Boston Hotel

Supported by Shire

Expert Insights on Shared Decision-making in the Treatment of PIDD

Presented by:
Marc A Riedl, MD
Richard L. Wasserman, MD

A non-CME interactive session that will explore immunoglobulin treatment options and approaches to shared treatment decision-making with primary immunodeficiency disease (PIDD) patients. The program will include two interactive cases that follow patients with PIDD through their diagnosis and treatment journeys. Attendees will participate by sharing their insights during the presentations.

Also visit Shire at Booth #2608.
Each e-poster has been assigned a specific presentation time in which the author will present their research from a dedicated presentation monitor and answer questions.

The e-posters will be on display in Halls C & D (2nd Floor) of the Hynes Convention Center and open during normal exhibit hours.

E-posters can be accessed online at college.acaai.org/eposters.

Late-Breaking Abstracts will be available online and are scheduled for presentation on Saturday, Oct. 28 and Sunday, Oct. 29 on Monitor 8, from 12:40-1:20 pm.

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRIDAY, OCTOBER 27</td>
<td></td>
<td>Validation of the Prescreening Intradermal Skin Test for Predicting Hypersensitivity of Iodinated Contrast Media</td>
<td>O. Kwon*, Seoul, Korea, Republic of.</td>
<td>DRUG</td>
<td>P001</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>1</td>
<td>Allergic Contact Dermatitis to Epoxy Resin</td>
<td>A. Wasan*, A. Nanda*, 1. McLean, VA; 2. Lewisville, TX.</td>
<td>SKIN</td>
<td>P476</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>2</td>
<td>The Role of Self-administered Icatibant in the Diagnosis of Hereditary Angioedema With Normal C1 Esterase</td>
<td>C. Erskine*, L. Yao*, 1. Glendale, AZ; 2. Laveen, AZ.</td>
<td>ANGIO</td>
<td>P151</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>3</td>
<td>Cetirizine 10mg Provides Effective Relief of Worst Seasonal Allergy Symptoms in Children 6-11 Years</td>
<td>H. Turner*, M. Patel*, M. Wu, K. Franklin*, 1. Fort Washington, PA; 2. Skillman, NJ.</td>
<td>RHIN</td>
<td>P426</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>6</td>
<td>Rash and Elevated Double Negative T-Cells: Is This a Case of Hypomorphic Autoimmune Lymphoproliferative Syndrome?</td>
<td>E. Coulson*, K. Sokol, Brookline, MA.</td>
<td>IMMUNO</td>
<td>P251</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>2</td>
<td>Allergic Contact Dermatitis: A Rare Systemic Presentation of a Common Problem</td>
<td>R. Singla*, R. Raveendran, 1. West Chester, OH; 2. Columbus, OH.</td>
<td>SKIN</td>
<td>P477</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>3</td>
<td>Omalizumab and Levothyroxine in the Treatment of Chronic Idiopathic Urticaria with Positive Thyroid Antibodies</td>
<td>A. Nanda, A. Wasan, 1. Lewisville, TX; 2. McLean, VA.</td>
<td>ANGIO</td>
<td>P152</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>4</td>
<td>Eosinophils in Nasal Discharge and Nasal Cavity Culture in Children</td>
<td>Y. Horikawa, Fukuoka, Japan.</td>
<td>RHIN</td>
<td>P427</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>6</td>
<td>Food-Induced Pulmonary Hemosiderosis</td>
<td>J. Alsukhon, A. Leonov, A. Elisa, G. Koon, 1. Portage, MI; 2. Kalamazoo, MI; 3. Jackson, MI.</td>
<td>FOOD</td>
<td>P327</td>
</tr>
<tr>
<td>3:40 pm</td>
<td>7</td>
<td>Association of P21R and H159Y Polymorphism With Common Variable Immunodeficiency and Protein Losing Enteropathy</td>
<td>E. Wang*, M. Konikoff, W. Owen, K. Maples, Norfolk, VA.</td>
<td>IMMUNO</td>
<td>P252</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>2</td>
<td>Successful Treatment of Refractory Itch With Aprepitant</td>
<td>C. Guo*, L. Cuervo-Pardo, K. McGrath, Chicago, IL.</td>
<td>SKIN</td>
<td>P478</td>
</tr>
</tbody>
</table>
## E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday  
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:50 pm</td>
<td>4</td>
<td><strong>The Empty Nose Syndrome (ENS): A Diagnostic and Therapeutic Challenge for the Allergist-Immunologist</strong></td>
<td>T. Nsouli*, N. Diliberto, A. Nsouli, S. Nsouli, J. Bellanti, Washington, DC.</td>
<td>RHIN</td>
<td>P428</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>5</td>
<td><strong>A Case of Bird Fancier's Lung</strong></td>
<td>T. Basen*, Los Angeles, CA.</td>
<td>ASTHMA</td>
<td>P203</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>6</td>
<td><strong>History of Milk or Soy Protein Intolerance in Infancy in Patients With Eosinophilic Esophagitis</strong></td>
<td>K. Kennedy*, M. DeFelice, S. Abraham, 1. Philadelphia, PA; 2. Gamet Valley, PA.</td>
<td>FOOD</td>
<td>P328</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>7</td>
<td><strong>Child With a History of Transplant and Pneumonias with Chronic Lymphocytic Bronchiolitis and Antibody Deficiency</strong></td>
<td>B. Ariue, C. Enweasor*, Loma Linda, CA.</td>
<td>IMMUNO</td>
<td>P253</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>1</td>
<td><strong>DRESS Secondary to Febuxostat in a Patient With Prior DRESS from Allopurinol</strong></td>
<td>R. Altisheh*, T. Carr, Tucson, AZ.</td>
<td>DRUG</td>
<td>P004</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>3</td>
<td><strong>Biomarkers Which May Predict Response to Omalizumab in Chronic Urticaria: Serum IgE and CD203c</strong></td>
<td>M. Straesser, T. Palacios, T. Kyin, L. Borish*, M. Lawrence, Charlottesville, VA.</td>
<td>ANGIO</td>
<td>P154</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>4</td>
<td><strong>ARIA and GINA Implementation in a Universalistic Health System</strong></td>
<td>F. Lamarra*, M. Mennini, L. Dahdah, R. Giampaolo, A. Campana, A. Fiochhi, 1. Roma, Holy See (Vatican City State); 2. Rome, Holy See (Vatican City State).</td>
<td>RHIN</td>
<td>P429</td>
</tr>
</tbody>
</table>
### E-poster Presentations

**3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday**

**Halls C & D (2nd Floor) • Hynes Convention Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 pm</td>
<td>6</td>
<td>Utility and Safety of the Intermittent Oral Immunotherapy, Step-Up Method, for Severe Food Allergy Patients</td>
<td>K. Kuzume*, M. Koizumiii, M. Okamotoi, K. Nishimurai, T. Asami, 1. Ehime, Japan; 2. Toon, Japan.</td>
<td>FOOD</td>
<td>P329</td>
</tr>
<tr>
<td>4:00 pm</td>
<td>7</td>
<td>A Case of a Woman With Relapsing Polychondritis, Celiac Disease, and Immunoglobulin A Deficiency</td>
<td>S. Clements*, A. Zelig, A. Rubinstein, 1. New York, NY; 2. Bronx, NY.</td>
<td>IMMUNO</td>
<td>P254</td>
</tr>
<tr>
<td>4:10 pm</td>
<td>1</td>
<td>Allergy to Cobalt-Containing Supplements: A Case Report</td>
<td>P. Staso*, A. Leonov, Kalamazoo, MI.</td>
<td>DRUG</td>
<td>P005</td>
</tr>
<tr>
<td>4:10 pm</td>
<td>3</td>
<td>Seasonal Correlations in Chronic Urticaria and Allergic Rhinitis</td>
<td>M. Straesser*, T. Palacios, T. Kyin, L. Borish, M. Lawrence, Charlottesville, VA.</td>
<td>ANGIO</td>
<td>P155</td>
</tr>
<tr>
<td>4:10 pm</td>
<td>4</td>
<td>Clinically Significant Improvement in Mini-RQLQ Scores in Patients With Nasal Polyps After Omalizumab Initiation</td>
<td>T. Carr, N. Griffin, M. Yang, K. Rosen, T. Casale, 1. Tucson, AZ; 2. South San Francisco, CA; 3. Tampa, FL.</td>
<td>RHIN</td>
<td>P430</td>
</tr>
<tr>
<td>4:10 pm</td>
<td>5</td>
<td>Experience With A Simplified Eucapnic Voluntary Hyperventilation (EVH) Device for Diagnosis of Exercise-Induced Bronchospasm</td>
<td>R. Rosenthal, Great Falls, VA.</td>
<td>ASTHMA</td>
<td>P205</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>1</td>
<td>Successful Desensitizations With Ceftriaxone and Azithromycin in a Patient With Mast Cell Activation Syndrome</td>
<td>P. Staso*, A. Leonov, Kalamazoo, MI.</td>
<td>DRUG</td>
<td>P006</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>3</td>
<td>Use of Rescue Medication in Hereditary Angioedema Attacks and Its Relation to Attack Severity.</td>
<td>J. Anderson¹, G. Krishnarajah¹, T. Craig¹, W. Lumry¹, D. Supina⁶, H. Feuersenger¹, I. Pragst⁶, T. Machnig¹, J. Bernstein¹, 1. Birmingham, AL; 2. King of Prussia, PA; 3. Hershey, PA; 4. Dallas, TX; 5. Malvern, PA; 6. Marburg, Germany; 7. Cincinnati, OH.</td>
<td>ANGIO</td>
<td>P156</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>4</td>
<td>Novel Photo-electrochemical Oxidation Air-Purification Technology Reduces Nasal and Ocular Allergy Symptoms</td>
<td>J. Wong¹, N. Rao*, S. Liggett¹, Y. Goswami², A. Kumar², 1. San Francisco, CA; 2. Tampa, FL.</td>
<td>RHIN</td>
<td>P431</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>5</td>
<td>Effect of Inhaled Corticosteroid Use on Weight (BMI) in Moderate to Severe Asthmatic Pediatric Patients</td>
<td>J. Han*, J. Nguyen², Y. Kim², A. Barber³, G. Romanowski³, S. Leibel³, B. Geng³, L. Alejandro³, J. Proudfoot³, R. Xu³, N. Griffin³, 1. Los Angeles, CA; 2. San Diego, CA; 3. La Jolla, CA; 4. South San Francisco, CA.</td>
<td>ASTHMA</td>
<td>P206</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>6</td>
<td>Risks of New Guidelines to Prevent Peanut Allergy; Peanut Anaphylaxis in a 6-month-old</td>
<td>S. Garon*, Chicago, IL.</td>
<td>FOOD</td>
<td>P331</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>7</td>
<td>Hypogammaglobulinemia as Presenting Sign of Nephrotic Syndrome</td>
<td>D. Dvorin*, K. Vadaketh, M. Goldstein, G. Belecanech, Philadelphia, PA.</td>
<td>IMMUNO</td>
<td>P256</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>1</td>
<td>Drug Rash Eosinophilia and Systemic Symptoms Syndrome Secondary to Vancomycin</td>
<td>A. Bansal*, L. Kallur, C. Cooper, A. Patel, G. Youngber, A. Gonzalez-Estrada, Johnson City, TN.</td>
<td>DRUG</td>
<td>P007</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>2</td>
<td>Urticaria-Like Follicular Mucinosis: A Rare Cause of Urticarial Facial Rash</td>
<td>C. Cranford*, G. Marshall, Jackson, MS.</td>
<td>SKIN</td>
<td>P482</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>3</td>
<td>Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous C1-inhibitor for the Prevention of Hereditary Angioedema Attacks</td>
<td>B. Zuraw¹, M. Cicardi², T. Craig³, W. Lumry³, 1. La Jolla, CA; 2. Milan, Italy; 3. Hershey, PA; 4. Dallas, TX.</td>
<td>ANGIO</td>
<td>P157</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>4</td>
<td>Use of Home BiPAP for Refractory Vocal Cord Dysfunction (VCD)</td>
<td>M. Wahidi*, W. Lee¹, D. Khan¹, 1. Dallas, TX; 2. Grapevine, TX.</td>
<td>RHIN</td>
<td>P432</td>
</tr>
</tbody>
</table>
### E-poster Presentations

**E-poster Presentations**

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday  
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 pm</td>
<td>5</td>
<td>Symptoms, Asthma Control, Lung Function, and Corticosteroid Sparing Following Omalizumab Initiation in Allergic Asthma Patients</td>
<td>D. Pilon¹, A. Kavati¹, B. Ortiz³, B. Paknis¹, A. Vegesna¹, B. Schiffman¹, M. Zhdanava¹, P. Lefebvre¹, B. Stone¹, 1. Montreal, QC, Canada; 2. East Hanover, NY; 3. East Hanover, NJ; 4. Winston-Salem, NC; 5. San Diego, CA.</td>
<td>ASTHMA</td>
<td>P207</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>6</td>
<td>Role of Toll-Like Receptor Signaling in Epithelial Barrier Dysfunction in Eosinophilic Esophagitis.</td>
<td>M. Ruffner*, S. Raman¹, K. Mauer¹, A. Muir², J. Spergel¹, K. Sullivan¹, 1. Rutledge, PA; 2. Philadelphia, PA; 3. Westfield, NJ.</td>
<td>FOOD</td>
<td>P332</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>7</td>
<td>Primary Immunodeficiency Cases Revealed by Low TREC Screens in West Texas</td>
<td>M. Kandalafte*, J. Tarbox, Lubbock, TX.</td>
<td>IMMUNO</td>
<td>P257</td>
</tr>
<tr>
<td>4:40 pm</td>
<td>1</td>
<td>Anaphylaxis: Closer to Home?</td>
<td>S. Anvari*, A. Blackman, A. Anagnostou, Houston, TX.</td>
<td>DRUG</td>
<td>P008</td>
</tr>
<tr>
<td>4:40 pm</td>
<td>2</td>
<td>A Severe Delayed Rash in a Pediatric Patient: The Dermatitis Is in the Detail</td>
<td>K. Dinsmore*, M. Kearns¹, K. Reddy¹, D. Armentrout³, A. Gonzalez-Estrada³, 1. Kingsport, TN; 2. Johnson City, TN; 3. Griffin, GA.</td>
<td>SKIN</td>
<td>P483</td>
</tr>
<tr>
<td>4:40 pm</td>
<td>3</td>
<td>Physician Perspectives on Long-Term Prophylaxis of Hereditary Angioedema: A Pragmatic Review</td>
<td>R. Beckerman¹, D. Barnes², D. Supina³, G. Krishnarajah¹, 1. New York, NY; 2. Ottawa, ON, Canada; 3. Malvern, PA; 4. King of Prussia, PA.</td>
<td>ANGIO</td>
<td>P158</td>
</tr>
</tbody>
</table>
### E-poster Presentations

**Time** | **Monitor No.** | **Title** | **Author(s)** | **Category** | **Poster No.**
--- | --- | --- | --- | --- | ---
4:40 pm | 7 | Missed Sequelae of CVID: A Case Presentation | C. Russo*, J. Shih, Atlanta, GA. | IMMUNO | P258
4:50 pm | 1 | Pediatric Intraoperative Anaphylaxis of Unknown Etiology | D. Paulk*, J. Kuhlen, C. Greene, Greenville, SC. | DRUG | P009
4:50 pm | 2 | Cobalt as the Culprit: Vitamin B12 Supplementation as a Trigger for Chronic Pruritis | S. Vakaljan*, J. Ohayon, Hamilton, ON, Canada. | SKIN | P484
4:50 pm | 4 | Efficacy and Safety of Olopatadine/Mometasone Combination Nasal Spray for the Treatment of Seasonal Allergic Rhinitis | P. Ratner1*, F. Hampel2, A. Breaza1, C. Caracta1, S. Tantry2, 1. San Antonio, TX; 2. New Braunfels, TX; 3. Mahwah, NJ. | RHIN | P434
4:50 pm | 7 | Optimizing Subcutaneous Dosing of Immunoglobulin in Obese Primary Immune Deficiency Patients Treated in the Home | A. Checkley1*, L. Kristofek1, S. Kile1, W. Bolgar1, L. Seidu2, 1. Denver, CO; 2. Atlanta, GA. | IMMUNO | P259
5:00 pm | 1 | Single and Two-Dose Oral Challenge With Trimethoprim-Sulfamethoxazole in HIV-Uninfected Adults Labeled as “Sulfa” Allergic | A. Abreo1*, C. Stone1, E. McKinnon2, E. Phillips3, 1. Nashville, TN; 2. Perth, WA, Australia. | DRUG | P010
5:00 pm | 2 | The Association of Allergic Diseases and Attention Deficit Hyperactivity: Who Is Egg Who Is Chicken? | I. Wang1*, J. Hsu2, 1. New Taipei City, Taipei, Taiwan; 2. Taipei, Taiwan. | OTHER | P376
<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 pm</td>
<td>4</td>
<td>Olopatadine/Mometasone Combination Nasal Spray Improves Seasonal Allergic Rhinitis Symptoms in a Ragweed Environmental Exposure Chamber</td>
<td>P. Patel¹, A. Salapatek¹, P. Agarwal¹, S. Tantry¹, 1. Mississauga, ON, Canada; 2. Navi Mumbai, India; 3. Mahwah, NJ.</td>
<td>RHIN</td>
<td>P435</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>5</td>
<td>Real-world Comparisons of Clinical Characteristics and Medication Utilization Pre- and Post-Omalizumab Initiation in Asthma Patients</td>
<td>Q. Huang¹, A. Kavati*¹, X. Ke¹, D. Wertz¹, L. Wang¹, V. Willey¹, J. Stephenson¹, B. Ortiz¹, R. Panettieri, Jr¹, J. Corren¹, 1. Wilmington, DE; 2. East Hanover, NJ; 3. New Brunswick, NJ; 4. Los Angeles, CA.</td>
<td>ASTHMA</td>
<td>P210</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>6</td>
<td>Gluten-specific IgG4 Is Elevated in Children With Eosinophilic Esophagitis Compared to an Unselected Community Cohort</td>
<td>M. Gupta*¹, J. Wilson¹, A. Schuyler¹, L. Workman¹, E. Erwin¹, T. Platts-Mills¹, 1. Charlottesville, VA; 2. Columbus, OH.</td>
<td>FOOD</td>
<td>P335</td>
</tr>
<tr>
<td>5:00 pm</td>
<td>7</td>
<td>A Complicated Case of Mycobacterium Kansasii-Triggered Hemophagocytic Lymphohistiocytosis in the Setting of Immunosuppression</td>
<td>D. Har*, C. Wysocki, Dallas, TX.</td>
<td>IMMUNO</td>
<td>P260</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>1</td>
<td>Serum Sickness-like Reaction to Omalizumab</td>
<td>A. Eapen*¹, K. Kloepfer², 1. Livonia, MI; 2. Indianapolis, IN.</td>
<td>DRUG</td>
<td>P011</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>2</td>
<td>The Spectrum and Prevalence of Reactions to Marijuana in a Colorado Allergy Practice</td>
<td>W. Silvers*, Englewood, CO.</td>
<td>OTHER</td>
<td>P377</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>3</td>
<td>Urticaria Activity and Impact Measure (U-AIm) Evaluates CSU/CIU Activity, Impact, and Control in Clinical Practice</td>
<td>M. Maurer*¹, E. Antonova², A. Iqbal¹, M. Yang¹, M. Holden³, J. Zazzali¹, 1. Berlin, Germany; 2. South San Francisco, CA; 3. San Francisco, CA.</td>
<td>ANGIO</td>
<td>P161</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>4</td>
<td>Efficacy of the SQ HDM SLIT-Tablet on Nasal Congestion Symptoms: Results From 2 DBPC Trials</td>
<td>S. Tilles²*, J. Corren¹, B. Riis¹, H. Nolte¹, 1. Seattle, WA; 2. Los Angeles, CA; 3. Horsholm, Denmark.</td>
<td>RHIN</td>
<td>P436</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>5</td>
<td>A Real-world Assessment of Asthma Exacerbations in Asthma Patients Newly Treated With Omalizumab</td>
<td>X. Ke¹, A. Kavati¹, D. Wertz¹, Q. Huang¹, L. Wang¹, V. Willey¹, J. Stephenson¹, B. Ortiz¹, R. Panettieri, Jr¹, J. Corren¹, 1. Wilmington, DE; 2. East Hanover, NJ; 3. New Brunswick, NJ; 4. Los Angeles, CA.</td>
<td>ASTHMA</td>
<td>P211</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>6</td>
<td>A 20-Month-Old Male With Anemia and Pneumonia</td>
<td>D. Munoz-Mendoza1, A. Chapa-Rodriguez1, J. Burkhardt1, S. Bahna1, 1. Shreveport, LA; 2. Bossier City, LA.</td>
<td>FOOD</td>
<td>P336</td>
</tr>
<tr>
<td>5:10 pm</td>
<td>7</td>
<td>A 15-Year Journey: From Relapsing Polychondritis to IgG4-Related Disease</td>
<td>W. Cosme-Blanco1, S. Nazario2, 1. Guaynabo, PR; 2. San Juan, PR.</td>
<td>IMMUNO</td>
<td>P261</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>1</td>
<td>Management of Ongoing Adalimumab Local Hypersensitivity Reactions After Rapid Subcutaneous Desensitization</td>
<td>F. Jiang1, A. Pham1, J. Yusin2, 1. Los Angeles, CA; 2. Stevenson Ranch, CA.</td>
<td>DRUG</td>
<td>P012</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>2</td>
<td>A Case of the Nerves Tiotropium for Treatment of Resistant Anaphylaxis with Vocal Cord Dysfunction</td>
<td>J. Kepes1, D. Bernstein1, T. Atkinson1, 1. Birmingham, AL; 2. Cincinnati, OH.</td>
<td>OTHER</td>
<td>P378</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>3</td>
<td>Real-World Treatment Patterns of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Patients in the United States</td>
<td>J. Eghrari-Sabet1, E. Sher1, P. Lefebvre1, D. Pilon1, M. Zhdanava1, M. Balp1, A. Kavati1, B. Ortiz1, J. Bernstein1, 1. Gaithersburg, MD; 2. Ocean, NJ; 3. Montreal, QC, Canada; 4. Basel, Switzerland; 5. East Hanover, NJ; 6. Cincinnati, OH.</td>
<td>ANGIO</td>
<td>P162</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>4</td>
<td>Clinical Relevance of the SQ HDM SLIT-Tablet in Moderate-To-Severe House Dust Mite Allergic Rhinitis</td>
<td>B. Prenner1, S. Dahlgren2, H. Noite2, D. Rehm2, J. Corren2, 1. San Diego, CA; 2. Horsholm, Denmark; 3. Los Angeles, CA.</td>
<td>RHIN</td>
<td>P437</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>5</td>
<td>A Real-world Assessment of Omalizumab Treatment Patterns in Asthma Patients Newly Treated With Omalizumab</td>
<td>X. Ke1, A. Kavati1, D. Wertz1, Q. Huang1, L. Wang1, V. Willey1, J. Stephenson1, B. Ortiz1, R. Panettieri, Jr1, J. Corren1, 1. Wilmington, DE; 2. East Hanover, NJ; 3. New Brunswick, NJ; 4. Los Angeles, CA.</td>
<td>ASTHMA</td>
<td>P212</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>6</td>
<td>Remission of Cow’s Milk Allergy During Rituximab Therapy: A Case Report</td>
<td>A. Stachowiak1, L. Kerns, Cleveland, OH.</td>
<td>FOOD</td>
<td>P337</td>
</tr>
<tr>
<td>5:20 pm</td>
<td>7</td>
<td>A 3-year-old Male With Recurrent Sinusitis and Biotinidase Deficiency.</td>
<td>J. Burkhardt1, S. Bahna1, 1. Bossier City, LA; 2. Shreveport, LA.</td>
<td>IMMUNO</td>
<td>P262</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>2</td>
<td>Getting With the Guidelines: A Primary Care Approach to Improving Pneumococcal Vaccine Administration</td>
<td>R. D’Mello*¹, P. Sandhu², 1. Buffalo, NY; 2. Niagara Falls, ON, Canada.</td>
<td>OTHER</td>
<td>P379</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>3</td>
<td>Angioedema Vanishing Into Thin Air</td>
<td>A. Pepper*, D. Ledford, R. Lockey, Tampa, FL.</td>
<td>ANGIO</td>
<td>P163</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>4</td>
<td>Efficacy of SQ SLIT-Tablets in Mono-And Poly-Sensitized HDM, Grass, and Ragweed Allergic Subjects</td>
<td>H. Nelson*¹, J. Kleine-Tebbe², H. Nolte³, B. Riis⁴, S. Durham⁴, D. Bernstein⁵, 1. Denver, CO; 2. Berlin, Germany; 3. Horsholm, Denmark; 4. London, United Kingdom; 5. Cincinnati, OH.</td>
<td>RHIN</td>
<td>P438</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>5</td>
<td>Efficacy of Inhaled Tiotropium for Asthmatics Uncontrolled Using Inhaled Corticosteroid Plus a Long-Acting Beta2-Agonist.</td>
<td>S. Nsouli*, Danville, CA.</td>
<td>ASTHMA</td>
<td>P213</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>7</td>
<td>A 5 Year-Old Child With Fever And Cervical Lymphadenopathy</td>
<td>M. Nassiri*¹, J. Burkhardt², L. Raymond³, M. Jeroudi³, J. Bocchini¹, S. Bahna¹, 1. Shreveport, LA; 2. Bossier City, LA.</td>
<td>IMMUNO</td>
<td>P263</td>
</tr>
<tr>
<td>5:40 pm</td>
<td>1</td>
<td>Characteristics of Anaphylactic Events in Schools: Results of the 2015-2016 EpiPen4Schools® Survey</td>
<td>M. White*¹, C. Herrem², R. Muniz³, 1. Wheaton, MD; 2. Canonsburg, PA.</td>
<td>DRUG</td>
<td>P014</td>
</tr>
<tr>
<td>5:40 pm</td>
<td>2</td>
<td>Increased Eosinophil Fraction, Decreased Cardiac Function</td>
<td>V. Wang*¹, N. Agnihotri¹, J. Yusin², M. Gianos³, 1. Los Angeles, CA; 2. Stevenson Ranch, CA.</td>
<td>OTHER</td>
<td>P380</td>
</tr>
</tbody>
</table>
E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:40 pm</td>
<td>3</td>
<td>Longitudinal Natural History of Patients With Type I/II Hereditary Angioedema: Icatibant Outcome Survey Data</td>
<td>M. Maurer¹, T. Caballero², W. Aberer³, A. Zanichelli⁴, L. Bouillet⁵, A. Bygum⁶, A. Grumach⁷, C. Pommie⁸, I. Andresen⁹, H. Longhurst⁹, 1. Berlin, Germany; 2. Madrid, Spain; 3. Graz, Austria; 4. Milano, Italy; 5. Grenoble, France; 6. Odense, Denmark; 7. Santo Andre, SP, Brazil; 8. Zug, Switzerland; 9. London, United Kingdom.</td>
<td>ANGIO</td>
<td>P164</td>
</tr>
<tr>
<td>5:40 pm</td>
<td>4</td>
<td>Estimating the Proportion of Patients Diagnosed With Allergic Rhinitis, At Risk of Developing Asthma</td>
<td>C. Burton¹, M. Romano¹, A. Domdey¹, P. Radford¹, M. Dungarwalla², N. Boxall², 1. Horsholm, Denmark; 2. London, United Kingdom.</td>
<td>RHIN</td>
<td>P439</td>
</tr>
<tr>
<td>5:40 pm</td>
<td>5</td>
<td>Mepolizumab Induction Therapy for Eosinophilic Granulomatosis With Polyangiitis (EGPA)</td>
<td>M. Goldstein*, K. Vadaketh, D. Dvorin, G. Belecanech, Philadelphia, PA.</td>
<td>ASTHMA</td>
<td>P214</td>
</tr>
<tr>
<td>5:40 pm</td>
<td>6</td>
<td>International Comparisons of Patient Characteristics in a Phase 3 Study of AR101 for Peanut Allergy</td>
<td>E. Zigmont⁴*, R. Zawadzki¹, K. Beyer¹, A. Burks¹, T. Casale⁴, J. Hourihane⁵, S. Jones⁵, A. Vereda¹, B. Vickery¹, D. Adelman¹, 1. Brisbane, CA; 2. Berlin, Germany; 3. Chapel Hill, NC; 4. Tampa, FL; 5. Cork, Ireland; 6. Little Rock, AR.</td>
<td>FOOD</td>
<td>P339</td>
</tr>
<tr>
<td>5:40 pm</td>
<td>7</td>
<td>An Expanding Spectrum of Autoinflammatory Syndromes: TNFAIP3-Related Disease</td>
<td>A. Rudert*, C. Saunders, N. Raje, M. Ibarra, Kansas City, MO.</td>
<td>IMMUNO</td>
<td>P270</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>1</td>
<td>Improvements in the Proper Management of Anaphylaxis in Schools: Results From the EpiPen4Schools® Survey</td>
<td>M. White¹, C. Herrerm*, R. Muniz², 1. Wheaton, MD; 2. Canonsburg, PA.</td>
<td>DRUG</td>
<td>P015</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>2</td>
<td>Urticaria Pigmentosa And Epilepsy... Or Is It Something More?</td>
<td>S. Adams¹, S. Dorris², 1. Madison, TN; 2. Nashville, TN.</td>
<td>OTHER</td>
<td>P381</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>3</td>
<td>Hereditary Angioedema Laryngeal Attacks Treated With Recombinant C1-INH: Report From the Czech National Registry</td>
<td>R. Hakl¹*, P. Kuklinek¹, I. Krcmova¹, P. Kralickova¹, J. Hanzlikova¹, M. Vachova¹, M. Sobotkova¹, J. Strenkova¹, J. Litzman¹, 1. Brno, Czech Republic; 2. Hradec, Czech Republic; 3. Pizen, Czech Republic; 4. Motol, Czech Republic.</td>
<td>ANGIO</td>
<td>P165</td>
</tr>
</tbody>
</table>
### E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:50 pm</td>
<td>4</td>
<td>Exhalation Delivery System With Fluticasone (EDS-FLU) Improves Sleep in Patients With CRS with Nasal Polyps</td>
<td>T. Murphy(^*), J. Messina(^2), J. Carothers(^3), P. Djupesland(^4), R. Mahmoud(^5), 1. Charleston, SC; 2. Yardley, PA; 3. Oslo, Norway.</td>
<td>RHIN</td>
<td>P440</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>5</td>
<td>Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including Those Initiated on Omalizumab</td>
<td>D. Pilon(^1), A. Kavati(^2), B. Ortiz(^2), B. Paknis(^3), A. Vegesna(^3), B. Schifman(^2), M. Zhdanava(^1), P. Lefebvre(^3), B. Stone(^*), 1. Montreal, QC, Canada; 2. East Hanover, NJ; 3. Winston-Salem, NC; 4. Montréal, QC, Canada; 5. San Diego, CA.</td>
<td>ASTHMA</td>
<td>P215</td>
</tr>
<tr>
<td>5:50 pm</td>
<td>7</td>
<td>Subcutaneous Immunoglobulin Therapy for a Pregnant Patient With CVID Who Reacted to Intravenous Immunoglobulin Replacement</td>
<td>J. Hsieh(^*), S. Bettschel, Toronto, ON, Canada.</td>
<td>IMMUNO</td>
<td>P290</td>
</tr>
</tbody>
</table>

### SATURDAY, OCTOBER 28TH

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 am</td>
<td>1</td>
<td>Drug Rash With Eosinophilia and Systemic Symptoms Progressing to Skin Blistering Without Mucosal Involvement</td>
<td>A. Long(^*), J. Naff(^2), K. Handfield(^3), T. Banks(^3), 1. Potomac, MD; 2. Bethesda, MD.</td>
<td>DRUG</td>
<td>P016</td>
</tr>
<tr>
<td>10:30 am</td>
<td>2</td>
<td>Familial Hypertryptasemia in Children</td>
<td>A. Ravi(^*), J. Butterfield, Rochester, MN.</td>
<td>OTHER</td>
<td>P382</td>
</tr>
<tr>
<td>10:30 am</td>
<td>3</td>
<td>Characteristics of Patients Receiving Omalizumab for Chronic Urticaria in the UAE</td>
<td>M. Nasir(^*), Abu Dhabi, United Arab Emirates.</td>
<td>ANGIO</td>
<td>P166</td>
</tr>
<tr>
<td>10:30 am</td>
<td>4</td>
<td>Exhalation Delivery System With Fluticasone (EDS-FLU) Improves Peak Nasal Inspiratory Flow (PNIF) in CRSwNP</td>
<td>E. Schenkel(^*), J. Messina(^2), J. Carothers(^3), P. Djupesland(^4), R. Mahmoud(^5), 1. Bethlehem Township, PA; 2. Yardley, PA; 3. Oslo, Norway.</td>
<td>RHIN</td>
<td>P441</td>
</tr>
<tr>
<td>10:30 am</td>
<td>5</td>
<td>Efficacy of Reslizumab in Eosinophilic Asthma Patients With Low Lung Function</td>
<td>R. Panettieri(^*), M. McDonald(^2), M. Germinaro(^2), 1. New Brunswick, NJ; 2. Malvern, PA.</td>
<td>ASTHMA</td>
<td>P216</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>10:30 am</td>
<td>6</td>
<td>Allergy to Duck Egg Without Sensitization to Hen Egg</td>
<td>K. Khalsa*, M. Pasha, B. Sundquist, Albany, NY.</td>
<td>FOOD</td>
<td>P341</td>
</tr>
<tr>
<td>10:30 am</td>
<td>7</td>
<td>Allogenic Hematopoietic Stem Cell Transplant in a Patient With Mast Cell Activation Syndrome</td>
<td>A. Chau*, A. Jongco, Great Neck, NY.</td>
<td>IMMUNO</td>
<td>P266</td>
</tr>
<tr>
<td>10:40 am</td>
<td>1</td>
<td>Induction of Tolerance to Temozolamide</td>
<td>I. Noor*, M. Aquino, M. Davis-Lorton, Mineola, NY.</td>
<td>DRUG</td>
<td>P017</td>
</tr>
<tr>
<td>10:40 am</td>
<td>2</td>
<td>Multiple Co-Morbid Conditions in Patient With Mast Cell Activation Syndrome</td>
<td>S. Szari*, J. Quinn, San Antonio, TX.</td>
<td>OTHER</td>
<td>P383</td>
</tr>
<tr>
<td>10:40 am</td>
<td>5</td>
<td>Salford Lung Study Chronic Obstructive Pulmonary Disease Follow-up Interviews: Analyses by Treatment Comparisons and Exacerbations</td>
<td>D. Whalley, H. Svedsater, L. Doward, R. Crawford, D. Leather, J. Lay-Flurrie, N. Bosanquet, Manchester, United Kingdom; 2. Brentford, United Kingdom; 3. Uxbridge, United Kingdom; 4. London, United Kingdom.</td>
<td>ASTHMA</td>
<td>P217</td>
</tr>
<tr>
<td>10:40 am</td>
<td>6</td>
<td>A Pediatric Case of Protein-Losing Enteropathy Induced by Cow’s Milk</td>
<td>M. Kitcharoensakkul, A. Weymann, St Louis, MO.</td>
<td>FOOD</td>
<td>P342</td>
</tr>
<tr>
<td>10:40 am</td>
<td>7</td>
<td>XMEN Disease: An Unexpected Presentation of a Rare Primary Immunodeficiency</td>
<td>C. Reynolds, C. Stein, T. Atkinson, A. Hurst, D. Kimberlin, Birmingham, AL.</td>
<td>IMMUNO</td>
<td>P267</td>
</tr>
<tr>
<td>10:50 am</td>
<td>1</td>
<td>The Utility of Skin Testing for Cross-Reactivity: Management of 5-Hydroxytryptamine3-Receptor Antagonist IgE-Mediated Reaction</td>
<td>C. Patel, B. Kaplan, Great Neck, NY.</td>
<td>DRUG</td>
<td>P018</td>
</tr>
<tr>
<td>10:50 am</td>
<td>2</td>
<td>Expanding the Role of Tryptase from Allergy to Cancer?</td>
<td>J. Hagan, T. Pongdee, Rochester, MN.</td>
<td>OTHER</td>
<td>P384</td>
</tr>
</tbody>
</table>
### E-poster Presentations

**E-poster Presentations**

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 am</td>
<td>3</td>
<td>Real-world Characteristics and Treatment Patterns in Urticaria Patients Initiating Omalizumab in the United States</td>
<td>L. Wang¹, A. Kavati¹, X. Ke¹, D. Wertz¹, Q. Huang¹, V. Willey¹, J. Stephenson¹, B. Ortiz¹, B. Paknis², J. Bernstein³, L. Beck⁴, 1. Wilmington, DE; 2. East Hanover, NJ; 3. Cincinnati, OH; 4. Rochester, NY.</td>
<td>ANGIO</td>
<td>P168</td>
</tr>
<tr>
<td>10:50 am</td>
<td>5</td>
<td>Primary Ciliary Dyskinesia Presents as New Onset Unilateral Wheezing</td>
<td>A. Pratt*, D. Hummell, A. Sokolow, Nashville, TN.</td>
<td>ASTHMA</td>
<td>P218</td>
</tr>
<tr>
<td>10:50 am</td>
<td>6</td>
<td>A Retrospective Review and Characterization of Cashew Allergy</td>
<td>J. Kimmel*, R. Sinit, S. Tilles, D. Petroni, Seattle, WA.</td>
<td>FOOD</td>
<td>P343</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>1</td>
<td>Anaphylaxis With First Dose of Ranitidine</td>
<td>S. Aljubran*, Kansas, MO.</td>
<td>DRUG</td>
<td>P019</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>2</td>
<td>A Case of Immune Thrombocytopenia (ITP) and Acquired Factor VIII Inhibitor Refractory to Immunosuppression</td>
<td>G. Patel¹, A. Chandra³, H. Rehman³, S. Guo³, 1. Piscataway, NJ; 2. New Brunswick, NJ.</td>
<td>OTHER</td>
<td>P385</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>3</td>
<td>When Angioedema is Not Angioedema</td>
<td>E. Schauburger*, J. Bernstein, Cincinnati, OH.</td>
<td>ANGIO</td>
<td>P169</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>4</td>
<td>Experience Using an Electronic Medical Record-Linked Biobank to Identify Nasal Polyposis Subjects for Biomarker Analysis</td>
<td>M. Desai*, New York, NY.</td>
<td>RHIN</td>
<td>P444</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>5</td>
<td>Isoflurane Therapy for Severe Refractory Status Asthmatic in Children.</td>
<td>O. Papadias Feria¹, M. Gazzaneo², 1. Edgewater, NJ; 2. Houston, TX.</td>
<td>ASTHMA</td>
<td>P219</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>6</td>
<td>Urticaria Associated With Alcoholic Beverage Ingestion and Subsequent Desensitization</td>
<td>M. Tsai¹, M. Garcia-Lloret³, 1. Irvine, CA; 2. Los Angeles, CA.</td>
<td>FOOD</td>
<td>P344</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>7</td>
<td>Immunological Phenotype of a Patient With Mandibulofacial Dysostosis Guion-Almeida Type With Novel ETFUD2 Splicing Variant</td>
<td>J. Caraballo*, M. Fasano³, A. Serrano Russi³, 1. Iowa City, IA; 2. Los Angeles, CA.</td>
<td>IMMUNO</td>
<td>P269</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>1</td>
<td>Serum Sickness-like Reactions to Ceftriaxone</td>
<td>J. Dorn*, N. Briese³, R. Shapiro³, T. Baril³, R. Divekar¹, 1. Rochester, MN; 2. Mineapolis, MN; 3. Mineapolis, MN.</td>
<td>DRUG</td>
<td>P020</td>
</tr>
</tbody>
</table>
## E-poster Presentations

### Time and Location

**3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday**

**Halls C & D (2nd Floor) • Hynes Convention Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:40 pm</td>
<td>2</td>
<td><strong>Twitter as an Opportunity for Public Health Campaigns on Immunodeficiency, Pneumonia, and Sinusitis</strong></td>
<td>S. Mahapatra, V. Dimov*, F. Eidelman, Weston, FL.</td>
<td>OTHER</td>
<td>P386</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>3</td>
<td><strong>Concomitant Omalizumab and Cyclosporine for Chronic Idiopathic Urticaria: a Case Series</strong></td>
<td>S. Mawhirt*, J. Diaz, L. Fonacier, Mineola, NY, 2. Great Neck, NY.</td>
<td>ANGIO</td>
<td>P170</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>4</td>
<td><strong>A Rare Cause of Upper Airway Impairment and Mouth Breathing in Adults: Adenoid Hypertrophy</strong></td>
<td>S. Mahapatra*, V. Dimov*, A. Gonzalez Estrada, Weston, FL.</td>
<td>RHIN</td>
<td>P445</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>5</td>
<td><strong>Association Between Blood Eosinophil Count and Benralizumab Efficacy for Adult Patients With Severe, Uncontrolled Asthma</strong></td>
<td>M. Goldman, I. Hirsch, J. Zangrilli, P. Newbold, X. Xu, Gaithersburg, MD.</td>
<td>ASTHMA</td>
<td>P220</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>1</td>
<td><strong>Drug Induced Leukocytoclastic Vasculitis Secondary to Cephalosporins</strong></td>
<td>C. Cooper*, S. Karakattu, N. Mungo, K. Devani, G. Youngberg, A. Gonzalez-Estrada, Elizabethton, TN; 2. Johnson City, TN.</td>
<td>DRUG</td>
<td>P021</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>2</td>
<td><strong>PR013 Reduces Hyperemia In Murine Models of Allergic Conjunctivitis and Both Histaminergic/Nonhistaminergic Itch In Vitro</strong></td>
<td>E. Solomon*, T. Fukuyama, M. Sampson, W. Baeumer, Malvern, PA; 2. Raleigh, NC.</td>
<td>AERO</td>
<td>P076</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>3</td>
<td><strong>A Case of a Pituitary Tumor Presenting as Recurrent Periorbital Angioedema</strong></td>
<td>J. Kwah, M. Dispenza, A. Peters, Chicago, IL.</td>
<td>ANGIO</td>
<td>P171</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>4</td>
<td><strong>Allergic Rhinitis: 3 Years Experience of Sensitization in Children by Skin Prick Test in Mexico</strong></td>
<td>A. Garcia, I. Campos, J. Marino, R. Collado, G. Eliosa, J. Hernandez, G. Velazquez, A. Velasco, Mexico City, DF, Mexico; 2. MEXICO, Mexico.</td>
<td>RHIN</td>
<td>P446</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>5</td>
<td><strong>Efficacy of Benralizumab for Patients With Severe, Uncontrolled Atopic Asthma by Serum Immunoglobulin E Concentrations</strong></td>
<td>B. Chipps, P. Newbold, I. Hirsch, F. Trudo, M. Goldman, 1. Sacramento, CA; 2. Gaithersburg, MD; 3. Wilmington, DE.</td>
<td>ASTHMA</td>
<td>P221</td>
</tr>
</tbody>
</table>
## E-poster Presentations

**E-poster Presentations**

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday

**Halls C & D (2nd Floor) • Hynes Convention Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:50 pm</td>
<td>6</td>
<td><strong>Practical Dietary Recommendations for Patients With Food Protein-Induced Enterocolitis Syndrome (FPIES)</strong></td>
<td>M. Robinson*, D. Jayaraman, B. Lanser, Denver, CO.</td>
<td>FOOD</td>
<td>P346</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>7</td>
<td><strong>Experience With Two Patients With Activated PI3K Delta Syndrome: Case Reports</strong></td>
<td>A. Stoner*, J. Kennedy, A. Berinski*, S. Jones*, A. Scurlock, 1. Little Rock, AR; 2. Little Rock, NC.</td>
<td>IMMUNO</td>
<td>P271</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>1</td>
<td><strong>A Suspected Case of Fatal Sugammadex Anaphylaxis During Surgery</strong></td>
<td>J. Gabriel*, C. Cook, E. Cook, B. McNew, A. Gonzalez-Estrada, Johnson City, TN.</td>
<td>DRUG</td>
<td>P022</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>2</td>
<td><strong>Incongruity in Detecting Dog Sensitized Individuals between Skin Prick and Specific Dog IgE Testing.</strong></td>
<td>S. Chan*, Denver, CO.</td>
<td>AERO</td>
<td>P077</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>3</td>
<td><strong>A Rare Subtype of Urticaria</strong></td>
<td>D. Lang, Moreland Hills, OH.</td>
<td>ANGIO</td>
<td>P172</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>4</td>
<td><strong>Subcutaneous Immunotherapy Induced Local Skin Necrosis</strong></td>
<td>D. Brauer*, A. White, San Diego, CA.</td>
<td>DIAGN</td>
<td>P101</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>5</td>
<td><strong>Effects of Immunoglobulin E Concentration, Eosinophil Concentration, and Atopy Status on Benralizumab Efficacy in Asthma</strong></td>
<td>P. Newbold, I. Hirsch, F. Trudo, M. Goldman, 1. Gaithersburg, MD; 2. Wilmington, DE.</td>
<td>ASTHMA</td>
<td>P222</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>6</td>
<td><strong>Correlation of Atopic Disorders With Severity of Eosinophilic Esophagitis</strong></td>
<td>I. Ezhuthachan*, D. Doshi, 1. Troy, MI; 2. Royal Oak, MI.</td>
<td>FOOD</td>
<td>P347</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>7</td>
<td><strong>Disseminated Cutaneous Warts in X-linked Hyper-IgM Syndrome: A Case Report</strong></td>
<td>H. Ho*, C. Cunningham-Rundles, New York, NY.</td>
<td>IMMUNO</td>
<td>P272</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>1</td>
<td><strong>A Case of Exercise-Induced Anaphylaxis Associated With the Use of Bee Pollen</strong></td>
<td>K. McNamara*, L. Pien, Cleveland, OH.</td>
<td>DRUG</td>
<td>P023</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>2</td>
<td><strong>Methods for Homogenizing Feld1 Levels in a Cat Allergen Exposure Chamber</strong></td>
<td>J. Falbo, J. Marcelo*, W. Yang, J. Yang, S. Kelly, J. Karsh, Ottawa, ON, Canada.</td>
<td>AERO</td>
<td>P078</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>3</td>
<td><strong>Physical Urticarias in a Child With Atopy</strong></td>
<td>M. Ford*, M. DeFelice, 1. Philadelphia, PA; 2. 1600 Rockland Rd, DE.</td>
<td>ANGIO</td>
<td>P173</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>4</td>
<td><strong>Clinical Improvement of Maize Based Occupational Rhinitis by a Course of Phleum Pretense Subcutaneous Immunotherapy</strong></td>
<td>W. Wagoner, M. Ebeling, T. Hulse, F. Schafer, 1. San Antonio, TX; 2. Charleston, SC; 3. Morgantown, WV.</td>
<td>DIAGN</td>
<td>P102</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>5</td>
<td><strong>Reslizumab Improves Spirometric Lung Age in Patients With Severe Eosinophilic Asthma</strong></td>
<td>W. Carr, M. McDonald, P. Meizlik, 1. Mission Viejo, CA; 2. Malvern, PA.</td>
<td>ASTHMA</td>
<td>P223</td>
</tr>
</tbody>
</table>
### E-poster Presentations

**3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday**

**Halls C & D (2nd Floor) • Hynes Convention Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:20 pm</td>
<td>1</td>
<td>DRESS Syndrome Secondary to Lamotrigine Complicated by Myocarditis, Heart Failure and a Polytropic B-Cell Subpopulation.</td>
<td>L. Cuervo-Pardo*, B. Bochner, P. Greenberger, Chicago, IL.</td>
<td>DRUG</td>
<td>P024</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>2</td>
<td>Anatomic Distribution of Feld1 and Feld4 in Domestic House Cats</td>
<td>W. Yang, S. Kelly*, J. Karsh, J. Yang, J. Marcelo, Ottawa, ON, Canada.</td>
<td>AERO</td>
<td>P079</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>3</td>
<td>Clinical and Demographic Characteristics of Patients With Hereditary Angioedema in the United States</td>
<td>A. Banerji†, K. Davis†, G. Devercelli†, K. Hollis†, S. Hunter†, G. Jain*, 1. Boston, MA; 2. Research Triangle Park, NC; 3. Lexington, MA.</td>
<td>ANGIO</td>
<td>P174</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>4</td>
<td>Systemic Reactions to Subcutaneous Immunotherapy (SCIT): A Descriptive Study</td>
<td>S. Sani*, L. Fonacier*, M. Davis-Lorton†, M. Aquino†, 1. Mineola, NY; 2. Great Neck, NY.</td>
<td>DIAGN</td>
<td>P103</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>6</td>
<td>Allergy Whey Proteins From Cow’s Milk Solved by Yogurt</td>
<td>V. Matheu*, A. Alonso-Larruga, P. Poza-Guedes, Y. Barrios, I. Sanchez-Machín, La Laguna, Spain.</td>
<td>FOOD</td>
<td>P349</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>1</td>
<td>An Unusual Case of Voriconazole Induced Pseudoporphyria</td>
<td>N. Mungo*, D. Youssef†, G. Youngberg†, A. Gonzalez-Estrada†, 1. Jonesborough, TN; 2. Johnson City, TN.</td>
<td>DRUG</td>
<td>P025</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>2</td>
<td>Patient Responses to Ragweed Challenge Validate the Allergen Challenge Theatre™</td>
<td>J. Falbo, W. Yang*, S. Kelly, J. Karsh, J. Yang, J. Marcelo, Ottawa, ON, Canada.</td>
<td>AERO</td>
<td>P080</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>3</td>
<td>Non-surgical Management of Intussusception in a Pediatric Patient With Hereditary Angioedema</td>
<td>Z. Rivera*, C. Ramos†, 1. San Juan, Puerto Rico; 2. San Juan, PR.</td>
<td>ANGIO</td>
<td>P175</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>4</td>
<td>Treatment Benefit With 300IR 5-Grass Tablet in Pediatric Patients: From Clinical Trial to Real-Life Settings</td>
<td>K. Relwani¹, K. Renahan¹, E. Karagiannis¹, J. Cognet-Sicé³, K. Abiteboul¹, 1. Cambridge, MA; 2. Kamp-Lintfort, Germany; 3. Antony, France.</td>
<td>DIAGN</td>
<td>P104</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>6</td>
<td>A Case of Phosphoacetylglucosamine Mutase (PGM3) Deficiency in a Patient with CFTR-related Metabolic Syndrome (CRMS)</td>
<td>B. Navetta-Modrov*, B. Kaplan, A. Jongco, Great Neck, NY.</td>
<td>IMMUNO</td>
<td>P289</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>7</td>
<td>Refractory Hypereosinophilia Manifesting as Nodalular Sclerosis Classical Hodgkin Lymphoma—A Case Presentation</td>
<td>L. Martorano*¹, P. Ogbovu², K. Strothman¹, 1. Columbus, OH; 2. Chagrin Falls, OH; 3. Plain City, OH.</td>
<td>IMMUNO</td>
<td>P275</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>1</td>
<td>Severe Anaphylaxis to Triamcinolone</td>
<td>A. Harish*¹, S. Brady², 1. Williamsville, NY; 2. Amherst, NY.</td>
<td>DRUG</td>
<td>P026</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>2</td>
<td>Effects of Time and Temperature on Pollen Counting in the US</td>
<td>J. Jones, Clinton, NJ.</td>
<td>AERO</td>
<td>P081</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>3</td>
<td>A Case of Acute Urticaria and Angioedema From an Underlying Bacterial Infection</td>
<td>G. Patel¹, E. Kellner, C. Saltoun, Chicago, IL.</td>
<td>ANGIO</td>
<td>P176</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>4</td>
<td>House Dust Mite Sublingual Tablets: Efficacy and Safety Results From Two Phase III Trials</td>
<td>K. Bergmann¹, K. Relwani², Y. Okamoto³, 1. Berlin, Germany; 2. Cambridge, MA; 3. Chiba, Japan.</td>
<td>DIAGN</td>
<td>P105</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>5</td>
<td>Spirometry Utilization in Primary Care: Adherence to National Asthma Guidelines</td>
<td>J. Badwal*, West Henrietta, NY.</td>
<td>ASTHMA</td>
<td>P226</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>6</td>
<td>Immunodeficiency and Persistent EBV Infection in a Patient with Jacobsen Syndrome: A Case Report</td>
<td>C. Lin*, C. Kuo, M. Garcia-Lloret, Los Angeles, CA.</td>
<td>IMMUNO</td>
<td>P265</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>7</td>
<td>Homozygous TRNT1 (tRNA Nucleotidyl Transferase 1) Mutation in a Patient With Pyroplikiosis and Humoral Immunodeficiency</td>
<td>R. Eisenberg¹, R. Mehta¹, A. Schneider*², J. Shlozberg³, 1. Bronx, NY; 2. NY, NY; 3. New York, NY.</td>
<td>IMMUNO</td>
<td>P276</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>1</td>
<td>Exaggerated Delayed Hypersensitivity Response to Insect Bites in a Patient With Chronic Lymphocytic Leukemia</td>
<td>Y. Mo*, M. Tobin, A. Trivedi, Chicago, IL.</td>
<td>DRUG</td>
<td>P037</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>3</td>
<td>Severe Chronic Idiopathic Urticaria and Angioedema With An Elevated Anti-IgE IgG Level</td>
<td>J. Brooks, F. Hsu, A. Helgeson*, New Haven, CT.</td>
<td>ANGIO</td>
<td>P178</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>4</td>
<td>Treatment With Grass Pollen SLIT Tablets is Associated With Long-Term Relief of Allergic Conjunctivitis</td>
<td>P. Devillier¹, U. Wahn², H. Richter³, M. Hadler⁴, E. Karagiannis⁴, L. Girard⁴, 1. Suresnes, France; 2. Berlin, Germany; 3. Frankfurt, Germany; 4. Kamp-Lintfort, Germany; 5. Antony, France.</td>
<td>DIAGN</td>
<td>P106</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>6</td>
<td>Heterozygous TACI Mutation in Patient With Recurrent Macrophage Activation Syndrome and Systemic JIA</td>
<td>J. Yonkof⁺¹, A. Vatsayan², J. Dalal², 1. Lyndhurst, OH; 2. Cleveland, OH.</td>
<td>IMMUNO</td>
<td>P291</td>
</tr>
<tr>
<td>3:20 pm</td>
<td>7</td>
<td>Hypereosinophilia With Systemic Symptoms Due to Pinworm</td>
<td>V. Nanagas*, J. Montejo, Ann Arbor, MI.</td>
<td>IMMUNO</td>
<td>P277</td>
</tr>
</tbody>
</table>

**SUNDAY, OCTOBER 29TH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 am</td>
<td>1</td>
<td>Adverse Drug Reactions to Lamotrigine Having Been Spontaneously Reported in a Korean Tertiary Hospital</td>
<td>Y. Koh*, Y. Choi, Seoul, Korea, Republic of.</td>
<td>DRUG</td>
<td>P027</td>
</tr>
<tr>
<td>9:45 am</td>
<td>2</td>
<td>Anaphylaxis to Crickets</td>
<td>J. Pier*, J. Lomas, Rochester, NY.</td>
<td>AERO</td>
<td>P083</td>
</tr>
<tr>
<td>9:45 am</td>
<td>3</td>
<td>An Atypical Case of Angioedema</td>
<td>A. Pandya*, Lenexa, KS.</td>
<td>ANGIO</td>
<td>P177</td>
</tr>
<tr>
<td>9:45 am</td>
<td>4</td>
<td>Treatment Benefit of the 5-Grass Tablet in Children: Assessment From the Patient’s Point of View</td>
<td>E. Karagiannis¹, M. Hadler¹, C. Blome², M. Augustin², 1. Kamp-Lintfort, Germany; 2. Hamburg, Germany.</td>
<td>DIAGN</td>
<td>P107</td>
</tr>
<tr>
<td>9:45 am</td>
<td>5</td>
<td>Change in Pulmonary Function Over Time in Obese Compared to Healthy Weight Asthmatics</td>
<td>M. Henao<em>¹, F. Ishmael</em>¹, 1. Harrisburg, PA; 2. Hershey, PA.</td>
<td>ASTHMA</td>
<td>P228</td>
</tr>
<tr>
<td>9:45 am</td>
<td>6</td>
<td>Do Serum Antibody Levels Tell the Whole Story of Secretory Immunity in CVID?</td>
<td>M. Slack*, Rochester, NY.</td>
<td>IMMUNO</td>
<td>P292</td>
</tr>
<tr>
<td>9:45 am</td>
<td>7</td>
<td>Alteration of Serum Immunoglobulin Concentrations in Dyslipidemia</td>
<td>M. Rusay, M. Bridgeman, M. Patel, L. Brunetti*, Piscataway, NJ.</td>
<td>IMMUNO</td>
<td>P278</td>
</tr>
<tr>
<td>9:55 am</td>
<td>1</td>
<td>Reaction to Lactose in an Albuterol Sulfate Dry Powder Inhaler Training Device</td>
<td>P. Maini*, M. Makhija, Chicago, IL.</td>
<td>DRUG</td>
<td>P028</td>
</tr>
</tbody>
</table>
### E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:55 am</td>
<td>2</td>
<td>Loss of Aspirin Tolerance After Successful Desensitization in Aspirin Exacerbated Respiratory Disease</td>
<td>N. Kabil*, T. Dy, St Louis, MO.</td>
<td>DRUG</td>
<td>P039</td>
</tr>
<tr>
<td>9:55 am</td>
<td>5</td>
<td>Birds of a Feather: A Case of Hypersensitivity Pneumonitis</td>
<td>L. Robinson*, C. Sokol, Boston, MA.</td>
<td>ASTHMA</td>
<td>P229</td>
</tr>
<tr>
<td>10:05 am</td>
<td>2</td>
<td>Low Vitamin D and Skin Prick Size Are Associated With Anaphylaxis in Accelerated Immunotherapy</td>
<td>Z. Marshall, N. McClarity, R. Tucker, A. Nguyen, D. Engler, Houston, TX.</td>
<td>DRUG</td>
<td>P040</td>
</tr>
</tbody>
</table>
# E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday  
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:05 am</td>
<td>4</td>
<td>Harbinger of a New Era in Allergy Treatment</td>
<td>V. Gomord¹, L. Vezina², A. Fitchette¹, V. Stordeur¹, G. Tropper³, L. Faye¹, Val de Reuil, France; 2. Quebec city, QC, Canada; 3. Boucherville, QC, Canada.</td>
<td>DIAGN</td>
<td>P109</td>
</tr>
<tr>
<td>10:05 am</td>
<td>5</td>
<td>Long-term Assessment of the Burden of Atopic Sensitization in Patients With Severe/Difficult-to-Treat Asthma</td>
<td>R. Zeiger⁴, B. Chipps¹, B. Ortiz³, F. Kianifard¹, B. Paknis¹, T. Haselkorn⁴, A. Foreman⁴, S. Szefler⁵, 1. San Diego, CA; 2. Sacramento, CA; 3. East Hanover, NJ; 4. South San Francisco, CA; 5. San Francisco, CA; 6. Aurora, CO.</td>
<td>ASTHMA</td>
<td>P230</td>
</tr>
<tr>
<td>10:05 am</td>
<td>6</td>
<td>Rhinitis Due to Serratia Marcescens Masquerading as Choanal Atresia in a Baby With Undiagnosed CGD</td>
<td>D. Rodriguez*, M. Dunham, L. Wall, New Orleans, LA.</td>
<td>IMMUNO</td>
<td>P294</td>
</tr>
<tr>
<td>10:05 am</td>
<td>7</td>
<td>Severe Combined Immune Deficiency in Cartilage Hair Hypoplasia</td>
<td>G. Harmon*, M. DeFelice¹, 1. Wilmington, DE; 2. Wilmington, DE.</td>
<td>IMMUNO</td>
<td>P280</td>
</tr>
<tr>
<td>10:15 am</td>
<td>2</td>
<td>Successful Administration of MenB-4C Vaccine in the Setting of an Adverse Reaction to MenB-FHbp</td>
<td>R. Kuriakose*, C. Patel¹, B. Kaplan¹, 1. Franklin Square, NY; 2. Great Neck, NY.</td>
<td>DRUG</td>
<td>P041</td>
</tr>
<tr>
<td>10:15 am</td>
<td>3</td>
<td>17 Year-Old Female With Idiopathic Hypereosinophilic Syndrome Presenting as Angioedema and Eosinophilic Pleural Effusions</td>
<td>M. Stone*, R. Eisenberg¹, J. Shlozberg¹, 1. Bronx, NY; 2. New York, NY.</td>
<td>ANGIO</td>
<td>P181</td>
</tr>
<tr>
<td>10:15 am</td>
<td>4</td>
<td>An Unusual Case of Delayed Pressure Urticaria After Rush Immunotherapy</td>
<td>K. Reddy⁵, J. Kirby¹, M. Kearns¹, I. Carrillo-Martin¹, L. Cuervo-Pardo¹, A. Gonzalez-Estrada¹, 1. Griffin, GA; 2. Johnson City, TN; 3. Madrid, Spain; 4. Chicago, IL.</td>
<td>DIAGN</td>
<td>P110</td>
</tr>
<tr>
<td>10:15 am</td>
<td>5</td>
<td>Assessing Follow up on Restrictive Pattern Identified by Outpatient Clinic Spirometry</td>
<td>R. Jones*, Hershey, PA.</td>
<td>ASTHMA</td>
<td>P231</td>
</tr>
<tr>
<td>10:15 am</td>
<td>6</td>
<td>Good Syndrome—Importance of Early Diagnosis</td>
<td>R. Eisenstadt*, V. Sueblinvong, J. Shih, Atlanta, GA.</td>
<td>IMMUNO</td>
<td>P295</td>
</tr>
<tr>
<td>Time</td>
<td>Monitor No.</td>
<td>Title</td>
<td>Author(s)</td>
<td>Category</td>
<td>Poster No.</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>10:15</td>
<td>7</td>
<td>Adverse Events and Infusion Parameters of IG20Gly in PIDD Patients Whose Pre-Study Treatment Was IVIG</td>
<td>K. Paris¹, I. Hussain¹, A. Darter¹, L. Kobrynski¹, T. Berner*¹, B. McCoy¹, C. Rabbat¹, L. Yel¹, 1. New Orleans, LA; 2. Tulsa, OK; 3. Oklahoma City, OK; 4. Atlanta, GA; 5. Chicago, IL; 6. Cambridge, MA.</td>
<td>IMMUNO</td>
<td>P281</td>
</tr>
<tr>
<td>12:30</td>
<td>1</td>
<td>A Case of Cefepime IgE-mediated Reaction With Negative Skin Testing. Should Current Concentrations be Reconsidered?</td>
<td>I. Carrillo-Martin*¹, K. Molony¹, K. Reddy¹, D. Youssef¹, A. Gonzalez-Estrada¹, 1. Madrid, Spain; 2. Johnson City, TN; 3. Griffin, GA.</td>
<td>DRUG</td>
<td>P031</td>
</tr>
<tr>
<td>12:30</td>
<td>2</td>
<td>Analysis of Referrals to an Allergist for Venom Hypersensitivity Reactions</td>
<td>P. Patel*¹, A. Wolff¹, 1. North Brunswick, NJ; 2. East Orange, NJ.</td>
<td>DRUG</td>
<td>P042</td>
</tr>
<tr>
<td>12:30</td>
<td>3</td>
<td>Hereditary Angioedema Flares Triggered by Concurrent Trauma and Viral Illness in an Autistic Child</td>
<td>K. McCormack*, D. Searing, Aurora, CO.</td>
<td>ANGIO</td>
<td>P182</td>
</tr>
<tr>
<td>12:30</td>
<td>4</td>
<td>Cough Hypersensitivity Syndrome Diagnosed After 30 Years: A Commonly Unrecognized Entity</td>
<td>P. Sankhyan*¹, J. Treece², N. Cuervo-Pardo², A. Kapila², A. Gonzalez-Estrada², 1. Johnson City, TN; 2. Johnson city, TN; 3. Cali, TN.</td>
<td>DIAGN</td>
<td>P111</td>
</tr>
<tr>
<td>12:30</td>
<td>5</td>
<td>Labile Asthma and Recurrent Pneumonia; A Pediatric Case of Eosinophilic Granulomatosis With Polyangiitis</td>
<td>K. Grisanti*, R. Scherzer, Columbus, OH.</td>
<td>ASTHMA</td>
<td>P232</td>
</tr>
<tr>
<td>12:30</td>
<td>6</td>
<td>Hypogammaglobulinemia in a Patient With Turner's Syndrome (TS) and Celiac Disease</td>
<td>F. Tabatabaian, Lutz, FL.</td>
<td>IMMUNO</td>
<td>P296</td>
</tr>
<tr>
<td>12:30</td>
<td>7</td>
<td>Recurrent Candidal Esophagitis in an Otherwise Healthy Host</td>
<td>K. Khalsa*, M. Pasha, Q. Yang, Albany, NY.</td>
<td>IMMUNO</td>
<td>P282</td>
</tr>
<tr>
<td>12:40</td>
<td>1</td>
<td>Latex-Papaya Syndrome: An Association Infrequent but of Great Relevance</td>
<td>V. Mandujano*, Mexico, Mexico City, Mexico.</td>
<td>DRUG</td>
<td>P032</td>
</tr>
<tr>
<td>12:40</td>
<td>2</td>
<td>First Case of Biopsy Proven Drug Eruption to Apremilast</td>
<td>H. Patel*¹, W. Calhoun², W. Tausend², B. Gibson², B. Goodwin², 1. League City, TX; 2. Galveston, TX.</td>
<td>DRUG</td>
<td>P043</td>
</tr>
<tr>
<td>12:40</td>
<td>3</td>
<td>Relapsing Polychondritis in a Patient With Chronic Urticaria</td>
<td>N. Thota*¹, T. Dy², 1. Bridgeton, MO; 2. St Louis, MO.</td>
<td>ANGIO</td>
<td>P183</td>
</tr>
<tr>
<td>12:40</td>
<td>4</td>
<td>Correlation Between Clinical Findings and Laboratory Tests for Alpha Gal Sensitivity</td>
<td>N. Krishna*, S. Krishna, R. Krishna, Winchester, MA.</td>
<td>DIAGN</td>
<td>P112</td>
</tr>
</tbody>
</table>
### E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:40 pm</td>
<td>5</td>
<td>Successful Recruitment Strategies in a Large-Scale Healthy Birth Cohort</td>
<td>S. Tilles*, J. Spergel², M. Lewis¹, 1. Philadelphia, PA; 2. Westfield, NJ.</td>
<td>ASTHMA</td>
<td>P233</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>7</td>
<td>Pneumococcal Osteomyelitis: A Rare Diagnosis Suggestive of Immune Deficiency</td>
<td>T. Peng*, M. Garcia-Lloret, Los Angeles, CA.</td>
<td>IMMUNO</td>
<td>P283</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>1</td>
<td>Cutaneous Adverse Drug Reaction Due to Apixaban</td>
<td>A. Albalbissi*, H. Balagoni, J. Treece, K. Al Balbissi, A. Gonzalez-Estrada, Johnson City, TN.</td>
<td>DRUG</td>
<td>P033</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>3</td>
<td>Aquagenic Urticaria</td>
<td>T. Aung*, L. Montelibano¹, K. Zin², 1. New Orleans, LA; 2. Savanna-la-mar, Jamaica.</td>
<td>ANGIO</td>
<td>P184</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>4</td>
<td>Patient Noncompliance With the Recommended 30-minute Post-SCIT Injection Wait Time</td>
<td>M. Tankersley*, Memphis, TN.</td>
<td>DIAGN</td>
<td>P113</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>5</td>
<td>Combination Omalizumab and Mepolizumab Therapy for Poorly-Controlled Severe Persistent Asthma</td>
<td>P. Tongchinsub*, T. Carr, Tucson, AZ.</td>
<td>ASTHMA</td>
<td>P234</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>6</td>
<td>Association Between DiGeorge and Bernard Soulier Syndromes</td>
<td>A. Odhav*, B. Lanser², P. Hauk³, 1. Glendale, CO; 2. Denver, CO.</td>
<td>IMMUNO</td>
<td>P298</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>7</td>
<td>STAT 1 Gain of Function Mutation Treated With Ruxolitinib</td>
<td>E. Schussler*, C. Cunningham-Rundles, New York, NY.</td>
<td>IMMUNO</td>
<td>P284</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>1</td>
<td>Amoxicillin Associated Acute Febrile Neutrophilic Dermatosis: A Case Report</td>
<td>C. Cook*, L. Kallur², J. Treece², V. Dimov³, A. Gonzalez-Estrada², 1. Piney Flats, TN; 2. Johnson City, TN; 3. Southwest Ranches, FL.</td>
<td>DRUG</td>
<td>P034</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>2</td>
<td>Nebulized Terbutaline Treats Uterine Cramping During Rush Immunotherapy</td>
<td>H. Wang*, Z. Marshall, D. Engler, Houston, TX.</td>
<td>DRUG</td>
<td>P045</td>
</tr>
</tbody>
</table>
### E-poster Presentations

**3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday**

**Halls C & D (2nd Floor) • Hynes Convention Center**

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm</td>
<td>3</td>
<td>Positive Autologous Serum and Plasma Skin Test Prevalence in Individuals With Chronic Idiopathic Urticaria</td>
<td>S. Gonzalez-Diaz¹, A. Arias-Cruz¹, A. Macias-Weinmann¹, L. Rangel Garza¹, D. Rangel Gonzalez², I. Perez Gomez³, 1. Monterrey, NL, Mexico; 2. Monterrey, Nuevo Leon, Mexico; 3. Monterrey, Mexico; 4. Monterrey, Mexico, Mexico.</td>
<td>ANGIO</td>
<td>P185</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>4</td>
<td>Measurement of Exhaled Breath Fraction Temperature in Patients Evaluation With Respiratory Allergy</td>
<td>R. Guzman-Avilan*, K. Guzman-Avilan, S. Gonzalez-Diaz, A. Arias-Cruz, B. Elizondo-Villarreal, Monterrey, NL, Mexico.</td>
<td>DIAGN</td>
<td>P114</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>5</td>
<td>Budgetary Impact Model on a Medicare Plan Adopting Short-Acting Beta-Agonist Inhalers With Integrated Dose Counters</td>
<td>R. Ariely⁴⁺, B. Chipps², S. Stoyanov³, L. Wang³, S. Shrestha³, O. Baser³, 1. Frazer, PA; 2. Sacramento, CA; 3. Plano, TX; 4. New York, NY.</td>
<td>ASTHMA</td>
<td>P235</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>6</td>
<td>Plasma Cell Dyscrasia in Primary Selective IgM Deficiency</td>
<td>S. Williams*, S. Gupta, Irvine, CA.</td>
<td>IMMUNO</td>
<td>P299</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>7</td>
<td>A Unique Adult Onset Immune Deficiency With Ectodermal Dysplasia</td>
<td>J. Chambliss⁴⁺, W. Calhoun², 1. Houston, TX; 2. Galveston, TX.</td>
<td>IMMUNO</td>
<td>P285</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>1</td>
<td>Atopy as a Risk Factor for Hypersensitivity to L-Asparaginase in Pediatric Patients With Leukemia</td>
<td>N. Padem*, D. Choi, Chicago, IL.</td>
<td>DRUG</td>
<td>P035</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>2</td>
<td>Rapid Oral Tolerance Induction Protocol to Trimetoprim and Sulfamethoxazol in a Patient With HIV</td>
<td>C. DeLira-Quezada⁴⁺, S. Gonzalez-Diaz³, A. Arias-Cruz³, R. Villarreal Gonzalez³, 1. Monterrey, NL, Mexico; 2. Monterrey, Nuevo Leon, Mexico; 3. Monterrey, Monterrey, Mexico.</td>
<td>DRUG</td>
<td>P046</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>5</td>
<td>Comorbidities Associated With Poor Short-Acting Beta-Agonist Inhaler Handling Among United States Respiratory Patients</td>
<td>K. Ramakrishnan⁷⁺, B. Chipps³, E. Parker³, R. Ariely¹, R. Parikh¹, S. Stoyanov¹, 1. Frazer, PA; 2. Sacramento, CA; 3. Eden Prairie, MN.</td>
<td>ASTHMA</td>
<td>P236</td>
</tr>
</tbody>
</table>
### E-poster Presentations

3:00 – 6:00 pm, Friday; 9:45 am – 4:00 pm, Saturday; and 9:45 am – 2:00 pm, Sunday
Halls C & D (2nd Floor) • Hynes Convention Center

<table>
<thead>
<tr>
<th>Time</th>
<th>Monitor No.</th>
<th>Title</th>
<th>Author(s)</th>
<th>Category</th>
<th>Poster No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:10 pm</td>
<td>6</td>
<td>NOD2 Compound Heterozygous Mutations in a Patient With Severe Crohn’s Disease</td>
<td>B. Lerman¹*, J. Verbsky², J. Routes³, M. Bausch-Jurken¹, 1. Brookfield, WI; 2. Milwaukee, WI.</td>
<td>IMMUNO</td>
<td>P300</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>7</td>
<td>Chronic Granulomatous Disease Post-Stem Cell Transplantation: Case Report</td>
<td>M. Mogica, Mexico city, Mexico.</td>
<td>IMMUNO</td>
<td>P286</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>1</td>
<td>A Case of Anaphylaxis to Sevoflurane</td>
<td>G. Sabharwal¹*, F. Ishmael, S. Lin, Hershey, PA.</td>
<td>DRUG</td>
<td>P036</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>3</td>
<td>Improvement of Eosinophilic Asthma Due to Two Part Paint Exposure With Mepolizumab</td>
<td>A. Zahiruddin¹*, W. Calhoun³, 1. Houston, TX; 2. Galveston, TX.</td>
<td>ASTHMA</td>
<td>P240</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>4</td>
<td>Evaluating the Validity of the Asthma Control Test (ACT) in Patients With Variable Education Backgrounds</td>
<td>S. Sekhsaria¹*, J. Pollack³, S. Bhasin³, 1. Waldorf, MD; 2. Baltimore, MD; 3. Annandale, VA.</td>
<td>ASTHMA</td>
<td>P242</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>5</td>
<td>Real World Effects of Reslizumab: A Retrospective Chart Review</td>
<td>L. Crowther, O. Gourgy Hacohen¹*, J. Jacobs, Walnut Creek, CA.</td>
<td>ASTHMA</td>
<td>P237</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>6</td>
<td>Omalizumab in Treatment of Mast Cell Activation Syndrome</td>
<td>R. Brown¹, L. Yao²*, 1. Phoenix, AZ; 2. Laveen, AZ.</td>
<td>PHARM</td>
<td>P401</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>7</td>
<td>The Big Masquerade: Atopy as the Presenting Symptom of DOCK8 Deficiency</td>
<td>C. Yeh¹*, H. Su¹, C. Martinez¹, R. Hunt¹, A. Freeman¹, N. Shah¹, C. Davis¹, 1. Houston, TX; 2. Rockville, MD; 3. Bethesda, MD.</td>
<td>IMMUNO</td>
<td>P287</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>1</td>
<td>A Case of Anaphylaxis to Methotrexate and Successful Desensitization</td>
<td>S. Joychan¹*, B. Patel³, J. Mayer¹, P. Sriaroon³, 1. St. Petersburg, FL; 2. Clearwater, FL; 3. St Petersburg, FL.</td>
<td>DRUG</td>
<td>P038</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>5</td>
<td>The Effect of Animal Exposures on Asthma Morbidity Independent of Allergen Among Inner-city Asthmatic Children</td>
<td>P. Tsou¹*, M. McCormack, E. Matsui, N. Hansel, G. Diette, M. Davis, Baltimore, MD.</td>
<td>ASTHMA</td>
<td>P238</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>6</td>
<td>Cost-Effectiveness of Exhaled Nitric Oxide (FeNO) Monitoring in Asthma Management</td>
<td>M. Massanari¹*, D. Aja¹, E. Brooks², 1. Morrisville, NC; 2. Asheville, NC.</td>
<td>PHARM</td>
<td>P402</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>7</td>
<td>Opportunism Is Not Opportunistic</td>
<td>N. Barberis¹*, Denver, CO.</td>
<td>IMMUNO</td>
<td>P288</td>
</tr>
</tbody>
</table>
Cem Akin, MD, PhD
Dr. Akin is Professor of Medicine at the University of Michigan with a clinical and research interest in mast cells, mastocytosis, and anaphylaxis.

Kim Alexander
Kim Alexander, Director of Operations, has been with Family Allergy & Asthma since 2010. She began her career with Family Allergy as Director of Financial Services and was promoted to Director of Operations in 2012. She has 30 years of management experience in physician billing, credentialing, patient access and compliance, and has worked in various healthcare environments including hospitals, billing services and physician groups.

Aikaterini Anagnostou, MD, PhD
Dr. Anagnostou is an Associate Professor of Pediatric Allergy and Director of the Food Immunotherapy Program at Texas Children’s Hospital. She is passionate about investigating new and innovative treatments for food allergy. She obtained her PhD from Cambridge University (UK) and her dissertation focused on two trials of peanut oral immunotherapy in children. Her research work was published in The Lancet and received international recognition. Dr. Anagnostou has a strong interest in preventing allergic disease and recently developed a food allergy prevention clinic. She is committed to improving the quality of life of allergic patients and their families.

Leonard Bacharier, MD
Dr. Bacharier is the Donald B. Strominger Professor of Pediatrics and Professor of Medicine at Washington University School of Medicine, Clinical Director of the Division of Pediatric Allergy, Immunology and Pulmonary Medicine, and Unit Co-leader for the Pediatric Patient Oriented Research Unit. Dr. Bacharier’s research focuses on childhood asthma, ranging from the role of RSV infection in disease inception to exploring novel management strategies in preschool children.

Susan Bailey, MD
Dr. Bailey Susan R. Bailey, MD, an allergist and immunologist from Fort Worth, Texas, was reelected speaker of the American Medical Association House of Delegates in June 2017. Previously, she served as vice speaker for four years. A tenacious advocate for physicians and the patients who depend on them, Dr. Bailey has held numerous positions for the AMA. She was chair of the AMA Council on Medical Education, chair of the Texas delegation to the AMA and served as the AMA representative to the Assembly of the American Board of Medical Specialties. She also completed a five-year term as the AMA nominee to the board of directors of the Accreditation Council for Continuing Medical Education. She currently represents the AMA on the board of directors of COLA.

Peter Barnes, DM, DSc
Peter Barnes is Margaret-Turner Warwick Professor of Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities and was appointed to his present post in 1987. He has published more than 1000 peer-review papers on asthma, COPD and related topics (h-index 155) and has written or edited over 50 books.

J. Andrew Bird, MD
Dr. Drew Bird is the director of the Food Allergy Center at Children’s Medical Center in Dallas and Associate Professor of Pediatrics and Internal Medicine in the Division of Allergy and Immunology at UT Southwestern Medical Center. His research interests are in understanding and treating life-threatening reactions to foods, and he is currently working with colleagues in several ongoing clinical trials using food proteins for immunotherapy.

Larry Borish, MD
Larry Borish received his MD from Boston University in 1979 and his clinical training in allergy/immunology at the New England Medical Center. His laboratory research interests involve mechanisms controlling the production and actions of chemical mediators of asthma and sinusitis. More recently, his focus has turned to immunological mechanisms of the immune response to rhinovirus that underlie asthma exacerbations.

A. Wesley Burks, MD
Dr. A. Wesley Burks is Executive Dean for the University of North Carolina School of Medicine. He heads a research team whose work centers on a better understanding of the basis of allergic disease and the development of treatment for food allergy. He and his colleagues identified the proteins in peanuts responsible for the allergic reaction and are leaders in the worldwide effort to develop treatment for food allergy, specifically peanut allergy. They have multiple clinical studies looking at different types of mucosal immunotherapy. He has been published in many distinguished journals.

Brendan Canning, PhD
Dr. Brendan J. Canning is a Professor of Medicine at the Johns Hopkins Asthma and Allergy Center in Baltimore. His NIH-funded research has focused on airway neural control, with an emphasis on defining the physiological and pharmacological properties of the cough reflex. Dr. Canning is an editorial board member for several journals focused on respiratory medicine and has been a scientific advisor and collaborator with over 20 pharmaceutical companies and biotech startups that aim to develop new therapies for cough and asthma.

Warner Carr, MD
Dr. Carr is a past BOR member who is in private practice in Southern California. He has extensive experience in clinical trials and regulatory affairs. He has numerous publications, including a recent book on pulmonary function testing. He served in the US Army for 17 years and also served as a new drug reviewer at the FDA.
Featured Lecturers and Faculty

Thomas Casale, MD
Dr. Casale is Professor of Medicine and Pediatrics and Chief of Clinical and Translational Research at University of South Florida in Tampa. He is a Past President of the AAAAI and is the current Executive Vice President. Dr. Casale’s research interests include the determination and treatment of the pathophysiologic mechanisms involved in asthma, COPD and allergic diseases. He has published over 350 scientific papers, reviews and chapters on these topics.

Mariana Castells, MD, PhD
Dr. Castells is a clinician, researcher and teacher at Brigham and Women’s Hospital and Dana Farber Cancer Institute. She is the director of the Drug Hypersensitivity and Drug Desensitization Center, as well as the director of the Mastocytosis Center and has served as the Allergy and Immunology Training Program Director for 15 years. She serves on the Board of Directors of the AAAAI.

Badrul Chowdhury, MD, PhD
Dr. Chowdhury is the Director of the Division of Pulmonary, Allergy and Rheumatology Products (DPARP) at the Center for Drug Education and Research of the U.S. Food & Drug Administration. DPARP regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Biologics Licensing Applications (BLAs) for prescription drugs and biologics intended for the prevention, treatment, or diagnosis of conditions. Dr. Chowdhury is an allergist-immunologist in Washington, District of Columbia. He received his medical degree from Dhaka Medical College and has been in practice for more than 20 years.

Christina Ciaccio, MD, MSc
Christina Ciaccio provides care for children and adults with food and environmental allergies, allergic rhinitis, urticaria and angioedema, allergic rashes and asthma. Her research is focused on understanding how nutrition (prebiotics) and microbial exposures (probiotics) affect immunoglobulin E (IgE) sensitization. She is currently working with other researchers to build a translational research program that will help influence preventive care strategies.

Antonella Cianferoni, MD
Dr. Cianferoni is an assistant professor at University of Pennsylvania and she practices pediatric allergy at the Children’s Hospital of Philadelphia Allergy Division and Center for Pediatric Eosinophilic Disorders. Dr. Cianferoni is active both in clinical and translational research. She is the co-director for the FARE center at CHOP and directs a laboratory studying IgE- and not-IgE-mediated food allergy, especially to milk. Her research has been funded by NIH. She is an author of more than 70 peer-reviewed publications and book chapters.

Kimberly Clay, RN, MSN, APRN, FNP-BC
Kimberly Clay, FNP, is a Family Nurse Practitioner from Marietta, GA. She has worked with Atlanta Allergy & Asthma for the last 7 years in the outpatient setting. She earned a Bachelor of Science in Nursing in 1998 and a Master of Nursing in 2003 from Medical College of Georgia. She is a member of ACAAII and AAAAI and is on the ACAAI Planning Committee for Allied Health.

Helen Combs
Helen Combs is Executive Director for the Alabama Allergy & Asthma Center. Her key focuses are practice management, utilization of technology within the practice and continued development of the excellent staff of Alabama Allergy. Helen is responsible for leading all teams in the develop of new programs and strategic planning and ensuring the practice is relevant and current to the specialty of allergy, asthma and immunology.

Timothy Craig, DO
Dr. Timothy Craig is an allergist-immunologist in Hershey, Pennsylvania and is affiliated with multiple hospitals in the area, including Lehigh Valley Hospital and Penn State Milton S. Hershey Medical Center. He received his medical degree from New York College of Osteopathic Medicine and has been in practice for more than 20 years.

Charlotte Cunningham-Rundles, MD, PhD
Dr. Cunningham-Rundles is Professor of Medicine and Pediatrics, Mount Sinai School of Medicine. Her work has been on the pathogenesis, characterization and treatment of primary human immune deficiency diseases. She is the author of more than 270 publications and numerous book chapters on topics of human immunity and immune deficiency and her research work is centered on the laboratory investigation on the defects of human B cells.

Peter Dicpinigaitis, MD
Peter Dicpinigaitis is Professor of Clinical Medicine at Albert Einstein College of Medicine/Montefiore Medical Center, New York. He serves as Site Director for Critical Care Medicine, and is founder of Montefiore Cough Center. Dr. Dicpinigaitis is active in clinical cough research, served as co-author of cough management guidelines published by American College of Chest Physicians and European Respiratory Society, and is founder and chairman of the biannual American Cough Conference.

Chitra Dinakar, MD
Dr. Chitra Dinakar is a Clinical Professor of Medicine at Stanford University and the Clinical Chief of Allergy, Asthma and Immunodeficiency, Stanford Health Care. Prior to coming to Stanford she was a Professor of Pediatrics at the University of Missouri-Kansas City; and Director, Food Allergy Center at Children’s Mercy Hospital, Kansas City. She completed her fellowship in allergy-immunology (A/I) at the Cleveland Clinic Foundation, Ohio, and her residency in pediatrics at Case Western Reserve University/Metrohealth Medical Center, Ohio. She completed her medical school and pediatric residency training at JIPMER, a premier medical institution in India.

Jeffrey Drazen, MD
Dr. Jeffrey Drazen graduated from Harvard Medical School in 1972. After serving his medical residency at Boston’s Peter Bent Brigham Hospital, he joined its Pulmonary Division and that of the Beth Israel Hospital, serving each as division chair for many years. In 2000, he assumed the post of Editor-in-Chief of the New England Journal of Medicine. During his tenure, the Journal has published major papers advancing the science of medicine.
Mark Dykewicz, MD  
Dr. Dykewicz is Raymond and Alberta Professor in Allergy & Immunology; Professor of Internal Medicine; Chief, Section of Allergy and Immunology; and Allergy and Immunology Fellowship Program Director at Saint Louis University School of Medicine. A recipient of the ACAAI Distinguished Service Award and AAAAI Special Recognition Award, his past service includes chair of the FDA Pulmonary Allergy Drug Advisory Committee and director of the ABAI and AAAAI.

Anne Ellis, MD, MSc  
Dr. Ellis is a Professor and Chair of the Division of Allergy & Immunology in the Department of Medicine at Queen’s University. Her role is Clinician Scientist with approximately 70% of her academic portfolio dedicated to research focused on cord blood predictors of future atopy and allergic rhinitis mechanisms and treatments. She is Director of the Environmental Exposure Unit (www.eeu.on.ca) and the Allergy Research Unit at Kingston General Hospital.

Stanley Fineman, MD, MBA  
Dr. Fineman is currently in private practice at Atlanta Allergy & Asthma and is Adjunct Associate Professor at Emory University. Dr. Fineman is a Past President of the American College of Allergy, Asthma & Immunology where he continues to serve on several committees. He is also Past President of the Southeastern Allergy Association, and he received their Lifetime Achievement Award in 2015. He currently serves on the Board of the WAO.

Bill Finerfrock  
Bill Finerfrock is the president and owner of Capitol Associates (CAI), a government relations/consulting firm based in Alexandria, Virginia. Prior to assuming ownership of CAI, in January, 2014, Finerfrock was a senior vice president in the firm for more than 20 years. Finerfrock specializes in health care financing, health systems reform, health workforce and rural health.

David Fleischer, MD  
Dr. Fleischer is currently an Associate Professor of Pediatrics, and Associate Section Head of Allergy/Immunology and Director of the Allergy and Immunology Center at Children’s Hospital Colorado. Dr. Fleischer’s primary clinical interest is food allergy, and his research has focused on the natural history of food allergy and novel treatments for food allergy, including oral, sublingual and epicutaneous immunotherapies. He is a Fellow of the ACAAI and AAAAI.

Luz Fonacier, MD  
Dr. Luz Fonacier is an allergist-immunologist in Mineola, New York and is affiliated with NYU Winthrop Hospital. She received her medical degree from University of the Philippines College of Medicine and has been in practice for more than 20 years.

Samuel Friedlander, MD  
Dr. Friedlander is an Assistant Clinical Professor at Case Western Reserve University and practices both allergy and sleep medicine in Cleveland. He trained in Internal Medicine and Pediatrics at Case. Dr. Friedlander completed his fellowship at the University of Wisconsin-Madison. He is board certified in allergy-immunology and also sleep medicine. He is former president of the Cleveland Allergy Society, author of book chapters and journal articles, and a reviewer for several journals.

Charlie Furr, MHA  
Charlie Furr has been the Practice Administrator at Carolina Asthma & Allergy Center in Charlotte, North Carolina for over six years. CAAC currently has twelve locations, fifteen board-certified allergists, and four mid-level providers. Prior to working at CAAC, Charlie served as the Chief Operating Officer at OrthoCarolina, President of MedCath Diagnostics LLC, and Vice President of Operations at Union Regional Medical Center. He received his undergraduate degree at the University of North Carolina at Chapel Hill and his Master in Health Administration from Virginia Commonwealth University.

David Golden, MD  
Dr. Golden is an Associate Professor of Medicine at Johns Hopkins University where he directed a program of research studies on insect sting allergy and anaphylaxis for 30 years. He has published numerous research articles, chapters and review articles. Dr. Golden is a member of the Joint Task Force on Practice Parameters, and is on the editorial boards of several major journals.

Mitchell Grayson, MD  
Dr. Grayson is Director of the Division of Allergy and Immunology and Professor of Pediatrics at Nationwide Children’s Hospital and The Ohio State University. Dr. Grayson oversees a National Institutes of Health (NIH) funded laboratory studying viral infections in development of allergic disease. He has published over 50 peer-reviewed articles and trained more than 14 post-doctoral or clinical research fellows, and is an elected member of the ASCI and CIA.

Matthew Greenhawt, MD, MBA, MSc  
Dr. Greenhawt is an Associate Professor with the Department of Pediatrics’ Allergy Section, Children’s Hospital Colorado and the University of Colorado School of Medicine and the director for the Children’s Hospital Colorado Food Challenge and Research Unit. A member of the AAAAI, ACAAI, and AAP, he is an associate editor for the Annals of Allergy, Asthma and Immunology and chair of the ACAAI Food Allergy Committee.

Luis Garcia  
Luis Garcia is the Patient Registry Director for the Food Allergy Research & Education (FARE). He plays a key role in the creation and implementation of the FARE Patient Registry, including platform and survey development, data curation and working closely with technology vendors and the medical advisory board and staff.

Maureen George, PhD, RN, AE-C  
Maureen George, PhD, RN, AE-C, FAAN, is an Associate Professor of Nursing at Columbia University School of Nursing. Dr. George has worked as an advance practice nurse in lung disease since 1986 and as certified asthma educator since 2002. She is a past president of the Association of Asthma Educators.
Justin Greiwe, MD
Currently partner at Bernstein Allergy Group, as well as Clinical Assistant Professor of Medicine at the University of Cincinnati. Dr. Greiwe’s practice has been offering oral immunotherapy for kids with food allergies for the last 3 years. Treatment provides a long-term solution for wheat-, egg-, peanut-, tree nut-, sesame-, and milk-allergic patients.

Gary Gross, MD
Gary N. Gross, MD, has practiced allergy in Dallas since 1975. He is a Clinical Professor of Medicine at the University of Texas Southwestern Medical School. He is currently practicing at the Dallas Allergy and Asthma Center, where he has practiced since 1978. Dr. Gross did his internship and his residency in internal medicine at the University of Utah Medical Center in Salt Lake City.

Ruchi Gupta, MD, MPH
Dr. Ruchi Gupta, MD, MPH, is Associate Professor of Pediatrics and Medicine at Northwestern Medicine and a clinical attending at Ann & Robert H. Lurie Children’s Hospital of Chicago. She leads the Science and Outcomes of Asthma and food Allergy Research (SOAAR) team at Northwestern and is nationally recognized for her groundbreaking research in the area of food allergy and asthma epidemiology; specifically, her research on childhood food allergy prevalence.

Emma Guttmann-Yassky, MD, PhD
Dr. Emma Guttmann-Yassky, MD, PhD, is Vice Chair of Research in the Dermatology Department, Professor of Dermatology & Immunology and Director of the Center for Excellence in Eczema, the Occupational/Contact Dermatitis clinic, and the Director of the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center in New York. She earned her MD degree from Sackler School of Medicine at Tel-Aviv University, and her PhD from Bar-Ilan University Ramat-Gan, Israel.

Daniel Hamilos, MD
Dr. Daniel Hamilos is an allergist-immunologist in Boston, Massachusetts and is affiliated with Massachusetts General Hospital. He received his medical degree from Northwestern University Feinberg School of Medicine and has been in practice for more than 20 years. He is one of 27 doctors at Massachusetts General Hospital who specialize in allergy-immunology.

Mary Lou Hayden, RN, MSN, FNP-BC, AE-C
Ms. Hayden has been active in the allergic diseases and asthma subspecialty for 35 years, providing patient care, participating in clinical research and precepting graduate students in both academia and in private practice. She has authored articles in peer-reviewed journals and presented topics in her specialty areas locally, nationally and internationally.

Stephen Imbeau, MD
Dr. Imbeau is board certified in internal medicine and allergy-immunology and has practiced allergy-immunology in Florence, SC for over 20 years. He is past president of the South Carolina Medical Association, the Joint Council of Allergy, Asthma and Immunology and serves as a delegate to the American Medical Association. He serves as a member of the Practicing Physicians Advisory Council of the Center for Medicare and Medicaid Services in Washington, DC.

Elliot Israel, MD
Dr. Elliot Israel is Professor of Medicine at Harvard Medical School in Boston, Massachusetts, and is the Director of Clinical Research for the Pulmonary Division at Brigham and Women’s Hospital in Boston. Dr. Israel’s major research interests include mediators of airway reactivity, the role of arachidonic acid metabolites in airway narrowing, and genetic influences in asthma pharmacotherapeutics, particularly as they relate to responses to beta-agonists.

Joshua Jacobs, MD
Dr. Jacobs completed his internal medicine and allergy-immunology training in the USAF. He completed nine years of service in the United States Air Force and served as the Chief of Internal Medicine for the 28th Medical Group at Ellsworth Air Force Base in South Dakota. Dr. Jacobs has been with Allergy & Asthma Medical Group since 1999 and is the Medical Director of Allergy and Asthma Clinical Research, Inc. He is a member of the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the European Academy of Allergy and Clinical Immunology.

Neal Jain, MD
Dr. Neal Jain is a practicing allergist in the Phoenix, Arizona community. He has spent time in Denver at National Jewish as a fellow and junior faculty as well as in Madison, Wisconsin at the University of Wisconsin and the Dean Clinic. He conducts clinical research and has a special interest in biomarkers for asthma and the use of exhaled nitric oxide.

Corinne Keet, MD
Corinne Keet is Associate Professor of Pediatrics at Johns Hopkins. She received her MD from the UCSF, residency and fellowship training and a PhD in epidemiology from Johns Hopkins. Her NIH-funded research focuses on the epidemiology and treatment of food allergy. She focuses on characterizing the “food allergy epidemic,” identifying environmental risk factors for food allergy and other allergic diseases, and on prevention and treatment of food allergy.

John Kelso, MD
Dr. Kelso completed fellowship training at the Mayo Clinic. He is on staff at Scripps Clinic in San Diego and Clinical Professor at the University of California San Diego. He has served on the Board of Directors of the ABAI and the AAAAI. He has authored over 100 publications, served on numerous editorial boards and is a frequent speaker at national and international medical meetings.
David Khan, MD
Dr. David A. Khan is Professor of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas. He is the Training Program Director for the allergy-immunology fellowship program at Southwestern. He is the Director of the Asthma Clinic at Parkland Memorial Hospital. Dr. Khan is a past president of the Texas Allergy, Asthma and Immunology Society and is a member of the Joint Task Force on Practice Parameters for Allergy & Immunology. Dr. Khan received his medical degree from the University of Texas at Austin. He is the Chief Operating Officer at Greater Austin Allergy, Asthma & Immunology and its subsidiaries. He is in charge of all business operations and administration for the company, which currently has 20 providers and 14 clinic locations across 3 states. In his prior role, Shaun designed high frequency sonars for the U.S. Navy. Shaun holds a Master of Business Administration degree and a Bachelor of Science in electrical engineering degree from The University of Texas at Austin.

Tanya Laidlaw, MD
Tanya Laidlaw completed her allergy-immunology fellowship at the Brigham and Women’s Hospital, with a focus on the pathogenesis of aspirin-exacerbated respiratory disease and nasal polyposis. She joined the faculty in 2009 and is now an Assistant Professor of Medicine at Harvard, as well as the Director of Translational Research in Allergy. Her AERD Center follows over 450 patients with AERD and has ongoing research studies that are recruiting and enrolling patients.

David Lang, MD
David Lang is Chairman of the Department of Allergy and Clinical Immunology, Training Program Director, and Co-director of the Asthma Center in the Cleveland Clinic Respiratory Institute. He teaches evidence-based medicine at the Cleveland Clinic Lerner College of Medicine and is Co-chair of the Practice Parameters Task Force. He has been active in National Quality Forum and development of quality measures. He currently serves on the AAAAI Executive Committee.

Bobby Lanier, MD
Dr. Bob Lanier has been a member of the ACAAI since 1977. He served on the board of directors twice, was vice president, president-elect and was president of the College in 2000. Dr. Lanier was instrumental in developing the college direction with Vision 20/20 as Executive Medical Director for the ACAAI for seven years. He has a special interest in the history of the college.

Jennifer Leiding, MD
Dr. Jennifer Leiding is Associate Professor, College of Medicine Pediatrics; Medical Director, Multidisciplinary Immunology Pediatrics; and Medical Director, SCID Newborn Screening Pediatrics at USF Health in St. Petersburg, Florida.

Donald Leung, MD, PhD
Dr. Donald Leung is Professor of Pediatrics at University of Colorado Denver School of Medicine. Between 1998-2015, he was Editor-in-Chief of the Journal of Allergy and Clinical Immunology, the most highly-cited journal in its field. Dr. Leung is the author of more than 600 publications and has received over 30 federally-funded grants. Many of these publications involve mechanisms and treatment of atopic dermatitis. From 2004 to the present, he was appointed Principal Investigator of a multi-medical center NIH/NIAID Atopic Dermatitis Research Network to study mechanisms underlying bacterial and viral infections in atopic dermatitis.

Megan Lewis, NP
Megan O. Lewis is a nurse practitioner and Program Manager of Allergy Research at the Children’s Hospital of Philadelphia. She graduated from the University of Virginia for both undergraduate and graduate degrees and completed a fellowship in developmental disabilities after graduation. She has practiced in the Division of Allergy for the past 8 years, seeing patients clinically and managing research studies.

James Li, MD, PhD
Dr. Li is Professor of Medicine and a previous chair of the Division of Allergic Diseases at Mayo Clinic, Rochester. Dr. Li is Director of the Allergy and Immunology Training Program at Mayo. He is past president of the American Academy of Allergy Asthma and Immunology (AAAAI). Previous appointments include Chair, ABAI; Chair, Pulmonary and Allergy Drug Advisory Committee (FDA); and Chair, RRC for Allergy and Immunology.

Jay Lieberman, MD
Dr. Lieberman is an associate professor at the University of Tennessee Health Science Center and LeBonheur Children’s Hospital. He has research interests in food allergy and anaphylaxis and was recently awarded the ACAAI Young Investigators Award for a project in eosinophilic esophagitis. He has published extensively in these fields and currently serves as an associate editor for the ACAAI’s official journal, the Annals of Allergy, Asthma, and Immunology.
William Lumry, MD
Dr. Lumry is in private practice in Dallas, Texas treating adults and children with allergic diseases and asthma. He is Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School in Dallas and teaches at Parkland Memorial Hospital in Dallas. Dr. Lumry is a Fellow of the American College of Physicians, AAAAI and ACAAI.

Gailen Marshall, MD, PhD
Gailen D. Marshall, Jr, MD, PhD, FACP, FACAAI is R. Faser Triplett, Sr., MD, Chair of Allergy and Immunology, Professor of Medicine, Pediatrics and Pathology, Vice Chair for Research and Director, Division of Clinical Immunology and Allergy at the University of Mississippi Medical Center. He received his MD and PhD from UTMB Galveston and did internal medicine at the University of Iowa and UT Memphis, where he also completed his A/I fellowship.

Bryan Martin, DO
Dr. Martin is a Past President of ACAAI, with over 15 years’ experience as an A/I Program Director, both at the National Capital Consortium at Walter Reed Army Medical Center and at Ohio State University. He is currently an Emeritus Professor at Ohio State, where he also served as the Associate Dean for Graduate Medical Education and Associate Medical Director, University Hospitals.

Richard Martin, MD
Richard J. Martin, MD, is Professor and Chair of the Department of Medicine at the National Jewish Health and holds the Edelstein Chair in Pulmonary Disease. Dr. Martin’s current areas of research include the distal airways in asthma, the effect of subacute bacterial infections on chronic asthma, and the mechanisms related refractory asthma. He has authored over 300 journal articles, books and chapters.

J. Allen Meadows, MD
Dr. Meadows is clinical instructor of internal medicine and family practice. He is a community-based practitioner at the Alabama Allergy & Asthma Clinic in Montgomery, AL. He is Chairman of the ACAAI Advocacy Council and past president of the JCAAI. He previously served on the ACAAI Board of Regents and as ACAAI Speaker of the House of Delegates. He lives with his wife Charlotte, an advocate for education issues.

Laura Meadows
Laura Meadows is the practice manager for Allergy Partners of Lynchburg, which opened in October, 2009. Laura has always had a great interest in allergy, as she experienced anaphylaxis for the first time at age four. She has been a patient since, and has a great passion for this specialty.

Eli Meltzer, MD
Eli O. Meltzer, MD is Clinical Professor, University of California, San Diego. Past Chief, Allergy/Immunology, Rady Children’s Hospital, San Diego, and clinician, Allergy & Asthma Medical Group & Research Center. He has participated in more than 650 research studies, authored over 600 scientific publications on diagnosis/treatment of respiratory diseases. He has been honored by ACAAI with the Distinguished Fellow and Gold Headed Cane awards.

James Mojica, MD
Dr. Mojica is a physician who specializes in breathing disorders experienced during sleep, exercise, and/or critical illness. His primary clinical interest and expertise is on the control of breathing and he dedicates most of his practice to caring for patients with these disorders at home, in the hospital wards, or in the intensive care unit. Dr. Mojica directs the Sleep Center at Spaulding Rehabilitation Hospital, in the care of patients with obstructive sleep apnea, central sleep apnea and hypoventilation syndrome. The sleep center performs outpatient sleep studies and bedside inpatient sleep studies, and offers both inpatient and outpatient consultations.

Anthony Montanaro, MD
Dr. Montanaro was born and raised in Seattle, where he attended the University of Washington to complete his undergraduate and medical studies. Following his internal medicine residency, he completed fellowships in rheumatology and allergy-immunology. He subsequently joined the faculty at the Oregon Health and Sciences University, where he has been chair of Allergy and Immunology for twenty years. He has devoted his career to patients, research and teaching.

Harold Nelson, MD
Dr. Nelson received his doctor of medicine degree from Emory University. He completed a fellowship in allergy-immunology at the University of Michigan. He is currently Professor of Medicine at National Jewish Health and the University of Colorado Denver School of Medicine.

Paul O’Byrne, MD
Paul O’Byrne is Dean and Vice President of the Faculty of Health Sciences at McMaster University. His research interests are on the mechanisms and treatment of asthma. He has published more than 440 peer-reviewed papers and edited 12 books. He has been elected Fellow of the Royal Society of Canada and to the Canadian Academy of Health Sciences. He was appointed Distinguished University Professor at McMaster University in 2015.

Peck Ong, MD
Dr. Ong’s focus has been in atopic dermatitis, specifically the infectious aspects of atopic dermatitis. His area of research has ranged from basic laboratory observations to clinical studies. Dr. Ong is particularly interested in the role of innate immune response in the pathogenesis and prevention of AD in young children. He has also seen many infectious complications of AD in the inpatient setting at CHLA past 14 years.
Reynold Panettieri, MD
Dr. Panettieri’s basic science interests focus on the molecular and cellular mechanisms of airway smooth muscle function and growth. He is the author of over 410 peer-reviewed publications, was chair of the NIH Lung Cellular, Molecular, and Immunobiology Study Section, is a member of the NIH Distinguished Editorial Panel, and is a member of the American Society for Clinical Investigation. He manages the comprehensive clinical care of patients with asthma.

Wanda Phipatanakul, MD, MS
Wanda Phipatanakul, MD, MS, has dedicated much of her career to clinical research aimed at reducing and preventing asthma and allergic diseases in children, particularly inner-city children. She directs the Asthma Clinical Research Center at Boston Children’s Hospital/ Harvard Medical School. Dr. Phipatanakul conducts both school- and home-based asthma studies with inner-city children and is overall PI for a nationwide, multicenter asthma prevention study evaluating anti-IgE in preventing asthma.

Marc Riedl, MD, MS
Marc Riedl, MD, MS, is Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at University of California – San Diego where he serves as Training Program Director for allergy-immunology. Dr. Riedl holds board certifications in allergy-immunology and clinical pharmacology and directs a clinical research program focused on angioedema and immunodeficiency conditions. Dr. Riedl serves on numerous editorial boards and appointed expert panels for FDA and NIH.

Lynda Schneider, MD
Lynda C. Schneider, MD, is Professor of Pediatrics at Harvard Medical School and Director of the Allergy Program, the Atopic Dermatitis Center at Boston Children’s Hospital and the Director of the FARE Food Allergy Clinical Center of Excellence at BCH. She is an investigator for the NIH-sponsored Atopic Dermatitis Research Network. Her current research interests include new therapies/approaches for atopic dermatitis and food allergy.

Tammy Peng, MD
Tammy Peng completed her undergraduate and medical school training at Drexel University in Philadelphia, Pennsylvania. She then completed residency in pediatrics at Rutgers University-Robert Wood Johnson Medical School. She recently completed her fellowship in allergy-immunology at UCLA in June and has since joined the faculty as a clinical instructor. Tammy is the current Fellows-In-Training (FITs) Senior Representative.

Anju Peters, MD
Anju Peters, MD, MSCI, is a professor of medicine at Northwestern University Feinberg School of Medicine. She graduated from University of Michigan Medical School and completed her residency in internal medicine and fellowship in allergy-immunology at Northwestern University prior to joining the faculty at Northwestern. Her main research and clinical interests are in rhinosinusitis.

John Routes, MD
Dr. Routes is the Division Head of Asthma, Allergy and Clinical Immunology and Professor of Pediatrics, Medicine, Microbiology and Immunology at the Medical College of Wisconsin. He has a longstanding clinical and research interest in primary immunodeficiency disorders and currently is the chairmain of the NIH study section entitled "Investigations In Primary Immunodeficiency."

Stephen Peters, MD, PhD
Dr. Peters holds the Thomas H. Davis Chair in Pulmonary Medicine, and is Chief of the Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases, Professor of Internal Medicine, Pediatrics, and Translational Science at Wake Forest University School of Medicine, Winston-Salem, North Carolina. He is also Executive Director, Respiratory Service Line, Wake Forest Baptist Health. He is PI of the Wake Forest NHLBI AsthmaNet and SPIROMICS clinical sites.

Marc Riedl, MD, MS
Marc Riedl, MD, MS, is Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at University of California – San Diego where he serves as Training Program Director for allergy-immunology. Dr. Riedl holds board certifications in allergy-immunology and clinical pharmacology and directs a clinical research program focused on angioedema and immunodeficiency conditions. Dr. Riedl serves on numerous editorial boards and appointed expert panels for FDA and NIH.

John Routes, MD
Dr. Routes is the Division Head of Asthma, Allergy and Clinical Immunology and Professor of Pediatrics, Medicine, Microbiology and Immunology at the Medical College of Wisconsin. He has a longstanding clinical and research interest in primary immunodeficiency disorders and currently is the chairmain of the NIH study section entitled "Investigations In Primary Immunodeficiency."

Robert Schleimer, PhD
Dr. Schleimer trained at UC San Diego (BA), UC Davis (PhD) and Johns Hopkins. He joined the faculty at Johns Hopkins and became Professor of Medicine in 1992. Dr. Schleimer became the Roy and Elaine Patterson Chair and Chief of Allergy-Immunology at Northwestern University in 2004. He has published over 350 papers, trained over 50 post-doctoral fellows and won numerous awards for his research on allergic disease.

Wanda Phipatanakul, MD, MS
Wanda Phipatanakul, MD, MS, has dedicated much of her career to clinical research aimed at reducing and preventing asthma and allergic diseases in children, particularly inner-city children. She directs the Asthma Clinical Research Center at Boston Children’s Hospital/ Harvard Medical School. Dr. Phipatanakul conducts both school- and home-based asthma studies with inner-city children and is overall PI for a nationwide, multicenter asthma prevention study evaluating anti-IgE in preventing asthma.

Marc Riedl, MD, MS
Marc Riedl, MD, MS, is Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at University of California – San Diego where he serves as Training Program Director for allergy-immunology. Dr. Riedl holds board certifications in allergy-immunology and clinical pharmacology and directs a clinical research program focused on angioedema and immunodeficiency conditions. Dr. Riedl serves on numerous editorial boards and appointed expert panels for FDA and NIH.

Lynda Schneider, MD
Lynda C. Schneider, MD, is Professor of Pediatrics at Harvard Medical School and Director of the Allergy Program, the Atopic Dermatitis Center at Boston Children’s Hospital and the Director of the FARE Food Allergy Clinical Center of Excellence at BCH. She is an investigator for the NIH-sponsored Atopic Dermatitis Research Network. Her current research interests include new therapies/approaches for atopic dermatitis and food allergy.

Lawrence Schwartz, MD, PhD
Lawrence Schwartz, MD, PhD, the Charles and Evelyn Thomas Professor of Medicine and Chair of the Division of Rheumatology Allergy and Immunology at VCU, is an innovative and leading translational research investigator who, with colleagues, has made fundamental discoveries about mast cells, including the discovery of human a/ß tryptases, proteases preferentially expressed by mast cells, the creation of clinically useful tryptase immunoassays, facilitating the diagnosis of systemic mastocytosis and systemic anaphylaxis, and the characterization of autosomal dominant alpha-tryptasemia. By caring for patients with such disorders, while being involved in related laboratory and clinical research, he brings a unique educational perspective.

Meagan Shepherd, MD
Meagan Shepherd is an Assistant Professor of Pediatrics at Marshall University in the Section of Allergy and Immunology. Dr. Shepherd completed her fellowship in allergy-immunology at Ohio State University and Nationwide Children’s Hospital. Currently she is the Associate Program Director for the Marshall University Med-Peds and Pediatrics Residency Programs. Dr. Shepherd has an active clinical practice and her research interests include asthma health literacy and asthma inhaler devices.
Wayne Shreffler, MD, PhD
Dr. Shreffler received his MD and PhD degrees from New York University and his pediatrics training at the Albert Einstein College of Medicine. He completed his fellowship in allergy-immunology at the Mount Sinai School of Medicine in 2003 where he was mentored by Drs. Hugh Sampson and Lloyd Mayer and established himself as a researcher of immune mechanisms of food allergy and asthma. He joined Massachusetts General Hospital and Harvard Medical School in late 2009 to establish a new translational research program focused on food allergy, and became Division Chief of Pediatric Allergy and Immunology in 2011.

Roxana Siles, MD
Dr. Siles was born in Bolivia and moved to the United States at a young age. She completed her undergraduate education and medical school training at Michigan State University. She pursued internal medicine residency training at McGaw Center of Medicine of Northwestern University in Chicago followed by allergy-immunology fellowship training at Cleveland Clinic Foundation. She currently works as staff in the Department of Allergy/Immunology in the Respiratory Institute at the Cleveland Clinic.

Jonathan Silverberg, MD, PhD, MPH
Dr. Silverberg is an Assistant Professor of Dermatology, Medical Social Sciences and Preventive Medicine at Northwestern University Feinberg School of Medicine, and Director of Northwestern Medicine’s Multidisciplinary Eczema Center and the patch testing clinic at Northwestern Memorial Hospital. His area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. Dr. Silverberg’s research interests include dermato-epidemiology, health services, patient-reported outcomes, comorbidities and burden of inflammatory skin disease and evidence-based dermatology.

Jacky Smith, MD
Jacky Smith is a Professor of Respiratory Medicine at the University of Manchester, UK and an Honorary Consultant at the University Hospital of South Manchester NHS Foundation Trust. She has over 15 years of experience in clinical trials assessing novel cough therapies and leads a specialist cough service. She graduated in medicine from Manchester University in 1992, completed training in general/respiratory medicine and obtained a PhD in the ‘Measurement of Cough’. In collaboration with Vitalograph Ltd, she has been responsible for the development of an ambulatory cough monitoring system, changing the standards by which new cough treatments are evaluated.

David Stukus, MD
Dr. Stukus is an Associate Professor of Pediatrics in the Division of Allergy and Immunology at Nationwide Children’s Hospital in Columbus, Ohio. His interests lie in social media for healthcare professionals and transitioning adolescents with allergic conditions to independent living. He served as a member of the expert panel and co-author of the NIAID Addendum Guidelines for the Prevention of Peanut Allergy.

James L. Sublett, MD
Dr. Sublett is the cofounder and Managing Partner of Family Allergy & Asthma and Clinical Professor of A&I at the University of Louisville School of Medicine. He is a past president of the ACAAI and currently serves as the College’s Executive Director for Advocacy and Governmental Affairs. He has been honored by the College as a Distinguished Fellow and serves on numerous committees and the Annals Editorial Board.

Kathleen Sullivan, MD, PhD
Dr. Sullivan is the Chief of the Division of Allergy-Immunology at The Children’s Hospital of Philadelphia (CHOP) and Professor of Pediatrics. She was the 2007-2008 president of the Clinical Immunology Society and a co-editor of the new Stiehm’s Immune Deficiencies.

Stanley Szefler, MD
Dr. Szefler is the Research Medical Director and Director of the Pediatric Asthma Research Program in the Breathing Institute of the Pediatric Pulmonary Section at Children’s Hospital Colorado. He is Professor of Pediatrics at the University of Colorado Denver School of Medicine. He is also the Deputy Editor for the Journal of Allergy and Clinical Immunology. His major contributions are directed toward the individualized use of asthma therapy.

Mike Tankersley, MD
Dr. Tankersley formerly practiced in Memphis, Tennessee. He is now retired and resides in Tupelo, MS. Dr. Tankersley received his medical degree from University of Tennessee College of Medicine and was in practice for more than 20 years.

Troy Torgerson, MD, PhD
With more than 12 years of experience as an attending clinical immunologist and pediatric rheumatologist at the University of Washington and Seattle Children’s Hospital, Dr. Torgerson has extensive experience in the diagnosis and management of patients with immunodeficiency. Since their immunodeficiency program serves as the primary referral program for the Pacific Northwest (Washington, Alaska, Idaho, Montana, Wyoming, and Oregon), Dr. Torgerson’s clinic follows a large number of patients with a variety of immunodeficiency disorders. Dr. Torgerson is also the Director of the Immunology Diagnostic Laboratory, a CLIA-approved molecular diagnostic lab focused on the characterization of primary immunodeficiency disorders.

Kay Tyler, BS, BA, MBA
Kay Tyler is the Chief Executive Officer of Family Allergy & Asthma based in Louisville, KY. Family Allergy is a 30-site practice with offices throughout Kentucky and Indiana. The practice consists of 21 physicians and 11 practitioners devoted to treating a full range of conditions related to allergic and asthmatic diseases. Ms. Tyler received her MBA from the University of Kentucky and BS and BA degrees from Truman State University.
**Carina Venter, PhD, RD**
Carina is appointed as an Assistant Professor at Cincinnati Children’s Hospital Medical Center. Carina is the Chair of the International Network of Dietitians and Nutritionists in Allergy and a registered dietitian in the UK and USA. She has had numerous publications in international journals and has authored book chapters. Carina was a member of the Expert Panel of the National Institutes for Allergy and Infectious Diseases Peanut Allergy Prevention Guidelines.

**Dana Wallace, MD**
Dr. Wallace is the current Education Council Chair and former president (2010-2011) of the American College of Allergy, Asthma and Immunology (ACAAI), and has received the ACAAI Distinguished Service Award (2009) and the ACAAI Woman in Allergy Award (2008). As a member of the JTF on Practice Parameters since 2005, Dr. Wallace was an editor of the 2009, 2011, 2012, 2013 Vaccine PP.

**Julie Wang, MD**
Julie Wang, MD, is an Associate Professor of Pediatrics in the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai. She completed pediatric residency training at the New York-Presbyterian/Weill Cornell Medical Center in New York, and an allergy-immunology fellowship program at the Mount Sinai. Her research interests include novel therapeutics for food allergy as well as diagnosis, epidemiology and management of food allergy.

**Robert Wood, MD**
Robert A. Wood is Professor of Pediatrics and Chief of Pediatric Allergy and Immunology at Johns Hopkins University. He is recognized internationally as an expert in both food allergy and childhood asthma and is a principal investigator in both ICAC and CoFAR, for which he is PI of the Leadership Center. He is currently president-elect of the American Academy of Allergy, Asthma & Immunology.

**Gil Yosipovitch, MD**
Gil Yosipovitch, MD, FAAD, is a Professor of Dermatology at the Miller School of Medicine at University of Miami, and Director of the Miami Itch Center, which focuses on chronic itch as a disease state. He has published more than 350 articles in books and peer-reviewed journals and has edited 3 books. Dr. Yosipovitch is the founder and past president of the International Forum for the Study of Itch (FSI).

---

**ACAAI Future Meeting Dates**

- **November 15-19, 2018**
  Seattle, Washington
- **November 7-11, 2019**
  Houston, Texas
- **November 12-16, 2020**
  Phoenix, Arizona
- **November 4-8, 2021**
  New Orleans, Louisiana
- **November 10-14, 2022**
  Louisville, Kentucky
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akin, C.</td>
<td>47, 109</td>
</tr>
<tr>
<td>Alexander, K.</td>
<td>74, 109</td>
</tr>
<tr>
<td>Alqurashi, W.</td>
<td>60</td>
</tr>
<tr>
<td>Alsgagaf, A.</td>
<td>69</td>
</tr>
<tr>
<td>Anagnostou, A.</td>
<td>43, 89, 109</td>
</tr>
<tr>
<td>Alsaggaf, A.</td>
<td>69</td>
</tr>
<tr>
<td>Anagnostou, A.</td>
<td>43, 89, 109</td>
</tr>
<tr>
<td>Aquino, M.</td>
<td>37, 48, 55, 96, 97, 100</td>
</tr>
<tr>
<td>Azar, A.</td>
<td>64</td>
</tr>
<tr>
<td>Bacharier, L.</td>
<td>35, 47, 89, 109</td>
</tr>
<tr>
<td>Bailey, S.</td>
<td>28, 49, 50, 109</td>
</tr>
<tr>
<td>Banerji, A.</td>
<td>37, 40, 60, 61, 65, 81, 85, 100</td>
</tr>
<tr>
<td>Banks, T.</td>
<td>38, 95</td>
</tr>
<tr>
<td>Barmettler, S.</td>
<td>60</td>
</tr>
<tr>
<td>Barnes, P.</td>
<td>63, 66, 109</td>
</tr>
<tr>
<td>Beigelman, A.</td>
<td>64</td>
</tr>
<tr>
<td>Bensch, G.</td>
<td>52, 82</td>
</tr>
<tr>
<td>Bernstein, C.</td>
<td>3, 79</td>
</tr>
<tr>
<td>Bernstein, J.</td>
<td>31, 64, 85, 86, 88, 90, 92, 96, 97</td>
</tr>
<tr>
<td>Bird, A.</td>
<td>43, 65, 82, 109</td>
</tr>
<tr>
<td>Boguniewicz, M.</td>
<td>42</td>
</tr>
<tr>
<td>Bonilla, F.</td>
<td>55</td>
</tr>
<tr>
<td>Borish, L.</td>
<td>1, 57, 86, 87, 109</td>
</tr>
<tr>
<td>Brooks, J.</td>
<td>68, 102</td>
</tr>
<tr>
<td>Brown-Whitehorn, T.</td>
<td>36</td>
</tr>
<tr>
<td>Brucker, H.</td>
<td>56</td>
</tr>
<tr>
<td>Bukstein, D.</td>
<td>35, 63</td>
</tr>
<tr>
<td>Burks, W.</td>
<td>43, 94, 109</td>
</tr>
<tr>
<td>Busse, P.</td>
<td>39</td>
</tr>
<tr>
<td>Canning, B.</td>
<td>52, 109</td>
</tr>
<tr>
<td>Capucilli, P.</td>
<td>69</td>
</tr>
<tr>
<td>Carr, W.</td>
<td>72, 99, 109, 123</td>
</tr>
<tr>
<td>Casale, T.</td>
<td>39, 55, 57, 87, 94, 103, 110</td>
</tr>
<tr>
<td>Castells, M.</td>
<td>40, 47, 65, 100</td>
</tr>
<tr>
<td>Celli, B.</td>
<td>40</td>
</tr>
<tr>
<td>Cheema, G.</td>
<td>70</td>
</tr>
<tr>
<td>Chipp, B.</td>
<td>1, 3, 5, 50, 54, 66, 89, 98, 104, 107, 122</td>
</tr>
<tr>
<td>Cho, S.</td>
<td>34, 36, 38</td>
</tr>
<tr>
<td>Chowdhury, B.</td>
<td>45, 110</td>
</tr>
<tr>
<td>Chu, K.</td>
<td>61</td>
</tr>
<tr>
<td>Ciaccio, C.</td>
<td>63, 76, 110</td>
</tr>
<tr>
<td>Cianferoni, A.</td>
<td>3, 43, 69, 110</td>
</tr>
<tr>
<td>Clay, K.</td>
<td>3, 76, 78, 110</td>
</tr>
<tr>
<td>Combs, H.</td>
<td>74, 110</td>
</tr>
<tr>
<td>Craig, T.</td>
<td>41, 53, 61, 85, 88, 90, 110</td>
</tr>
<tr>
<td>Cunningham-Rundles, C.</td>
<td>3, 68, 72, 99, 100, 106, 110</td>
</tr>
<tr>
<td>Davis, R.</td>
<td>33, 35, 56</td>
</tr>
<tr>
<td>Davis-Lorton, M.</td>
<td>37, 96, 100</td>
</tr>
<tr>
<td>Desai, M.</td>
<td>39, 97</td>
</tr>
<tr>
<td>Dickens, M.</td>
<td>79</td>
</tr>
<tr>
<td>Dicpinigaitis, P.</td>
<td>52, 110</td>
</tr>
<tr>
<td>Dinakar, C.</td>
<td>37, 44, 110</td>
</tr>
<tr>
<td>Dixit, A.</td>
<td>1, 16, 72</td>
</tr>
<tr>
<td>Drazen, J.</td>
<td>66, 110</td>
</tr>
<tr>
<td>Dykewicz, M.</td>
<td>44, 111</td>
</tr>
<tr>
<td>Elliott, T.</td>
<td>36</td>
</tr>
<tr>
<td>Ellis, A.</td>
<td>3, 56, 80, 111</td>
</tr>
<tr>
<td>Engler, D.</td>
<td>33, 103, 106</td>
</tr>
<tr>
<td>Fineman, S.</td>
<td>33, 76, 82, 111</td>
</tr>
<tr>
<td>Finerfrock, B.</td>
<td>49, 58, 111</td>
</tr>
<tr>
<td>Fiocchi, A.</td>
<td>61, 86</td>
</tr>
<tr>
<td>Fleischer, D.</td>
<td>28, 59, 82, 111</td>
</tr>
<tr>
<td>Fonacier, L.</td>
<td>1, 34, 40, 42, 67, 98, 100, 111</td>
</tr>
<tr>
<td>Freeman, T.</td>
<td>41, 51</td>
</tr>
<tr>
<td>Friedlander, S.</td>
<td>53, 111</td>
</tr>
<tr>
<td>Furr, C.</td>
<td>74, 111</td>
</tr>
<tr>
<td>Garcia, L.</td>
<td>43, 111</td>
</tr>
<tr>
<td>George, M.</td>
<td>3, 80, 111</td>
</tr>
<tr>
<td>Gobin, K.</td>
<td>7, 70, 73</td>
</tr>
<tr>
<td>Golden, D.</td>
<td>72, 111</td>
</tr>
<tr>
<td>Goldsobel, A.</td>
<td>3, 52, 55</td>
</tr>
<tr>
<td>Grayson, M.</td>
<td>44, 111</td>
</tr>
<tr>
<td>Greenhawt, M.</td>
<td>3, 34, 44, 51, 59, 82, 111</td>
</tr>
<tr>
<td>Grewe, J.</td>
<td>78, 112</td>
</tr>
<tr>
<td>Gross, G.</td>
<td>7, 35, 76, 112</td>
</tr>
<tr>
<td>Gupta, R.</td>
<td>51, 69, 82, 112</td>
</tr>
<tr>
<td>Guttman-Yassky, E.</td>
<td>42, 112</td>
</tr>
<tr>
<td>Hamilos, D.</td>
<td>45, 112</td>
</tr>
<tr>
<td>Abedi, Y.</td>
<td>68</td>
</tr>
<tr>
<td>Hayden, M.</td>
<td>3, 76, 79, 112</td>
</tr>
<tr>
<td>Hernandez-Trujillo, V.</td>
<td>64</td>
</tr>
<tr>
<td>Hill, D.</td>
<td>7, 73</td>
</tr>
<tr>
<td>Hoffmann, B.</td>
<td>69</td>
</tr>
<tr>
<td>Imbeau, S.</td>
<td>7, 35, 58, 112</td>
</tr>
<tr>
<td>Irani, A.</td>
<td>39</td>
</tr>
<tr>
<td>Israel, E.</td>
<td>57, 112</td>
</tr>
<tr>
<td>Jackson, E.</td>
<td>61</td>
</tr>
<tr>
<td>Jacobs, J.</td>
<td>46, 61, 85, 108, 112</td>
</tr>
<tr>
<td>Jacobsen, C.</td>
<td>3, 77, 80</td>
</tr>
<tr>
<td>Jain, S.</td>
<td>68</td>
</tr>
<tr>
<td>Jain, N.</td>
<td>52, 112, 123</td>
</tr>
<tr>
<td>Jean, T.</td>
<td>70, 98</td>
</tr>
<tr>
<td>Johnson, J.</td>
<td>60</td>
</tr>
<tr>
<td>Jordan, D.</td>
<td>62</td>
</tr>
<tr>
<td>Jose, J.</td>
<td>61</td>
</tr>
<tr>
<td>Joshi, S.</td>
<td>70</td>
</tr>
<tr>
<td>Keet, C.</td>
<td>43, 112</td>
</tr>
<tr>
<td>Kelso, J.</td>
<td>44, 112</td>
</tr>
<tr>
<td>Khan, D.</td>
<td>3, 44, 70, 88, 113</td>
</tr>
<tr>
<td>Kobrynski, L.</td>
<td>3, 36, 105</td>
</tr>
<tr>
<td>Koepke, J.</td>
<td>34, 36, 38</td>
</tr>
<tr>
<td>Korenblat-Hanin, M.</td>
<td>78, 113</td>
</tr>
<tr>
<td>Kwan, S.</td>
<td>75, 113</td>
</tr>
<tr>
<td>Laidlaw, T.</td>
<td>45, 113</td>
</tr>
<tr>
<td>Lang, D.</td>
<td>35, 45, 99, 113</td>
</tr>
<tr>
<td>Lanier, B.</td>
<td>9, 50, 84, 85, 113</td>
</tr>
<tr>
<td>Leiding, J.</td>
<td>71, 113</td>
</tr>
<tr>
<td>Lester, M.</td>
<td>1, 57</td>
</tr>
<tr>
<td>Leung, D.</td>
<td>56, 67, 113</td>
</tr>
<tr>
<td>Lewis, M.</td>
<td>78, 106, 113</td>
</tr>
<tr>
<td>Li, J.</td>
<td>44, 113</td>
</tr>
<tr>
<td>Lieberman, J.</td>
<td>47, 57, 69, 93, 95, 113</td>
</tr>
</tbody>
</table>
Lightdale, J. ........................ 36
Lio, P. ............................ 34, 55
Liu, M. ............................ 34, 55
Long, A. ........................... 37, 65, 69, 95
Lumry, W. .......................... 41, 46, 61, 81, 83, 85, 88, 114
Mahr, T. ............................ 1, 3, 39, 47, 53
Maibach, H. ........................ 35, 64
Manning, M. ........................ 1, 3, 46, 61, 64, 85, 90
Marshall, G. ........................ 1, 9, 50, 63, 76, 88, 114
Martin, B. ........................... 1, 33, 45, 63, 72, 114
Martin, R. ............................ 63, 114
Mathur, S. ............................ 55
Matsui, E. ............................ 38, 108
McGrath, K. .......................... 3, 58, 85
Meadows, A. ...................... 28, 39, 49, 58, 74, 79, 114
Meadows, C. ........................ 1, 50, 54, 66
Meadows, L. .......................... 75, 114
Meltzer, E. ........................... 9, 45, 83, 114
Mitsui, C. ............................. 62
Mojica, J. ............................. 53, 114
Montanaro, A. ........................ 44, 114
Murphy, K. ........................... 33, 36, 38
Naimi, D. ............................. 56
Nanda, A. ............................. 64, 84, 85
Nassef, M. ............................ 55
Nath, P. ............................... 60
Nelson, H. ............................ 9, 44, 83, 93, 114
Nelson, M. ............................ 33
O’Byrne, P. ........................... 28, 57, 66, 114
Ogbogu, P. ............................ 55, 101
Oloroso-Chavez, K. .................. 68
Olson, G. .............................. 36
Ong, P. ................................. 42, 62, 114
Oppenheimer, J. .................... 3, 39, 48, 57
Panettieri, R. ....................... 63, 91, 92, 95, 115
Peden, D. .............................. 38
Peng, T. .............................. 1, 3, 16, 72, 106, 115
Peppers, B. ........................... 7, 60, 68, 73
Peters, A. ............................. 44, 98, 115
Peters, S. .............................. 52, 55, 115
Petersen, M. .......................... 38
Pfeifer, J. .............................. 74
Pham, M. .............................. 68, 92
Phipatanakul, W. .................... 47, 115
Pichard, D. ............................ 37
Pistiner, M. ............................ 40
Portnoy, J. ............................ 36, 39, 49, 77
Preston, D. ............................. 70
Pulver, D. .............................. 36, 38
Rachid, R. .............................. 40
Ramsey, A. ............................. 60
Riedl, M. .............................. 44, 46, 61, 83, 85, 115
Rosenwasser, L. ..................... 48
Rothstein, L. ........................... 68
Routes, J. .............................. 36, 44, 55, 108, 115
Sacco, K. .............................. 70
Salapatek, A. ........................... 60, 91
Sanchez-Borges, M. .................. 48
Sandhu, P. ............................. 60, 70, 93
Sands, M. .............................. 37
Schleimer, R. ........................... 45, 115
Schneider, L. .......................... 40, 42, 67, 115
Schwartz, L. ........................... 47, 65, 115
Settipane, R. ........................... 39
Shepherd, M. ........................... 72, 115
Sher, M. ................................ 55, 65
Shih, J. ................................. 36, 90, 104
Shreffler, W. ........................... 43, 59, 116
Shrestha, P. ............................ 62
Shroba, J. .............................. 3, 76, 77, 78, 80
Siles, R. ............................... 80, 116
Silverberg, J. ........................... 42, 87, 116
Silvers, W. ............................. 1, 56, 77, 91
Sindher, S. ............................. 69, 107
Smith, J. ............................... 52, 116
Smits, W. ............................... 61
Steven, G. ............................... 35
Stone, C. ............................... 60, 90
Storms, W. ............................. 65
Stukus, D. .............................. 3, 34, 51, 56, 78, 92, 116
Sublett, J.L. ........................... 1, 58, 66, 116
Sublett, J.W. ............................ 64
Sullivan, K. ............................ 37, 68, 71, 89, 116
Swain, S. ............................... 62
Szefler, S. .............................. 47, 64, 104, 116
Tankersley, M. .......................... 33, 53, 106, 116
Tilles, S. ............................... 1, 48, 50, 51, 54, 66, 72, 79, 91, 93, 95, 97, 106
Tolomeo, C. .............................. 79
Torgerson, T. ............................. 71, 116
Tracy, J. ............................... 1, 39, 41
Tyler, K. ............................... 33, 74, 75, 116
Venter, C. ............................... 51, 117
Walker, M. ............................... 55
Wallace, D. ............................. 49, 80, 117
Wang, I. ............................... 62, 68, 70, 90
Wang, J. ............................... 57, 59, 65, 117
Warren, C. .............................. 69
Wasserman, R. .......................... 64, 71, 83, 103
Wasserman, S. .......................... 51, 72
Wechsler, M. ............................ 65, 66, 122
Welsher, K. .............................. 79
Westley, R. .............................. 36, 38
Wilson, J. ............................... 69, 91
Wolfson, A. .............................. 60, 85
Wolverton, J. ............................. 77
Wood, R. ............................... 43, 117
Yang, B. ............................... 70
Yosipovitch, G. ........................ 34, 67, 87, 117
Social Events

FIT Welcome Reception
6:30 – 7:30 pm • Friday
Back Bay Ballroom Salons BCD (2nd Floor)
Sheraton Boston Hotel

Fellows-in-Training (FITs) are invited to attend the FIT Welcome Reception. It’s the perfect place to kick back and connect with FITs from other programs across the country after a day packed with learning.

Supported by Stallergenes Greer

26th Annual FIT Bowl Competition
5:00 – 7:00 pm • Saturday
Ballroom BC (3rd Floor)
Hynes Convention Center

Test your knowledge, sharpen your wits and join in the fun at the dynamic, fast-paced FIT Bowl!

Participating teams from training programs around the country will compete to answer a variety of serious (and not so serious) questions posed by an expert panel. In 2016, 31 teams from the US and Mexico participated at this popular game show.

Supported by Teva Respiratory

Alliance International Reception
6:00 – 7:00 pm • Saturday
Constitution Ballroom Salon A (2nd Floor)
Sheraton Boston Hotel

International attendees are cordially invited to attend the International Reception hosted by the ACAAI Alliance.

Awards Ceremony
7:00 – 7:45 pm • Saturday
Constitution Ballroom Salon B (2nd Floor)
Sheraton Boston Hotel

The College invites all registrants to the ACAAI Awards Ceremony on Saturday at the Sheraton Boston Hotel. The College will formally welcome our newly approved Fellows and recognize the recipients of the College’s Distinguished Fellow, International Distinguished Fellow, Distinguished Service, Clemens von Pirquet, Woman in Allergy, and Young Faculty Support Awards. Finally, we’ll introduce this year’s recipient of the College’s prestigious Gold Headed Cane Award.

Supported by Mylan

President’s Welcome Reception
7:45 – 9:00 pm • Saturday
Grand Ballroom (2nd Floor)
Sheraton Boston Hotel

All attendees are invited to the ACAAI President’s Welcome Reception, which will immediately follow the Awards Ceremony. It’s the perfect place to catch up with old friends, make new acquaintances and meet the College President, President-Elect and the Alliance President. Plan to join us for this fun-filled event.

Supported by Genentech, Inc. and Novartis Pharmaceuticals Corporation

Fundraising Event
6:45 – 10:30 pm • Sunday
Grand Ballroom (2nd Floor)
Sheraton Boston Hotel
Tickets Required

Don’t miss this year’s fundraising event featuring Landau Eugene Murphy Jr., 2011 winner of “America’s Got Talent.” Tickets are available at $250 each (includes reception and dinner) or $55 for the performance only. The program will also feature a live auction where some fantastic items will be auctioned off to the highest bidders, with the proceeds going to the ACAAI Foundation. Tickets are required to attend the event.

6:45 pm Reception
7:45 pm Dinner
9:00 pm Doors open for “show only” ticket holders
9:15 pm Auction
9:40 pm Landau Eugene Murphy Jr. performance
The Alliance of the American College of Allergy, Asthma & Immunology hosts a variety of social events and programs throughout the annual meeting.

Alliance Hospitality Suite
8:00 – 10:30 am • Friday through Monday
Republic Ballroom (2nd Floor) • Sheraton Boston Hotel

Registered spouses and guests are invited to start the day with a visit to the hospitality suite. It’s a perfect way to connect with friends and meet new ones.

Enjoy the following complimentary programs in the hospitality suite:

- **Mindfulness Meditation for Stress Relief and Relaxation**
  8:30 – 9:30 am • Friday
  Join Clinical Psychologist and mindfulness teacher, Meghan Searl, PhD, for a morning of guided meditation. In addition to leading the group through a selection of different practices, she will also present a brief overview of the role of mindfulness meditation in coping with stress. Dr. Searl is a clinical neuropsychologist at Harvard Medical School and Brigham & Women’s Hospital in Boston, MA. She is also a qualified Mindfulness-Based Stress Reduction (MBSR) teacher and offers MBSR and other classes at BWH’s Osher Center, a multi-disciplinary center for Integrative Health.

- **Abstract Art with Barbara Leiner Greenstein and Mary Hughes**
  8:30 – 10:30 am • Saturday
  The Copley Society of Art (Co|So) is the oldest non-profit art association in the United States, with a history dating back to 1879. Co|So currently represents over 400 living artist members, ranging in experience from students to nationally-recognized artists and in style from traditional and academic realists to contemporary and abstract painters, photographers, and sculptors.

- **Wine Blind Tasting Experience**
  8:30 – 9:30 am • Sunday
  Join us as the sommelier of the Sheraton Boston Hotel leads a blind tasting experience. The highly engaging lesson will then be put to the test as you sample several different wines and attempt to identify them based on the flavors detected.

Alliance International Reception
6:00 – 7:00 pm • Saturday
Constitution Ballroom Salon A • Sheraton Boston Hotel

International attendees are cordially invited to attend the Alliance International Reception hosted by the ACAAI Alliance.

Alliance Annual Business Meeting and Brunch
Noon – 2:30 pm • Sunday
Top of the Hub • Prudential Tower • 52nd Floor
Tickets Required • $30 • Limit 50

Active members of the Alliance are invited to attend the Annual Business Meeting and Brunch.
These are commercial presentations conducted by exhibiting companies in specially constructed theaters on the exhibit floor. This year we will have two Product Theaters located in Halls C & D (2nd Floor) of the Hynes Convention Center, where a limited number of 25-minute and 55-minute sessions will be presented each day during the refreshment and lunch breaks. Product theaters are non-CME forums organized by industry and designed to enhance your learning experience.

**Saturday, 10:35 – 11:00 am**

**Product Theater 1**

**HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]): A New Era in the Management of Hereditary Angioedema**

*Supported by CSL Behring*

Presented by: Don Levy, MD

Hereditary angioedema (HAE) is a rare, potentially fatal genetic disorder that requires appropriate management to maximize patients’ health and well-being. Prior prophylactic options aided in the fight against HAE, but still faced unmet needs. This program is designed to inform clinicians about a newly approved subcutaneous treatment to effectively prevent HAE attacks.

*Also visit CSL Behring at Booth #2420.*

**Product Theater 2**

**A Novel Nonsteroidal Topical Prescription for Mild-to-moderate Atopic Dermatitis**

*Supported by Pfizer, Inc.*

Presented by: Linda Stein-Gold, MD

*Also visit Pfizer, Inc. at Booth #2226.*

---

**Saturday, 12:35 – 1:30 pm**

**Product Theater 1**

**Uncontrolled Asthma – Expanding Your View of a Constricting Disease**

*Supported by Boehringer Ingelheim Pharmaceuticals, Inc.*

Presented by: Bradley Chipps, MD

Join us to explore the underlying causes of uncontrolled asthma and review different approaches to managing treatment.

*Also visit Boehringer Ingelheim Pharmaceuticals, Inc. at Booth #2214.*

---

**Product Theater 2**

**Redefining Severe Uncontrolled Asthma: Exploring the Role of Eosinophils as a Mechanism of Disease**

*Supported by AstraZeneca*

Presented by: Michael Wechsler, MD

A national thought leader will review current perspectives on the cells and pathways driving disease and explore the specific impact of eosinophils as contributors to airway damage in the context of severe asthma.

*Also visit AstraZeneca at Booths #2534 and #2633.*
These are commercial presentations conducted by exhibiting companies in specially constructed theaters on the exhibit floor. This year we will have two Product Theaters located in Halls C & D (2nd Floor) of the Hynes Convention Center, where a limited number of 25-minute and 55-minute sessions will be presented each day during the refreshment and lunch breaks. Product theaters are non-CME forums organized by industry and designed to enhance your learning experience.

**Saturday, 3:05 – 3:30 pm**

**Approaches to HAE Patient Management**  
Supported by Shire

A leading expert in HAE will present brief patient vignettes demonstrating varying levels of HAE impact and approaches to patient management.  
*Also visit Shire at Booth #2608.*

**Considering Xolair® (Omalizumab) to Treat Moderate-to-severe Allergic Asthma**  
Supported by Genentech, Inc. and Novartis Pharmaceuticals Corporation

Presented by: Jacqueline Eghrari-Sabet, MD  
*Also visit Genentech, Inc. and Novartis Pharmaceuticals Corporation at Booth #1905.*

**Sunday, 10:05 – 10:30 am**

**Type 2 Asthma: A Greater Understanding of Difficult-to-control Asthma**  
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals

Presented by: William Busse, MD  
This presentation will educate HCPs about current understandings of type 2 asthma including ongoing challenges of poor asthma control, disease heterogeneity, an evolving definition for type 2 asthma, critical roles for type 2 cytokines in disease pathophysiology and the clinical features and biomarkers that define patients with type 2 asthma.  
*Also visit Sanofi Genzyme and Regeneron Pharmaceuticals at Booths #2014 and #2322.*

**Sunday, 12:35 – 1:30 pm**

**DUPIXENT® (Dupilumab): FDA-Approved**  
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals

Presented by: Warner W. Carr, MD  
DUPIXENT is approved by the FDA. Come learn about clinical efficacy, safety information, MOA, and dosing and administration, and how DUPIXENT may help your patients.  
*Also visit Sanofi Genzyme and Regeneron Pharmaceuticals at Booths #2014 and #2322.*

**Fractional Exhaled Nitric Oxide (FeNO), A Tool to Aid in the Diagnosis and Management of Asthma**  
Supported by Circassia Pharmaceuticals, Inc.

Presented by: Neal Jain, MD  
*Also visit Circassia Pharmaceuticals, Inc. at Booth #2008.*
Halls C & D (2nd Floor) • Hynes Convention Center

Exhibit Hours:
3:00 – 6:00 pm, Friday
9:45 am – 4:00 pm, Saturday
9:45 am – 2:00 pm, Sunday

Exhibits

Gold Partner

Aimmune Therapeutics
8000 Marina Blvd, Suite 300
Brisbane, CA 94005
Phone: (650) 399-4036
Website: www.aimmune.com
Contact Name: Eric Jordan
Contact Email: ejordan@aimmune.com

Aimmune Therapeutics, Inc., is a biopharmaceutical company dedicated to improving and protecting the lives of the growing number of people with food allergies, who must practice constant vigilance to avoid the risk of potentially life-threatening anaphylaxis. Based on its characterized oral desensitization immunotherapy (CODIT™) system, Aimmune is developing treatments designed to provide patients with clinically meaningful protection from their allergens, so that they can safely and reliably tolerate accidental exposures. The company is currently conducting multiple international Phase 3 trials for its lead CODIT product candidate, AR101 for the treatment of peanut allergy.

Allergy & Asthma Network
8229 Boone Blvd Ste. 260
Vienna, VA 22182-2661
Phone: (703) 641-9595
Website: www.allergyasthmanetwork.org
Contact Name: Sue Lockwood
Contact Email: slockwood@allergyasthmanetwork.org

Allergy & Asthma Network is the nation’s leading patient advocacy organization that works to connect the collaborative care team for people who suffer with allergies, asthma and related conditions. The Network’s mission is to end needless death due to allergies, asthma, food allergies and related conditions through outreach, education, advocacy and research.

ALK
1700 Royston Ln.
Round Rock, TX 78664
Phone: (512) 252-4255
Website: www.alk-abello.com/us
Contact Name: Rachel Mann
Contact Email: Rachel.Mann@alk.net

ALK is a research-driven, global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. As the world leader in allergy immunotherapy, a treatment given to increase immunity to substances causing allergic symptoms, ALK is devoted to improving the quality of life for people with allergies by creating products that treat the cause of allergies. ALK is also committed to supporting the business of allergy by providing diagnostic tools, automation software and customized business, technical and clinical consulting services.

Allergy & Asthma Proceedings
450 Veterans Memorial Parkway, Bldg. #15
East Providence, RI 2914
Phone: (800) 255-3749
Website: www.allergyandasthmaproceedings.org
Contact Name: Ginny Loiselle
Contact Email: ginnyloiselle@oceansidepubl.com

The primary focus of Allergy & Asthma Proceedings is directed to the publication of articles with the highest degree of clinical relevance for the practicing allergist/immunologist. Additionally, the Proceedings is committed to medical education and encourages the submission of manuscripts by allergy/immunology Fellows-in-Training. Academically, the Proceedings has established a 37-year reputation as a National Library of Medicine/PubMed-indexed journal with print circulation at 5,000 and impact factor of 2.709.

The Proceedings, together with American Journal of Rhinology & Allergy and Allergy & Rhinology (open access) are published by OceanSide Publications, Providence, RI.
Exhibits

**Allergy Partners**
1978 Hendersonville Road, Suite 130A
Asheville, NC 28803
Phone: (828) 277-1300
Fax: (828) 277-2499
Website: www.allergypartners.com
Contact Name: Melody Interlicchia
Contact Email: melody@allergypartners.com

Allergy Partners, P.A. is the nation’s largest single-specialty practice specializing in allergic disease, asthma and immunology. Comprised of 58 practices and 135 total locations of service across 23 states, Allergy Partners offers a wide variety of geographic locations in which to provide patients with the highest quality and most cost-effective allergy and asthma care possible.

We strive to be recognized as leaders in the development and delivery of high-quality health care for patients with asthma and allergic disease. Our vast care network of providers works together to promote education, research and innovation in the field of allergy and asthma care.

**Alletess Medical Laboratory**
P.O. Box 343
14 Howard Street
Rockland, MA 2370
Phone: (781) 871-4426
Website: www.foodallergy.com
Contact Name: Heather Hanley
Contact Email: hhanley@foodallergy.com

Alletess Medical Laboratory has provided allergy and immunology testing services to health care practitioners worldwide since 1980. We offer food allergy and allergen component testing, inhalant allergy testing, mold exposure profiles and food sensitivity testing, as well as panels for autoimmune disorders. We use state-of-the-art analyzers, offer a quick turnaround and maintain competitive pricing. Please visit us at Booth 2823 to find out more, or check out our website, www.foodallergy.com.

**American Board of Allergy & Immunology (ABAI)**
1835 Market Street
Ste. 1210
Philadelphia, PA 19103
Website: www.abai.org
Contact Name: Gina Capozzoli
Contact Email: gcapozzoli@abai.org

The ABAI was established in 1971 as a Conjoint Board of the ABIM and ABP. The internal medicine subspecialty existed from 1936-1971, and the pediatric subspecialty existed from 1944-1971. The ABAI is committed to working closely with its parent boards to maintain the highest educational and clinical standards in the specialty of allergy/immunology.

**American Partnership for Eosinophilic Disorders (APFED)**
P.O. Box 29545
Atlanta, GA 30359
Phone: (713) 493-7749
Website: www.apfed.org
Contact Name: Lisa Brunet
Contact Email: lisa@apfed.org

The American Partnership for Eosinophilic Disorders (APFED) is a 501c3 nonprofit organization founded in December 2001 by a group of mothers of young children living with eosinophil-associated diseases. We are a patient advocacy group dedicated to improving the lives of those living with eosinophilic disorders. Our mission is to passionately embrace, support and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support and advocacy. APFED’s vision is the development of a cure while improving the quality of life for those suffering with eosinophil-associated diseases.

---

**AllergyEHR, a division of Meditab Software Inc**
2233 Watt Ave.
Suite 360
Sacramento, CA 95825
Phone: (615) 682-2021
Website: www.allergyehr.com
Contact Name: Shameer Nalli
Contact Email: shameern@meditab.com

Established in 1998, Meditab Software Inc., developers of AllergyEHR and IMS (Intelligent Medical Software), offers clinical automation systems that maximize productivity, advance patient care, manage utilization and reduce costs. Meditab develops and supports a multi-award-winning, multi-certified EHR system that combines clinical charting, e-prescribing, population management, decision support, practice analytics, document imaging and much more, on a single database platform. The company takes tremendous pride in providing comprehensive, user-friendly and affordable solutions for each practice’s unique needs.
The Asthma and Allergy Foundation of America (AAFA), founded in 1953, is dedicated to improving the quality of life for people with asthma, food allergy and other allergic diseases through education, advocacy, support and research. Our patient services include free online courses for a new diagnosis of asthma or food allergy, web-based patient education and community outreach through online patient communities, an 800 line and an “Ask the Allergist” service. We can also connect patients with local AAFA chapters and support groups. AAFA is actively engaged in patient-centered outcomes research and other research studies. Visit us at aafa.org or kidswithfoodallergies.org.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – oncology, cardiovascular and metabolic diseases and respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Germany, the company operates globally with more than 50,000 employees. The family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine. Visit us at www.us.boehringer-ingelheim.com, or on Twitter @BoehringerUS.

Boston Scientific is dedicated to transforming lives through innovative medical solutions and multi-disciplinary approaches that improve the health of patients around the world. We partner with allergist asthma experts to advance the management and treatment of severe asthma. Bronchial thermoplasty (BT) delivered by the Alair™ System is a safe, one-time, non-drug intervention for adult patients with severe asthma – clinically proven to provide long-lasting reduction in exacerbations. 79% of patients treated with BT report experiencing a significant improvement in their asthma-related quality of life.
Bio Products Laboratory (BPL) is a global company with 60 years of history in plasma research, technology, and manufacturing. Originally part of the world-famous Lister Institute, BPL has a full line of products derived from plasma collected at 35 company-owned collection centers across the US. For more information please visit www.bpl-us.com.

Ceela Naturals registered with the FDA in 2014 as a pharmaceutical manufacturer of cosmetics and OTC products. Our products address the published concerns of allergists and immunologists to avoid allergens (“bland skincare”), particularly for skin with impaired barrier function. We manufacture skin hydration, cleansing, and OTC products for acne, psoriasis and seborrheic dermatitis. Ceela manufactures all of our products within a fully dedicated “bland” facility. We use only strictly vegan and “top-8 plus corn”-free ingredients. Our water meets USP standards for irrigation (free of endotoxin, sterile and pure). Pure. Natural. Simple Science.

Chattem, Inc. is part of the Sanofi-Aventis Group. Sanofi U.S. is an affiliate of Sanofi-Aventis, a leading global pharmaceutical company that discovers, develops, and distributes therapeutic solutions to improve lives. Sanofi-Aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Circassia is a specialty pharmaceutical company focused on respiratory diseases. Their growing commercial organization promotes NIOX®, an innovative diagnostic and monitoring tool to aid in asthma management, directly to health care providers. They also have a broad pipeline of asthma and COPD treatments in development.

CLn Skin Care provides innovative, gentle, non-drying washes that effectively cleanse skin prone to eczema, infection, acne, folliculitis and other conditions. The patented CLn® BodyWash has been through two clinical studies, conducted by internationally recognized dermatologists, for the treatment of staph bacteria-colonized eczema, each demonstrating symptom improvement, exceptional safety and tolerability in children as young as 6 months. www.clnwash.com

CVS Specialty and Coram provide compassionate, high-quality infusion care to patients where they live, work or travel. Local teams from more than 90 locations throughout the country offer the highest level of personalized care, education and support. With nearly 1,200 skilled clinicians and more than 30 years of experience, Coram CVS Specialty Infusion Services leads the industry with commitment from the heart. The company has achieved a 96% patient satisfaction rating for seven years.
CSL Behring  Booth 2420
1020 First Ave.
King of Prussia, PA 19406
Phone: (610) 878-4682
Website: www.CSLBehring.com
Contact Email: molly.hessknodel@cslbehring.com

CSL Behring is a leading global biotherapeutics company with a broad range of innovative plasma-derived and recombinant therapies. For over a century, we have been driven by our promise to save lives. Today, our therapies include those to treat coagulation disorders, primary immune deficiencies and hereditary angioedema, among others.

Daavlin  Booth 2702
205 W. Bement St.
Bryan, OH 43506
Phone: (419) 636-6304
Fax: (419) 636-1739
Website: www.daavlin.com
Contact Name: Robert Golding
Contact Email: rgolding@daavlin.com

Daavlin is a leading manufacturer of phototherapy medical devices, with its headquarters and manufacturing operations in Bryan, OH. Daavlin’s devices are FDA-cleared for a large array of treatment indications, including atopic dermatitis.

Products include devices for use in clinical settings, as well as home products for patient use. In addition to producing medical devices, Daavlin provides industry-leading insurance reimbursement assistance and aftersale service.

DBV Technologies  Booth 2620
25 Deforest Ave.
Suite 203
Summit, NJ 7091
Website: www.dbv-technologies.com
Contact Name: Roberto Laset
Contact Email: roberto.laset@dbv-technologies.com

DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy. We are committed to finding a safe, patient-friendly and effective therapy for food allergic patients, for whom there are no currently approved treatments. DBV is the creator of an innovative investigational patch technology platform. This novel approach is called epicutaneous immunotherapy (EPIT). DBV is focused on becoming a leader in the development and commercialization of food allergy treatments. Our development program includes peanut and milk allergy, as well as broader applications in the field of food allergies, including eosinophilic esophagitis.

Dyson  Booth 2102
600 W. Chicago Ave. #275
Chicago, IL 60654
Phone: (312) 708-2263
Website: www.dyson.com
Contact Name: Ryan McAuliffe
Contact Email: ryan.mcauliffe@dyson.com

Dyson is a global technology company that transforms every category it enters with radical and iconic reinventions that work, perform and look very different. Dyson is all about better ideas and better technologies to solve the problems that others often ignore. Dyson is committed to educating consumers on the importance of a healthy home environment and, as experts in dust removal and filtration, has the largest range of certified Asthma and Allergy Friendly technology in America.
The eClinicalWorks EHR has the allergy and immunology functionality you need for testing and treatment of allergies. For skin tests, the module contains configurable worksheets for antigen tests and treatments and is fully integrated in the clinical workflow. The data automatically creates the antigen formulation and generates a shot schedule. Lab staff may then document lot number and expiration date and notify the patient. After review by a supervising physician, the shot schedule is activated.

Edge Pharmaceuticals, LLC

1181 S. Rogers Circle #14
Boca Raton, FL 33487
Phone: (877) 580-3343
Fax: (877) 581-3343
Website: www.edgepharmaceuticals.com
Contact Name: Richard Aloi
Contact Email: sales@edgepharmaceuticals.com

We specialize in:
- Sublingual Immunotherapy (SLIT) – Metered Dose Delivery Bottles
- Allergy testing and treatment supplies – extracts, diluent, etc
- Specialty pharmacy compounding services and products

We look forward to meeting with you. Please stop by our booth to see us.

Elsevier

1600 JFK Blvd.
Suite 1600
Philadelphia, PA 19103
Phone: (215) 239-3354
Website: www.elsevier.com
Contact Name: Ryan O’Hara
Contact Email: r.o'ara@elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health and technology professionals, empowering them to make better decisions, deliver better care and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions – among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey – and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries. www.elsevier.com

Food Allergy & Anaphylaxis Connection Team (FAACT)

P.O. Box 511
West Chester, OH 45071
Phone: (815) 276-3015
Website: www.FoodAllergyAwareness.org
Contact Name: Eleanor Garrow-Holding
Contact Email: eleanor.garrow@foodallergyawareness.org
FAACT’s mission is to educate, advocate and raise awareness for all individuals and families affected by food allergies and life-threatening anaphylaxis. FAACT is also your voice for food allergy awareness. Whether it’s keeping children safe at school, responding to food allergy bullying, dealing with workplace issues, or simply taking the family out for a bite to eat, this web site has all the facts you need to manage food allergies and stay healthy.

Food Allergy Research & Education (FARE)

7925 Jones Branch Drive
Suite 1100
McLean, VA 22102
Phone: (703) 563-3071
Fax: (703) 563-3071
Website: www.foodallergy.org
Contact Name: Quyen Dinh
Contact Email: q.dinh@foodallergy.org
Food Allergy Research & Education (FARE) works on behalf of the 15 million Americans with food allergies, including all those at risk for life-threatening anaphylaxis. This potentially deadly disease affects 1 in 13 children in the United States – or roughly two in every classroom. FARE's mission is to improve the quality of life and the health of individuals with food allergies and to provide them hope through the promise of new treatments. For more information, please visit www.foodallergy.org.

G.S. Innovations

7182 Galley Drive
Las Vegas, NV 89147
Phone: (844) 556-3120
Fax: (415) 374-4438
Website: www.gsinnovationsins.com
Contact Name: Gal Shalvi
Contact Email: gal@dermalx.com
G.S. Innovations provides a variety of health care solutions to many different industries. We work on developing and identifying the best medical care to help diverse professional groups overcome their challenges.
Exhibits

Gold Partner

**GSK**

- Booth 2020
- 5 Moore Drive
- Research Triangle Park, NC 27709
- Phone: (732) 274-2000
- Website: www.gsk.com
- Contact Name: Jennifer Alslev
- Contact Email: jennifer.alslev@impact-xm.com

GSK is a science-led global health care company with a mission to help people do more, feel better, live longer. We research, manufacture and make available a broad range of medicines, vaccines and consumer health care products. Visit our exhibit for information about our products and resources.

**Healix Infusion Therapy**

- Booth 2400
- 14140 SW Freeway, Suite 400
- Sugar Land, TX 77478
- Phone: (281) 295-4000
- Fax: (281) 295-4050
- Website: www.healix.net
- Contact Name: John Park
- Contact Email: jpark@healix.net

As a national leader in managing Office Infusion Centers, Healix® offers customized infusion therapy solutions for medications administered in the physician’s office or self-administered at home. The Healix immunology program is a flexible suite of clinical and business services created to help you in-source patient care and internalize all revenue from your subcutaneous immune globulin (SC Ig) patients that is currently being lost to third-party providers. Our service offerings include a wide range of pharmaceutical dispensing, clinical support and revenue cycle services that help optimize your resources and improve your efficiency. Learn more at www.healix.net/immunology.

**HollisterStier Allergy**

- Booth 2026
- 3525 North Regal Street
- Spokane, WA 99207-5796
- Website: www.hsallergy.com
- Contact Name: Mary Miller
- Contact Email: karndt@jhs.jubl.com

Strength. Balance. Consistency. With nearly 100 years of leadership in research, extract production and immunotherapy products, doctors around the world choose HollisterStier Allergy. Our promise has always been to provide quality products, services and resources to physicians and allergy patients, and we remain committed to those ideals today. Our complete line of high quality products – including phenol-free extracts – and testing supplies, allows physicians to provide patients with the best possible care. Allergy experts since 1921. Commitment since day one.

**Helen of Troy/Kaz USA, Inc.**

- Booth 2810
- 400 Donald Lynch Blvd.
- Marlboro, MA 1752
- Phone: (508) 490-7214
- Fax: (508) 251-2427
- Website: www.kaz.com
- Contact Name: Cheryl Wright
- Contact Email: dwoods@kaz.com

Honeywell is the market leader in portable air purification products, offering True Hepa permanent filtration, providing your patients with superior air cleaning products for over 25 years!

**HollisterStier Allergy**

- Booth 2026
- 3525 North Regal Street
- Spokane, WA 99207-5796
- Website: www.hsallergy.com
- Contact Name: Mary Miller
- Contact Email: karndt@jhs.jubl.com

Strength. Balance. Consistency. With nearly 100 years of leadership in research, extract production and immunotherapy products, doctors around the world choose HollisterStier Allergy. Our promise has always been to provide quality products, services and resources to physicians and allergy patients, and we remain committed to those ideals today. Our complete line of high quality products – including phenol-free extracts – and testing supplies, allows physicians to provide patients with the best possible care. Allergy experts since 1921. Commitment since day one.

**Immune Deficiency Foundation**

- Booth 2816
- 110 West Road, Suite 300
- Towson, MD 21204-4803
- Website: www.primaryimmune.org
- Contact Name: Carissa Merritt
- Contact Email: cmerritt@primaryimmune.org

The Immune Deficiency Foundation is the national patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research.

**Infinity Massage Chairs**

- Booth 2733
- 72 Stard Rd., Unit 2
- Seabrook, NH 3874
- Phone: (603) 347-6006
- Fax: (603) 642-9291
- Website: www.infinitymassagechairs.com
- Contact Name: Michael Garceau
- Contact Email: mgarceau@infinitymassagechairs.com

Infinite Massage Chairs is a leading manufacturer of high-end luxurious massage chairs. The Infinity Deluxe Massage Chair is 100% genuine leather, has 62 different functions, and comes with 11 preset programs. Our chair delivers the ultimate in massage therapy, offering a range of massage functions from shiatsu to rolling and Swedish, combined with 8 therapeutic recline technologies, including the patented Zero-Gravity and Inversion Therapy positions. Come let the Infinity take you away.
Exhibit

**Inspirotec Inc.**

Booth 2433
3307 Meadow Ln
Glenview, IL 60025
Phone: (847) 528-2927
Website: www.exhalenow.com
Contact Name: Craig Williamson
Contact Email: cwilliamson@inspirotec.com

Exhale powered by Inspirotec makes NASA’s rocket science accessible to everyone to accurately measure your allergen exposure.

Exhale’s patented technology combines ionic propulsion developed more than 5 decades ago for space travel with cutting edge molecular biology used to detect disease in human blood and urine samples. It works at the molecular level, so we can measure the actual molecules that lead to your symptoms.

Unlike indoor air quality professionals and sensors, Exhale can pinpoint the exact allergens at the molecular level, making Exhale the only product that can provide the full spectrum of indoor allergens.

**Lincoln Diagnostics, Inc.**

Booth 2634
P.O. Box 1128
Decatur, IL 62525
Phone: (800) 537-1336
Fax: (217) 877-5645
Website: www.lincolndiagnostics.com
Contact Name: John Lenski Jr
Contact Email: jlenski@lincolndiagnostics.com

Lincoln Diagnostics is displaying state-of-the-art, safety-engineered skin testing devices that meet all current OSHA requirements – Multi-Test® PC (Pain Control), UniTest® PC (Pain Control), Multi-Test® II, Multi-Test®, Duotip-Test® II, and Duotip-Test®. Please visit our exhibit to learn about the economic value of using Lincoln’s devices and why they are the most widely-used and most extensively published-on devices available.

**Live Pure, Inc.**

Booth 2425
101 Shattuck Way, Suite 1
Newington, NH 3801
Phone: (603) 319-8414
Website: www.livepureinc.com
Contact Name: Charlene Ohlen
Contact Email: clo@livepureinc.com

Live Pure’s yogi is a do-it-yourself indoor air and drinking water assessment kit. A simple three-step process enables those with limited experience to collect samples for irritants and toxins including mold, allergens, radon, lead, asbestos, VOCs, formaldehyde and water contaminants.

Samples are examined by an independent certified lab, ensuring unbiased analysis. A certified industrial hygienist reviews each report and relays results privately via email. Health care providers and their patients, equipped with identifiable and quantifiable indoor environmental sample results, can make informed decisions about limiting asthma and allergy triggers, reducing ER visits and increasing quality of life.

**Micro Direct, Inc.**

Booth 2819
803 Webster St.
Lewiston, ME 4240
Phone: (207) 786-7808
Fax: 207-786-7280
Website: www.mdspiros.com
Contact Name: Ann Therriault
Contact Email: ann.therriault@mdspiros.com

Micro Direct is pleased to offer Total Spirometry Solutions with five models priced from $195 to $2,295, all designed to meet your needs; and each with your choice of inexpensive cardboard mouthpieces, one-way mouthpieces or full protection pulmonary filters. Micro Direct also offers an inexpensive peak flow meter for home and office use and home spirometers for patient use. Stop by our booth to see the complete Micro Direct product line and ask about our show specials!
Mission: Allergy, Inc.
28 Hawleyville Rd.
Hawleyville, CT 6440
Phone: (203) 364-1570
Fax: (203) 426-5607
Website: www.missionallergy.com
Contact Name: Jeffrey Miller
Contact Email: jmiller@missionallergy.com

Leading allergists and allergy divisions recommend Mission: Allergy by for its scientific accuracy and highest quality products for allergen avoidance. In addition to manufacturing our own microfiber pillow and mattress encasings and comforters, we distribute the full line of BlueAir air cleaners and AD RescueWear garments for wet-wrap therapy of atopic dermatitis. Please stop by our booth to see the one and only MITEMOBILE and to view an unusual display of live dust mites.

ModuleMD, LLC
8359 Office Park Dr.
Grand Blanc, MI 48439
Phone: 877-EHR-SYSTEM
Website: www.modulemd.com
Contact Name: Rod Miller
Contact Email: info@modulemd.com

ModuleMD enhances clinical, operational and financial performance of allergy practices. The ModuleMD WISE™ software suite streamlines practice processes with an integrated 2015 Edition ONC-certified EHR, skin testing, immunotherapy, practice management, revenue management, e-prescribe, appointment reminder, and patient engagement software. When you select ModuleMD WISE™ for your practice, you receive more than just a product or a service, you have a dedicated partner with an interest in the success of your practice. In addition to technology, ModuleMD offers comprehensive billing and revenue management services. Providing solutions...not just software. Contact us for a demo today: info@modulemd.com.

Molekule
1184 Harrison St
San Francisco, CA 94103
Phone: (407) 490-2758
Website: www.molekule.com
Contact Name: Jenny Wong
Contact Email: jwong@molekule.com

Meet Molekule, the world's first molecular air purifier. Molekule uses nanotechnology to break down and completely eliminate pollutants on a molecular level, while current air purifiers try to catch pollutants in filters. Allergens, mold, bacteria, viruses, and airborne chemicals are completely destroyed by breaking them down.

Morgan Scientific, Inc
151 Essex St.
Ste. 8
Haverhill, MA 1832
Phone: (978) 521-4440
Fax: (978) 521-4445
Website: www.morgansci.com
Contact Name: Gareth Morgan
Contact Email: gmorgan@morgansci.com

Spirometry testing, interpretation and data integration at its finest! Morgan Scientific is a radically different company in the spirometry testing market. We pair the industry-leading ComPAS software with Vitalograph’s Pneumotrac spirometer to create a combination that exceeds expectations for any spirometry scenario. IT solutions, EMR interfacing and special requests are what we do best! We can convert your legacy data for data trending, we have a research query tool to mine your data and we have a dragon!

Morgan Scientific is a 3rd-generation family owned and operated business that has specialized in PFT testing since 1980.

MotherToBaby Pregnancy Studies
9500 Gilman Dr., MC 0828
La Jolla, CA 92039
Website: www.mothertobaby.org
Contact Name: Diana Johnson
Contact Email: mothertobaby@ucsd.edu

MotherToBaby, a non-profit service of the Organization of Teratology Information Specialists (OTIS), is dedicated to providing evidence-based information to mothers, health care professionals, and the general public about medications and other exposures during pregnancy and while breastfeeding. MotherToBaby’s research division is conducting an observational research study to evaluate the effects to the fetus from asthma and the safety of medications and vaccinations used during pregnancy.
Mylan Inc.  
Booth 2208  
1000 Mylan Blvd.  
Canonsburg, PA 15317  
Website: www.mylan.com  
Contact Name: Kathleen Theiss  
Contact Email: kathleen.theiss@mylan.com

Mylan is one of the world’s leading global pharmaceutical companies. Our portfolio of more than 7,500 marketed products includes generic, brand name and over-the-counter medicines. Our specialty business focuses on the development, manufacturing and marketing of prescription drug products for respiratory diseases, life-threatening allergic reactions, general anesthesia and psychiatric disorders.

National Allergy/Allergy Control Products  
Booth 2308  
1620-D Satellite Blvd.  
Duluth, GA 30097  
Phone: (770) 495-3353  
Fax: (800) 395-9303  
Website: www.NationalAllergy.com or www.allergycontrol.com  
Contact Name: Carlton Hardee  
Contact Email: chardee@allergypreventionteam.com

Welcome to National Allergy and Allergy Control Products. We are one of the nation’s largest asthma, sinus and allergy products suppliers. Our goal is to help make your environment allergen-free. The allergy products we carry are for personal and home use, and are offered at a competitive price! For more information contact us at www.NationalAllergy.com, www.allergycontrol.com or call (800) 522-1448.

NeilMed Pharmaceuticals, Inc.  
Booth 2007  
601 Aviation Blvd  
Santa Rosa, CA 95404  
Phone: (707) 525-3784  
Fax: (707) 525-3785  
Website: www.neilmed.com  
Contact Name: Ashly Guntz  
Contact Email: tradeshows@neilmed.com

The mission of the company is to create and maintain safe, affordable and effective products to sustain long-term growth and create drug-free and effective nasal/sinus, ear and wound care devices for millions of consumers worldwide. Please visit the website www.neilmed.com for more details.

Novartis  
Booth 1914  
1 Health Plaza  
East Hanover, NJ 7936  
Phone: (862) 778-9612  
Website: www.novartis.com  
Contact Email: jennifer.matyas@novartis.com

Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing and marketing prescription drugs that help meet our customers’ medical needs and improve their quality of life. Please visit the Novartis exhibit where our sales representatives will be available to discuss our products.

Novartis  
Booth 1905  
1 Health Plaza  
East Hanover, NJ 7936  
Phone: (862) 778-0198  
Website: www.novartis.com  
Contact Name: Gail Wills  
Contact Email: gail.wills@novartis.com

Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing and marketing prescription drugs that help meet our customers’ medical needs and improve their quality of life. Please visit the Novartis exhibit where our sales representatives will be available to discuss our products.
nSpire Health, Inc.  
1830 Lefthand Circle  
Longmont, CO 80501  
Website: www.nspirehealth.com  
Contact Name: Teri Shjandemaar  
Contact Email: sales@nspirehealth.com

nSpire Health™ is a global respiratory information systems software developer and medical device manufacturing company. We are the exclusive provider and developer of Iris™, the world’s first Integrated Respiratory Information System; and KoKo™ pulmonary function testing, diagnostic spirometry and respiratory home monitoring devices. Together, our expert, scalable software solutions and sophisticated data collection products empower health care providers to advance respiratory diagnostic processes and improve patient outcomes while meeting the demanding clinical and business objectives of thought leaders in respiratory care.

P & M Harmony, LLC  
2251 S. Fort Apache Road  
Suite 1148  
Las Vegas, NV 89117  
Website: www.pmharmonyllc.com  
Contact Name: Moshe Harel  
Contact Email: mosh@pmharmonyllc.com

Pfizer  
235 East 42nd Street  
New York, NY 10017  
Phone: (212) 244-7181  
Fax: (212) 244-7181  
Website: www.pfizer.com  
Contact Name: Patricia Purcell  
Contact Email: patricia.purcell@pfizer.com

Silver Partner

Pharming Healthcare Inc.  
685 Route 202/206  
Suite 202  
Bridgewater, NJ 8807  
Phone: (201) 799-4861  
Website: www.pharming.com  
Contact Name: Lauren Hass  
Contact Email: lauren.hass@prihcs.com

PulmOne Advanced Medical Devices  
2711 Centerville Road  
Suite 400  
Wilmington, DE 19808  
Phone: (844) 785-6663  
Website: www.pulm-one.com  
Contact Name: Avi Lazar  
Contact Email: usinfo@pulm-one.com

PulmOne’s MiniBox+ is the world’s first desktop, gasless, cabinless device for measurement of lung volumes, as well as spirometry and DLCO testing, in any clinical setting. MiniBox+ is easy to operate, with fully automatic lung volume measurements (LVM) performed in only 2 minutes of tidal breathing. Clinically validated, MiniBox+ is highly accurate, based on comparative data from leading body plethysmography devices. In use by physicians in over 14 states. All MiniBox tests are fully reimbursable. See live demos with the MiniBox at Pulmone’s booth during exhibition hours.

Rabbit Air  
125 N. Raymond Ave.  
Suite 308  
Pasadena, CA 91103  
Phone: (562) 861-4688  
Website: www.rabbitair.com  
Contact Name: Olivia Raya  
Contact Email: oliviar@rabbitair.com

Our Los Angeles-based company is dedicated to improving quality of life through clean air. Rabbit Air’s purifiers have a HEPA filter so advanced that it not only traps but also reduces buildup of common allergens for optimum efficiency and performance. Certified Asthma and Allergy Friendly™ by the Asthma and Allergy Foundation of America, our MinusA2 air purifier offers a choice of filters to target specific contaminants – pet dander, germs, chemical toxins and odors – and defends even the most sensitive respiratory systems. Our products are portable, and customized filters are interchangeable to grow with families and their environments.
Regeneron Pharmaceuticals/Sanofi Genzyme

777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: (914) 847-7689
Website: www.regeneron.com
Contact Name: Marina Yurovitsky
Contact Email: marina.yurovitsky@regeneron.com

Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. All Regeneron commercialized medicines were discovered and developed by our scientists, including therapies for eye diseases, high LDL cholesterol, atopic dermatitis, rheumatoid arthritis and a rare inflammatory condition. Sanofi, a global health care leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer health care, emerging markets and animal health. Sanofi Genzyme focuses on rare diseases, multiple sclerosis, oncology and immunology. Learn more at www.sanogenzyme.com or www.regeneron.com

Shire

300 Shire Way
Lexington, MA 2421
Phone: (781) 482-6579
Website: www.shire.com
Contact Name: Dawn Rafferty
Contact Email: drafferty0@shire.com

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products across our core therapeutic areas including hematology, immunology, neuroscience, ophthalmics, lysosomal storage disorders, gastrointestinal/ internal medicine/endocrine, hereditary angioedema and oncology.

Rosch Visionary Systems, Inc.

501 Howard Ave., Ste. A204
Altoona, PA 16601
Website: www.roschvisionary.com
Contact Name: Heather Wallen
Contact Email: rvssales@roschvisionary.com

Rosch Visionary Systems is the leading provider of allergy software. Rosch Immunotherapy is designed to manage allergy extract mixing, injections and reactions. Our system is lined with multiple safety features and complies with all regulations involving the 2013 Compounding Allergenic Extract Rule, 95165 Renewal Checklist, ICD-10 billing and much more.

Rosch Skin Testing electronically records all prick and intradermal testing, using the results to build the patient’s immunotherapy prescription.

Visionary Allergy Tracker will remind patients when they are due for their injection(s) via text, email and push notifications, as well as tracking their immunotherapy history via our state-of-the-art phone app.

Southern California Permanente Medical Group – Kaiser Permanente

393 E. Walnut St.
Pasadena, CA 91188
Phone: (800) 541-7946
Website: scpmgphysiciancareers.com
Contact Name: Stephen Niarhos
Contact Email: stephen.niarhos@kp.org

Kaiser Permanente

Within the Permanente Medical Groups, physicians find recognition, stability, opportunity and independence. Driven by the needs of our members and built on a platform in which medical decisions are made by physicians, each of our locations is able to self-manage the resources necessary for the delivery of excellent patient care. Beyond the practice of medicine, our physicians are provided with many personal and professional opportunities, including research, teaching and participation in leadership activities. In addition, our physicians donate countless hours of their time by volunteering to help the causes of hundreds of community health organizations.
At Squip, we strive to introduce high quality, unique and affordable natural OTC health products. Under the direction of our medical staff, our products are carefully researched for their effectiveness before they are released into the market. The labeling and presentation of our products are in compliance with all regulations. Our products are selected for their ability to make a substantial difference in people’s lives and for their contribution to good health. Our products include: Nasaline and Squeezie – nasal irrigation systems; Kyrosol – ear wax removal system; Snooze – anti-snoring device; Baby NasaKleen – baby aspirator.

Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the development and commercialization of allergy immunotherapy products and services for use in the diagnosis and treatment of allergies. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Additional information is available at www.stallergenesgreer.com.

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
The US Hereditary Angioedema Association (HAEA) is a non-profit patient advocacy organization, providing a wide range of patient services, dedicated patient advocates and clinical research support for this rare genetic blood disease. We display information on HAE diagnosis, treatment, our patient registry and the US HAEA Angioedema Center at UCSD.

Vitalograph, Inc. is a global pulmonary diagnostic device manufacturer and clinical trial professional services provider. Our extensive respiratory range includes world-class spirometers, asthma monitors, COPD screeners, peak flow meters, e-diaries and inhaler trainers. Our latest version of Spirotrac V software offers advanced spirometry, pulse oximetry, ECG, network and EHR connectivity. We also collaborate with Morgan Scientific, providing the most advanced spirometry solution for allergists, ComPAS 2. Come see why leading respiratory practitioners worldwide continue to look to Vitalograph for innovation and enduring quality for over half a century.

The World Allergy Organization (WAO) is an international umbrella organization whose members consist of 97 regional and national allergology and clinical immunology societies from around the world. By collaborating with member societies, WAO provides direct educational outreach programs, symposia and lectureships to members in nearly 100 countries around the globe.

Xtract Solutions provides the finest software applications for allergen immunotherapy. We work with clinics who are frustrated that their allergy shot practice is technologically behind the times. Some are unsatisfied that their EMR doesn’t have a good immunotherapy solution. Others are in fear of making a mistake while mixing or delivering allergy shots. Whatever the issues might be, Xtract Solutions has the experience and know-how necessary to solve most problems that modern allergy practices face daily. Contact us if any of the above sounds familiar, or if you have a different immunotherapy workflow issue you’re interested in solving.
## Index of Exhibits

### Exhibits – Listed by Category

#### Allergy Extracts
- ALK ............................................. 2120
- HollisterStier Allergy ..................... 2026
- Stallergenes Greer .......................... 2002 2302

#### Clinical Research Organizations
- Vitalograph, Inc. ............................. 2407

#### Computer Hardware/Software
- AllergyEHR, a division of Meditab Software Inc. 2128
- ModuleMD, LLC .............................. 2724
- Rosch Visionary Systems, Inc. .............. 2821
- Xtract Solutions ............................. 2801 2802

#### Diagnostic Equipment
- Circassia ..................................... 2008
- Lincoln Diagnostics, Inc. .................... 2634
- Micro Direct, Inc. ............................ 2819
- PulmOne Advanced Medical Devices ...... 2538
- nSpire Health, Inc. ........................... 2320

#### Diagnostic Testing
- Alletess Medical Laboratory ................. 2823
- Edge Pharmaceuticals, LLC .................. 2304
- HollisterStier Allergy ......................... 2026
- Lincoln Diagnostics, Inc. .................... 2634
- Live Pure, Inc. ................................ 2425
- Morgan Scientific, Inc. ...................... 2409
- PulmOne Advanced Medical Devices ...... 2538
- Thermo Fisher Scientific ...................... 2300

#### Environmental Products
- Dyson ......................................... 2102
- Helen of Troy/Kaz USA, Inc. ............... 2810
- Insprirotec Inc. ............................... 2433
- Live Pure, Inc. ................................ 2425
- Mission: Allergy, Inc. ........................ 2500
- Rabbit Air .................................... 2438

#### Equipment/Supplies
- Daavlin ........................................ 2702
- G.S. Innovations .............................. 2833
- Mission: Allergy, Inc. ........................ 2500

#### Health/Body Care
- Ceela Naturals ............................... 2401
- G.S. Innovations .............................. 2833
- Infinity Massage Chairs ..................... 2733
- NeilMed Pharmaceuticals, Inc. ............. 2007
- P & M Harmony, LLC .......................... 2535
- SmartPractice ................................ 2325
- Squip, Inc. .................................... 2225

#### Immunotherapy
- ALK ............................................. 2120
- Aimmune Therapeutics ....................... 1909 2114
- BPL .............................................. 2826
- DBV Technologies ............................ 2620
- Edge Pharmaceuticals, LLC ................. 2304
- Healix Infusion Therapy ...................... 2400
- Rosch Visionary Systems, Inc. ................ 2821
- Stallergenes Greer .......................... 2002 2302
- Xtract Solutions ............................. 2801 2802

#### Office Management
- Allergy Partners ............................. 2306
- Healix Partners ............................... 2306
- Healix Partners ............................... 2400

#### Other
- Elsevier ........................................ 2701
- Infinity Massage Chairs ..................... 2733
- ModuleMD, LLC .............................. 2724
- Molekule ...................................... 2421
- National Allergy/Allergy Control Products 2308
- Rabbit Air .................................... 2438
- eClinicalWorks .............................. 2735
Pharmaceuticals

Aimmune Therapeutics .......................... 1909 2114
AstraZeneca Pharmaceuticals .................. 2534 2633
Boehringer Ingelheim Pharmaceuticals, Inc. ........ 2214
Boston Scientific Corporation ................... 2820
CLn Skin Care .................................. 2403
CSL Behring ................................. 2420
Chattem, Inc. .................................. 2720
Circassia ...................................... 2008
DBV Technologies .............................. 2620
GSK ........................................ 2020
Kaleo Pharmaceuticals ........................... 2728
Mylan Inc. ..................................... 2208
NOVARTIS .................................. 1914
NeilMed Pharmaceuticals, Inc. .................... 2007
Novartis ...................................... 1905
Pharming Healthcare Inc. .......................... 2108
Regeneron Pharmaceuticals/Sanofi Genzyme ........ 2014 2322
Shire .......................................... 2608 2840
Teva Respiratory ................................ 2408

Physician Education

American Board of Allergy & Immunology (ABAI) .................. 2818
American Partnership for Eosinophilic Disorders (APFED) ........ 2405
Helen of Troy/Kaz USA, Inc. .......................... 2810
Immune Deficiency Foundation .................... 2816

Physician Recruitment

Allergy Partners .................................. 2306
Southern California Permanente Medical Group - Kaiser Permanente .... 2402

Publications

Allergy & Asthma Network .......................... 2814
Allergy & Asthma Proceedings .................. 2419
Elsevier ........................................ 2701

Spirometry

Micro Direct, Inc. ............................... 2819
Morgan Scientific, Inc. ............................ 2409
Vitalograph, Inc. .................................. 2407
nSpire Health, Inc. ............................... 2320

Technology

AllergyEHR, a division of Meditab Software Inc. ........ 2128
Dyson .......................................... 2102
Inspirotec Inc. ................................... 2433
Molekule ........................................ 2421

Websites

Asthma and Allergy Foundation of America (AAFA) .................. 2542 2635
## Index of Exhibitors

### Exhibits – Listed by Booth

<table>
<thead>
<tr>
<th>Booth</th>
<th>Exhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1905</td>
<td>Novartis</td>
</tr>
<tr>
<td>1907</td>
<td>Ndd Medical Technologies</td>
</tr>
<tr>
<td>1909</td>
<td>Aimmune Therapeutics</td>
</tr>
<tr>
<td>1914</td>
<td>NOVARTIS</td>
</tr>
<tr>
<td>2002</td>
<td>Stallergenes Greer</td>
</tr>
<tr>
<td>2007</td>
<td>NeilMed Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>2008</td>
<td>Circassia</td>
</tr>
<tr>
<td>2014</td>
<td>Regeneron Pharmaceuticals/ Sanofi Genzyme</td>
</tr>
<tr>
<td>2020</td>
<td>GSK</td>
</tr>
<tr>
<td>2026</td>
<td>HollisterStier Allergy</td>
</tr>
<tr>
<td>2102</td>
<td>Dyson</td>
</tr>
<tr>
<td>2108</td>
<td>Pharming Healthcare Inc.</td>
</tr>
<tr>
<td>2120</td>
<td>ALK</td>
</tr>
<tr>
<td>2128</td>
<td>AllergyEHR, a division of Meditab Software Inc.</td>
</tr>
<tr>
<td>2208</td>
<td>Mylan Inc.</td>
</tr>
<tr>
<td>2214</td>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>2225</td>
<td>Squip, Inc.</td>
</tr>
<tr>
<td>2226</td>
<td>Pfizer</td>
</tr>
<tr>
<td>2300</td>
<td>Thermo Fisher Scientific</td>
</tr>
<tr>
<td>2301</td>
<td>US Hereditary Angioedema Association</td>
</tr>
<tr>
<td>2304</td>
<td>Edge Pharmaceuticals, LLC</td>
</tr>
<tr>
<td>2306</td>
<td>Allergy Partners</td>
</tr>
<tr>
<td>2308</td>
<td>National Allergy/Allergy Control Products</td>
</tr>
<tr>
<td>2320</td>
<td>nSpire Health, Inc.</td>
</tr>
<tr>
<td>2325</td>
<td>SmartPractice</td>
</tr>
<tr>
<td>2400</td>
<td>Healix Infusion Therapy</td>
</tr>
<tr>
<td>2401</td>
<td>Ceela Naturals</td>
</tr>
<tr>
<td>2402</td>
<td>Southern California Permanente Medical Group - Kaiser Permanente</td>
</tr>
<tr>
<td>2403</td>
<td>CLn Skin Care</td>
</tr>
<tr>
<td>2405</td>
<td>American Partnership for Eosinophilic Disorders (APFED)</td>
</tr>
<tr>
<td>2407</td>
<td>Vitalograph, Inc.</td>
</tr>
<tr>
<td>2408</td>
<td>Teva Respiratory</td>
</tr>
<tr>
<td>2409</td>
<td>Morgan Scientific, Inc.</td>
</tr>
<tr>
<td>2419</td>
<td>Allergy &amp; Asthma Proceedings</td>
</tr>
<tr>
<td>2420</td>
<td>CSL Behring</td>
</tr>
<tr>
<td>2421</td>
<td>Molekule</td>
</tr>
<tr>
<td>2425</td>
<td>Live Pure, Inc.</td>
</tr>
<tr>
<td>2433</td>
<td>Inspirotec Inc.</td>
</tr>
<tr>
<td>2534</td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>2435</td>
<td>MotherToBaby Pregnancy Studies</td>
</tr>
<tr>
<td>2438</td>
<td>Rabbit Air</td>
</tr>
<tr>
<td>2500</td>
<td>Mission: Allergy, Inc.</td>
</tr>
<tr>
<td>2535</td>
<td>P &amp; M Harmony, Inc.</td>
</tr>
<tr>
<td>2536</td>
<td>Food Allergy Research &amp; Education</td>
</tr>
<tr>
<td>2538</td>
<td>PulmOne Advanced Medical Devices</td>
</tr>
<tr>
<td>2542</td>
<td>Asthma and Allergy Foundation of America (AAFA)</td>
</tr>
<tr>
<td>2568</td>
<td>Shire</td>
</tr>
<tr>
<td>2620</td>
<td>DBV Technologies</td>
</tr>
<tr>
<td>2634</td>
<td>Lincoln Diagnostics, Inc.</td>
</tr>
<tr>
<td>2701</td>
<td>Elsevier</td>
</tr>
<tr>
<td>2702</td>
<td>Daavlin</td>
</tr>
<tr>
<td>2720</td>
<td>Chattem, Inc.</td>
</tr>
<tr>
<td>2724</td>
<td>ModuleMD, LLC</td>
</tr>
<tr>
<td>2728</td>
<td>Kaleo Pharmaceuticals</td>
</tr>
<tr>
<td>2733</td>
<td>Infinity Massage Chairs</td>
</tr>
<tr>
<td>2734</td>
<td>Coram CVS Specialty Infusion Services</td>
</tr>
<tr>
<td>2735</td>
<td>eClinicalWorks</td>
</tr>
<tr>
<td>2800</td>
<td>World Allergy Organization (WAO)</td>
</tr>
<tr>
<td>2801</td>
<td>Xtract Solutions</td>
</tr>
<tr>
<td>2810</td>
<td>Helen of Troy/Kaz USA, Inc.</td>
</tr>
<tr>
<td>2814</td>
<td>Allergy &amp; Asthma Network</td>
</tr>
<tr>
<td>2816</td>
<td>Immune Deficiency Foundation</td>
</tr>
<tr>
<td>2818</td>
<td>American Board of Allergy &amp; Immunology (ABAI)</td>
</tr>
<tr>
<td>2819</td>
<td>Micro Direct, Inc.</td>
</tr>
<tr>
<td>2820</td>
<td>Boston Scientific Corporation</td>
</tr>
<tr>
<td>2821</td>
<td>Rosch Visionary Systems, Inc.</td>
</tr>
<tr>
<td>2823</td>
<td>Alletess Medical Laboratory</td>
</tr>
<tr>
<td>2826</td>
<td>BPL</td>
</tr>
<tr>
<td>2832</td>
<td>Food Allergy &amp; Anaphylaxis Connection Team (FAACT)</td>
</tr>
<tr>
<td>2833</td>
<td>G.S. Innovations</td>
</tr>
</tbody>
</table>
## Index of Exhibitors

### Exhibits – Listed by Company Name

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aimmune Therapeutics</td>
<td>1909</td>
</tr>
<tr>
<td>ALK</td>
<td>2120</td>
</tr>
<tr>
<td>Allergy &amp; Asthma Network</td>
<td>2814</td>
</tr>
<tr>
<td>Allergy &amp; Asthma Proceedings</td>
<td>2419</td>
</tr>
<tr>
<td>Allergy Partners</td>
<td>2306</td>
</tr>
<tr>
<td>AllergyEHR, a division of Meditab Software Inc.</td>
<td>2128</td>
</tr>
<tr>
<td>Allestess Medical Laboratory</td>
<td>2823</td>
</tr>
<tr>
<td>American Board of Allergy &amp; Immunology (ABAI)</td>
<td>2818</td>
</tr>
<tr>
<td>American Partnership for Eosinophilic Disorders (APFED)</td>
<td>2405</td>
</tr>
<tr>
<td>Asthma and Allergy Foundation of America (AAFA)</td>
<td>2542</td>
</tr>
<tr>
<td>AstraZeneca Pharmaceuticals</td>
<td>2534</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td>2214</td>
</tr>
<tr>
<td>Boston Scientific Corporation</td>
<td>2820</td>
</tr>
<tr>
<td>BPL</td>
<td>2826</td>
</tr>
<tr>
<td>Ceela Naturals</td>
<td>2401</td>
</tr>
<tr>
<td>Chattem, Inc.</td>
<td>2720</td>
</tr>
<tr>
<td>Circassia</td>
<td>2008</td>
</tr>
<tr>
<td>CLn Skin Care</td>
<td>2403</td>
</tr>
<tr>
<td>Coram CVS Specialty Infusion Services</td>
<td>2734</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>2420</td>
</tr>
<tr>
<td>Daavlin</td>
<td>2702</td>
</tr>
<tr>
<td>DBV Technologies</td>
<td>2620</td>
</tr>
<tr>
<td>Dyson</td>
<td>2102</td>
</tr>
<tr>
<td>eClinicalWorks</td>
<td>2735</td>
</tr>
<tr>
<td>Edge Pharmaceuticals, LLC</td>
<td>2304</td>
</tr>
<tr>
<td>Elsevier</td>
<td>2701</td>
</tr>
<tr>
<td>Food Allergy &amp; Anaphylaxis Connection Team (FAACT)</td>
<td>2832</td>
</tr>
<tr>
<td>Food Allergy Research &amp; Education</td>
<td>2536</td>
</tr>
<tr>
<td>G.S. Innovations</td>
<td>2833</td>
</tr>
<tr>
<td>GSK</td>
<td>2020</td>
</tr>
<tr>
<td>Healix Infusion Therapy</td>
<td>2400</td>
</tr>
<tr>
<td>Helen of Troy/Kaz USA, Inc.</td>
<td>2810</td>
</tr>
<tr>
<td>HollisterStier Allergy</td>
<td>2026</td>
</tr>
<tr>
<td>Immune Deficiency Foundation</td>
<td>2816</td>
</tr>
<tr>
<td>Infinity Massage Chairs</td>
<td>2733</td>
</tr>
<tr>
<td>Inspirotec Inc.</td>
<td>2433</td>
</tr>
<tr>
<td>Kaleo Pharmaceuticals</td>
<td>2728</td>
</tr>
<tr>
<td>Lincoln Diagnostics, Inc.</td>
<td>2634</td>
</tr>
<tr>
<td>Live Pure, Inc.</td>
<td>2425</td>
</tr>
<tr>
<td>Micro Direct, Inc.</td>
<td>2819</td>
</tr>
<tr>
<td>Mission: Allergy, Inc.</td>
<td>2500</td>
</tr>
<tr>
<td>ModuleMD, LLC</td>
<td>2724</td>
</tr>
<tr>
<td>Molekule</td>
<td>2421</td>
</tr>
<tr>
<td>Morgan Scientific, Inc.</td>
<td>2409</td>
</tr>
<tr>
<td>MotherToBaby Pregnancy Studies</td>
<td>2435</td>
</tr>
<tr>
<td>Mylan Inc.</td>
<td>2208</td>
</tr>
<tr>
<td>National Allergy/Allergy Control Products</td>
<td>2308</td>
</tr>
<tr>
<td>Ndd Medical Technologies</td>
<td>1907</td>
</tr>
<tr>
<td>NeilMed Pharmaceuticals, Inc.</td>
<td>2007</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>1914</td>
</tr>
<tr>
<td>Novartis</td>
<td>1905</td>
</tr>
<tr>
<td>nSpire Health, Inc.</td>
<td>2320</td>
</tr>
<tr>
<td>P &amp; M Harmony, LLC</td>
<td>2535</td>
</tr>
<tr>
<td>Pfizer</td>
<td>2226</td>
</tr>
<tr>
<td>Pharming Healthcare Inc.</td>
<td>2108</td>
</tr>
<tr>
<td>PulmOne Advanced Medical Devices</td>
<td>2538</td>
</tr>
<tr>
<td>Rabbit Air</td>
<td>2438</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals/Sanoﬁ Genzyme</td>
<td>2014</td>
</tr>
<tr>
<td>Rosch Visionary Systems, Inc.</td>
<td>2821</td>
</tr>
<tr>
<td>Shire</td>
<td>2608</td>
</tr>
<tr>
<td>SmartPractice</td>
<td>2325</td>
</tr>
<tr>
<td>Southern California Permanente Medical Group - Kaiser Permanente</td>
<td>2402</td>
</tr>
<tr>
<td>Squip, Inc.</td>
<td>2225</td>
</tr>
<tr>
<td>Stallergenes Greer</td>
<td>2002</td>
</tr>
<tr>
<td>Teva Respiratory</td>
<td>2408</td>
</tr>
<tr>
<td>Thermo Fisher Scientiﬁc</td>
<td>2300</td>
</tr>
<tr>
<td>US Hereditary Angioedema Association</td>
<td>2301</td>
</tr>
<tr>
<td>Vitalograph, Inc.</td>
<td>2407</td>
</tr>
<tr>
<td>World Allergy Organization (WAO)</td>
<td>2800</td>
</tr>
<tr>
<td>Xtract Solutions</td>
<td>2801</td>
</tr>
<tr>
<td><strong>Total Booths:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Booths:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total Exhibitors:</strong></td>
<td></td>
</tr>
</tbody>
</table>